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DISSERTATION ABSTRACT 
 
Vienna E. Brunt 
 
Doctor of Philosophy 
 
Department of Human Physiology 
 
June 2016 
 
Title: Chronic Passive Heat Therapy as a Novel Means of Improving Vascular Function 
in Sedentary Humans 
 
 
 Cardiovascular disease is the leading cause of death in the developed world. The 
majority of cardiovascular diseases are characterized by disorders of the arteries, 
predominantly caused by endothelial dysfunction and arterial stiffening. Passive heat 
stress results in elevations in core temperature (inducing heat shock protein expression) 
and changes in cardiovascular hemodynamics, such as increased cardiac output and shear 
stress, that are similar to exercise. Thus, repeated passive heat stress (“heat therapy”) may 
provide an alternative means of improving cardiovascular health, particularly for patients 
with limited exercise tolerance and/or capabilities. Therefore, the goal of this dissertation 
was to perform integrative studies to determine the effects of heat therapy on vascular 
function and the associated cellular pathways in young, sedentary humans.  
 Twenty subjects were assigned to participate in 8 weeks (4-5x/week) of heat 
therapy (N=10; immersion in a 40.5°C bath sufficient to maintain rectal temperature 
≥38.5°C for 60 min/session) or thermoneutral water immersion (N=10; sham).  
 As discussed in Chapter V, we found that heat therapy improved numerous well-
established biomarkers of conduit vessel/macrovascular function, including flow-
mediated dilation (a measure of endothelial function), arterial stiffness, intima media 
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thickness, and blood pressure. Heat therapy also improved microvascular function, as 
discussed in Chapter VI, measured as improved cutaneous thermal hyperemia and nitric 
oxide-dependent dilation (the difference between microdialysis sites receiving Lactated 
Ringer’s [control] and nitric oxide synthase inhibition). No changes were observed in any 
variables in sham subjects. In Chapter VII, we showed that both direct cellular heating 
and serum collected from human subjects following heat therapy improved nitric oxide 
bioavailability and angiogenesis in cultured endothelial cells, providing potential 
mechanisms by which heat therapy improves vascular function in vivo.  
 Therefore, the studies described herein provide comprehensive evidence that 
passive heat therapy improves vascular health and insight into the mechanisms involved.  
Our data presented in Chapters IV-VII, combined with pilot data we conducted in spinal 
cord injured individuals (Chapter VIII), strongly indicate that passive heat therapy could 
be used as a simple and effective tool to improve cardiovascular health in a variety of 
patient populations. 
This dissertation includes published and unpublished co-authored material.  
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CHAPTER I 
INTRODUCTION 
 
BACKGROUND 
 Cardiovascular disease is the number one cause of death in the developed world, 
contributing to 34% of deaths in the United States in 2011 [1]. As the average life span of 
Americans is increasing, the prevalence of cardiovascular disease is increasing 
proportionally. Furthermore, the prevalence of risk factors for cardiovascular disease, 
such as obesity and hypertension, are increasing at an even greater rate [1]. In 2011, only 
18% of Americans had >5 traditional risk factors that fell in the ideal range (out of 11) 
[1]. There is clearly desperate need for novel interventions to reduce risk of 
cardiovascular disease and incidence of cardiovascular-related mortality.  
Exercise training has long been considered to be the ideal lifestyle intervention for 
reducing risk of cardiovascular-related and other diseases. However, there are many 
populations who are either unable to exercise to a great enough extent to induce 
cardiovascular adaptation or who are unwilling to do so. For example, patients who have 
sustained a spinal cord injury (SCI) are only able to perform some limited modalities of 
exercise training, many of which do not confer the same benefits as whole-body dynamic 
exercise [2,3]. Many other disease states are characterized by impaired exercise tolerance, 
e.g., patients with heart failure, peripheral artery disease, and obesity. Alternative 
therapies are needed to reduce cardiovascular risk in these patients.  
Heat therapy, in the form of chronic use of hot baths and saunas, is an 
intervention which may confer similar cardiovascular benefits to exercise training. Both 
heat exposure and exercise result in an increase in body core temperature, which induces 
the expression of heat shock proteins (HSPs). In turn, HSPs upregulate and stabilize a 
variety of proteins important to the cardiovascular system. These include proteins which 
improve nitric oxide (NO) signaling [4], reduce oxidative stress [5] and reduce vascular 
inflammation [6], all of which greatly influence cardiovascular health. Additionally, both 
heat exposure and exercise increase heart rate and cardiac output, thereby increasing 
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blood flow and shear stress on the arteries [7]. Intermittent increases in shear stress are 
known to promote beneficial vascular remodeling. Indeed, it has been proposed that 
many of the beneficial effects of exercise training are mediated through increases in core 
temperature [8,9] and subsequent increases in blood flow and shear stress [10,11]. 
Therefore, heat therapy may offer a novel therapeutic tool for improving cardiovascular 
health.  
While heat therapy has been used for centuries in several cultures, with common 
reports of improved well-being and quality of life [12], relatively few studies have 
investigated the physiological health benefits in humans. Recently, a 30-year prospective 
study revealed lifetime sauna use resulted in significantly reduced incidence of 
cardiovascular-related mortality, sudden cardiac death, and all-cause mortality [13], 
providing strong evidence that heat therapy could be used feasibly and effectively to treat 
cardiovascular risk. Additionally, studies in animals have demonstrated extensive 
cardioprotective benefits of >4 weeks of continuous heat exposure [14,15].  
 
STATEMENT OF THE PROBLEM 
Very few studies have investigated the physiological effects of heat therapy in 
humans. There is evidence that heat therapy can be used to treat clinical symptoms of 
cardiovascular diseases, but these studies were short-term (2-3 weeks) and offer little 
mechanistic insight. Only two studies have investigated changes in vascular function 
following greater than 3 weeks of heat therapy [16,17], and experimental limitations of 
these studies warrant further investigation. No studies have previously investigated the 
molecular mechanisms behinds improvements associated with heat therapy.   
Therefore, the studies described in this dissertation are the first to 
comprehensively investigate the physiological benefits of long-term heat therapy in 
humans. As such, we chose to study a non-patient population in order to gather a 
thorough understanding of the mechanisms by which heat therapy improves vascular 
health. Since exercise training has profound CV effects on sedentary individuals, we 
expected to observe similar improvements with heat therapy. As the majority of CV 
diseases are characterized by vascular dysfunction [1], including impaired endothelial-
dependent dilation and arterial stiffening, we chose to focus on vascular function. A 
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period of 8 weeks was chosen as studies in animals have demonstrated >4wks of passive 
heat exposure are required to induce complete cellular adaptation [14].  
The overall purpose of this dissertation was to investigate the effects of 8 weeks 
of passive heat therapy on biomarkers of vascular function and on the associated 
molecular mechanisms in young, sedentary humans. Importantly, we were interested in 
both conduit vessel (macro-)vascular function and microvascular function, as these two 
sections of the vasculature are affected differently by cardiovascular disease progression 
and can respond differently to interventions.  
In order to address this purpose, we performed one large study, in which twenty 
subjects were assigned to participate in 8 weeks of either heat therapy or thermoneutral 
water immersion, which served as a sham. The physiological responses experienced by 
subjects during heat therapy and thermoneutral water immersion sessions, and the 
adaptations they experienced across the 8 weeks, are characterized in Chapter IV. 
Subjects reported to the laboratory before, every 2 weeks during, and after the 8-week 
intervention for experimental testing. Subjects participated in two types of experimental 
sessions. In the first type of session, we investigated the effects of heat therapy on 
clinically relevant biomarkers of macrovascular function, the results of which are 
discussed in Chapter V. In the second type of session, we investigated the effects of heat 
therapy on cutaneous microvascular function, discussed in Chapter VI. During these 
studies, we performed cutaneous microdialysis, a technique which allows for the delivery 
of pharmacological agents to a localized area of skin. Using this technique, we were able 
to investigate some of the mechanisms behind potential improvements in microvascular 
function. In order to further elucidate the molecular mechanisms behind potential 
improvements in vascular function, we utilized a cell culture model. We isolated the 
effects of physiological elevations in temperature from the effects of circulating factors 
upregulated by heat therapy by incubating cultured endothelial cells at 39°C (to match the 
body temperature reached by subject undergoing heat therapy) or with serum collected 
from the human subjects before and after heat therapy. The results of these studies are 
discussed in Chapter VII. By performing these studies, we hoped to gain a 
comprehensive understanding of how heat therapy affects the vasculature.  
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Lastly, in order to test the translatability of our findings to a patient population, 
we conducted a pilot study in a small group of subjects who had sustained complete 
spinal cord injury (SCI), discussed in Chapter VII. SCI is a clinical population with a 
very high rate of cardiovascular-related deaths (~40%), who demonstrate impairments in 
many biomarkers of cardiovascular health, and who are unable to exercise to an extent 
great enough to gain the full cardioprotective effects of exercise. By studying these 
subjects, we were able to confirm that heat therapy is a viable treatment option for at-risk 
patient populations.  
 
HYPOTHESES 
The studies described in this dissertation were designed to test the following 
hypotheses, summarized in Figure 1.1 (next page):  
1. In Chapter IV, we hypothesized that, relative to thermoneutral water immersion, 8 
weeks of heat therapy would result in similar adaptations as are observed with 
exercise heat acclimation. Specifically, we hypothesized that resting core temperature 
and resting heart rate would be reduced, sweat rate during heat stress would be 
increased, and basal HSP expression in primary peripheral blood mononuclear cells 
would be increased. As a sub-aim, we also hypothesized that plasma volume would 
be expanded (measured in a sub-set of subjects).  
2. In Chapter V, we hypothesized that, relative to thermoneutral water immersion, 8 
weeks of heat therapy would improve clinically relevant biomarkers of macrovascular 
function. Specifically, we hypothesized that brachial artery flow-mediated dilation, 
carotid and superficial arterial compliance, aortic pulse wave velocity, carotid and 
superficial femoral intima media thickness, and blood pressure would all be 
improved.  
3. In Chapter VI, we hypothesized that relative to thermoneutral water immersion, 8 
weeks of heat therapy would improve cutaneous microvascular function. Specifically, 
we hypothesized that plateau cutaneous vascular conductance during local skin 
heating and NO-dependent dilation (difference in plateau between microdialysis sites 
receiving Lactated Ringer’s [Control] and a NO synthase inhibitor) would be 
improved and that Tempol-mediated dilation (difference in plateau between 
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microdialysis sites receiving Lactated Ringer’s and Tempol, a superoxide dismutase 
mimetic; an indicator of oxidative stress) would be reduced.  
4. In Chapter VII, we hypothesized that simulating heat therapy in cultured endothelial 
cells would result in improved NO signaling, reduced oxidative stress, and increased 
angiogenesis. Specifically, we hypothesized that cultured endothelial cells exposed to 
physiological levels of direct heat (relative to cells incubated at 37°C) or to sera from 
heat-acclimated human subjects (relative to exposure to sera collected prior to heat 
therapy) would result in increased expression of endothelial NO synthase and 
superoxide dismutase, reduced superoxide production, and increased endothelial 
tubule formation (indicative of angiogenesis).  
 
 
Figure 1.1 Schematic of our hypotheses for how heat therapy will improve 
cardiovascular health. Text in parentheses denotes outcome variables measured as part of 
this dissertation. Abbreviations: HSP, heat shock protein; PBMCs, peripheral blood 
mononuclear cells; ECs, endothelial cells; SOD, superoxide dismutase; SO, superoxide; 
eNOS, endothelial nitric oxide synthase; NO, nitric oxide; PWV, pulse wave velocity; 
FMD, flow-mediated dilation. 
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SIGNIFICANCE 
Although hot tubs and saunas have been used for their health benefits for 
centuries, very few studies have explored the physiological effects of heat therapy, and 
only two investigations have studied effects beyond 3 weeks, and none have investigated 
the mechanisms behind improvements. The studies described in this dissertation provide 
novel comprehensive insight into the physiological benefits of heat therapy.  
The long-term goal of this line of research is to develop a model for improving 
cardiovascular health, which could be used as an alternative or adjunctive therapy for 
patient populations who are unable to exercise to an extent great enough to gain 
cardioprotective effects. While we studied SCI patients as add-on experiment to this 
dissertation, there are many other patient populations who have limited exercise 
capabilities (e.g., amputees, advanced diabetics, morbidly obese, heart failure patients, 
etc.). Heat therapy has the potential to improve cardiovascular health and mortality in all 
of these patient populations. Therefore, our research seeks to shift the face of clinical 
practice regarding the treatment of these patient groups, hopefully thereby improving 
quality of life, reducing morbidity and mortality, and reducing the societal healthcare 
burden of treating cardiovascular diseases in these populations.  
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CHAPTER II 
REVIEW OF THE LITERATURE 
 
INTRODUCTION 
While heat therapy has been used for centuries in several cultures, with common 
reports of improved well-being and quality of life [12], relatively few studies have 
investigated the physiological health benefits in humans. As introduced in the previous 
chapter, we believe that the mechanisms underlying potential improvements in vascular 
function with heat therapy are two fold. First, increases in body core temperature induce 
expression of heat shock proteins (HSPs), which in turn stabilize a variety of proteins 
important to the cardiovascular system. Secondly, hyperthermia increases cardiac output 
and therefore increases shear stress on the vasculature, which is known to promote 
beneficial vascular remodeling [18]. The cellular effects of both HSPs and of increases in 
shear stress have been well characterized. Therefore, in this chapter, we will start by 
characterizing the acute effects of heat stress. We will then present the evidence for how 
increased expression of HSPs improves vascular health, focusing on both data 
characterizing the direct intracellular effects of HSPs and the essential role of HSPs in 
whole-organism adaptation and protection against novel stressors, as demonstrated in 
animal studies. Next, we will present evidence for how increases in shear stress improve 
vascular function, demonstrating why shear stress is essential for arterial adaptation. 
Lastly, we will describe the studies that have been performed thus far in humans. While 
the human studies are limited in number, the evidence supporting heat therapy as a viable 
treatment option for cardiovascular risk is compelling.  
 
PHYSIOLOGICAL EFFECTS OF ACUTE PASSIVE HEATING  
 Although the long-term effects of heat therapy have been under-studied, the acute 
effects of passive heat stress have been well characterized. There are a few different 
modalities available for eliciting whole-body passive heat stress. In laboratory settings, 
the most commonly used method for passive heating has been water-perfused suits. 
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Subjects wear a nylon suit that has tubes sewn into the lining, which covers their entire 
body with the exception of their hands, feet, and face. Water can then be circulated 
through the tubing at any temperature, thereby increasing skin temperature.  
Saunas and hot tubs are the modalities for heating most-widely used in 
community settings. There are two predominant types of saunas: traditional Finnish 
saunas, and far infrared saunas popularized by the Japanese (also referred to as 'Waon 
therapy'). Finnish saunas are typically maintained with air temperatures of 80-100°C. 
Increases in humidity can be achieved by pouring water over hot rocks. The Finns 
typically enter the sauna for 1-5 min at a time in order to increase body core temperature 
and initiate sweating. They will then exit and rest outside the sauna for 15-30 min. They 
may repeat these cycles 1-5 more times, depending on how accustomed they are to sauna 
use. In far infrared saunas, body temperature is increased by infrared waves that penetrate 
the body, and thus the air temperature is kept cooler at around 50-60°C. Individuals 
typically remain in these saunas for 15-30 min at a time.  
Although widely used and available for community-use in many cultures, less has 
been documented regarding hot baths and Jacuzzis. Hot water immersion is advantageous 
because the conduction of heat in water is approximately 24x that in air, meaning that 
water temperature can be considerably lower than air temperature needs to be to achieve 
similar increases in body core temperature. Water temperature in hot tubs is typically 
kept around 38-41°C. A key difference of hot water immersion compared to other types 
of passive heating is hydrostatic pressure, which is known to have some effects on 
cardiovascular hemodynamics [19,20].  
 
Core temperature 
 The goal of all modes of passive heating is to increase body core temperature. The 
rate at which increases occur will be dependent on the transfer of heat from the 
environment to the body and the effectiveness of the body's heat loss mechanisms. In 
both air and water, heat is transferred from the environment to the body through 
conduction, or the transfer of heat energy between objects. Via convection in the blood, 
this heat is transferred from the skin to the body core. Infrared saunas transfer heat in a 
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different way, through radiation. Infrared waves are able to penetrate the skin, effectively 
heating the body from the inside out.  
Under resting thermoneutral conditions, heat is lost from the body to the 
environment primarily through radiation. During hyperthermia, increases in skin blood 
flow routes warm blood from the core to the surface of the skin and sweating allows for 
this heat to be lost by evaporation. In the majority of environmental conditions found on 
Earth, humans are able to dissipate heat so effectively (in air) that it is difficult to achieve 
increases in body core temperature at rest. As such, traditional saunas have to be as hot as 
80-100°C in order to increase core temperature at a reasonable rate. Increases in hot 
water are much easier to achieve. Not only is heat transferred at a faster rate, but the 
body's cooling mechanisms do not work under water - a phase change from liquid to air 
is required for sweating to remove heat and the core-to-skin temperature gradient must 
favor heat loss (whereas it favors heat gain when skin temperature, i.e., hot water 
temperature, is greater than core temperature).  
In typical Finnish sauna sessions, rectal temperatures increase by 0.2-1.0°C, 
depending on air temperature and length of stay (70-100°C for 15-30 min) [21]. This is a 
fairly modest increase in core temperature relative to theoretical thresholds that are 
considered to be necessary in order to elicit long-term adaptation, and yet a multitude of 
long-term benefits have been reported. Based on animal and some human work, the 
general consensus in the field is that body core temperature needs to reach 38.0-38.5°C 
during sessions in order to confer adaptation [22]. With far infrared sauna, core 
temperature has been reported to increase by 1.0-1.2°C in 15 min sessions [23,24]. The 
rate of rise in core temperature with hot water immersion depends on the water 
temperature and how deeply immersed individuals are in the water. Increases of 1.0-
1.2°C in just 10 min have been reported in 41°C water [24].  
 
Sweating and skin blood flow 
The thermoregulatory centers in the hypothalamus respond to elevations in skin 
and body core temperature by first withdrawing cutaneous adrenergic sympathetic 
vasoconstriction and then by proportionally increasing cutaneous cholinergic sympathetic 
output. The cutaneous cholinergic sympathetic nerves co-release acetylcholine and 
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unknown neurotransmitter(s) [25], stimulating the sweat glands to increase sweat output 
and the cutaneous microvessels to vasodilate. Acetylcholine is the primary stimulus for 
inducing sweating, but inhibition of acetylcholine has little effect on skin blood flow 
during hyperthermia [25]. Instead, the unknown neurotransmitter(s) are thought to be the 
primary signal for active vasodilation. These unknown neurotransmitter(s) are thought to 
be vasointestinal peptide (VIP) [26], pituitary adenylate cyclase activating peptide 
(PACAP) [27], and/or substance P [28]. Additionally, ~30-45% of the vasodilation can 
be blocked with NOS inhibition [29-31]. During passive heating, neuronal NOS appears 
to be the primary isoform responsible for NO production [32,33], suggesting NO may be 
one of the unknown ‘neutrotransmitters’ released from the sympathetic nerves.  
Active skin vasodilation and sweating are initiated once body core temperature 
reaches a temperature threshold, usually ~0.4°C above resting core temperature [7]. Skin 
temperature modulates this, in that, the higher the skin temperature, the lower this 
threshold [34]. With passive heat stress, skin blood flow can increase as much as 4.5-7.0L 
above resting [35].  
 
Cardiovascular hemodynamics 
 Cardiac output must increase to support the increased skin blood flow and 
sweating. The magnitude of increase will be dependent on the rise in core temperature, 
but increases to as high as 13 L/min have been reported with passive heat stress [35]. 
With traditional Finnish sauna, there have been varying reports from only a small 
increase in cardiac output (0.47L/min) [36] up to a 75% increase [37,38]. This variability 
is likely attributable to the varying air temperatures and duration of sauna exposure used 
by community members. Far infrared sauna and hot water immersion elicit similar 
increases in cardiac output, with increases of 30-50% typically reported with both [24]. 
The effects on other cardiovascular hemodynamics can differ between different 
modalities of heat stress. In all modalities, cutaneous vasodilation shifts blood volume 
towards the skin for thermoregulation. Blood is redistributed away from the splanchnic 
and renal circulations in order to support the increased skin blood flow [39,40]; however, 
venous return to the heart and thus cardiac filling pressure are still reduced relative to 
normothermia. The reduced venous return limits increases in stroke volume despite the 
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effects of the sympathetic nervous system on contractility. Changes in stroke volume will 
depend on the balance between reductions in filling pressure, sympathetically-mediated 
increases in contractility, and the effects of temperature of myocardial function 
(contractility can be impaired during severe hyperthermia, i.e., core temperature >40°C 
[41,42]). As such, studies have shown that stroke volume either does not change during 
heat stress or only increases minimally [43-46]. With hot water immersion, the 
compressive hydrostatic force exerted on the body by water should aid venous return and 
allow for greater increases in stroke volume; however, the one study which has directly 
compared hemodynamic effects between sauna and hot water immersion observed no 
difference in stroke volume between the two heating modalities [24].  
Heart rate can increase fairly high, to levels similar to moderate intensity exercise. 
Since increases in stroke volume are minimal, the high heart rates are necessary to 
support increases in cardiac output. Heat may also have a direct chronotropic effect on 
the sinoatrial node [47,48], although this will have much less a contribution to the 
increased heart rate compared to neural input. In general in humans, heart rate increases 
by approximate 30 beats per minute for every degree increase in core temperature [7].  
As a result of the cutaneous vasodilation, peripheral vascular resistance generally 
decreases, although this is offset by increases in splanchnic and renal vascular resistance 
[40]. Systolic blood pressure typically increases due to increases in cardiac output and 
heart rate [40]; however, reductions in systolic blood pressure may be observed with 
sauna [24,49]. Diastolic blood pressure can decrease considerably, particularly with 
sauna [24,49]. Hydrostatic pressure with hot water immersion may help limit decreases in 
diastolic blood pressure. Importantly, intermittent reductions in peripheral vascular 
resistance and diastolic blood pressure with passive heat stress (along with other 
mechanisms, such as improved endothelium-dependent dilation and angiogenesis) may 
help facilitate reductions in resting blood pressure with chronic use of heat therapy.  
 
Intracardiac pressures 
 As discussed, the result of redistribution of blood to the skin for thermoregulation 
is a reduction in central venous pressure [35,40,50]. Left ventricular filling pressure, as 
measured by pulmonary capillary wedge pressure, has been shown to decrease in parallel 
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[50,51]. Pulmonary artery pressure may either increase [52,53] or decrease [45,54,55], 
depending on the balance between increases in right heart cardiac output and reductions 
in pulmonary vascular resistance. In contrast, intracardiac pressures increase during hot 
water immersion as the hydrostatic compressive force of the water aids venous return to 
the heart [24,56]. Due to this difference, it has been proposed that sauna bathing may be 
safer for heart failure patients than hot water immersion, as strain on the heart is reduced 
[24]. However, the patterns observed with hot water immersion mimic the hemodynamic 
effects of exercise more closely and so may be more effective at inducing cardiovascular 
adaptations. 
 
Potential negative effects of passive heat stress 
 In Finland, the vast majority of residents participate in sauna bathing at least once 
per week. Sauna bathing is a cultural activity that families and communities participate in 
together, and thus individuals begin participating as children and tend to continue to do 
so their entire lives. Because of the widespread prevalence of sauna bathing, and because 
of the contention in Western medicine that passive heat stress is potentially dangerous, 
the Finns have performed a multitude of studies demonstrating no adverse effects of 
sauna bathing across many populations (see Kukkonen-Harjula & Kauppinen, 2006 [57] 
for a review). These include patients with stable cardiovascular diseases [58,59], such as 
hypertension and heart failure, children [60,61], and pregnant women [62,63]. 
Additionally, long-term sauna has no effect on fertility, which has been regarded as a 
concern in the Western world. Although some studies have reported reductions in sperm 
count following acute sauna bathing [64,65], Finnish men on average have higher sperm 
counts than men in other countries [66] and time to pregnancy (a indicator of fertility) is 
shorter in Finland compared to other countries [67]. Especially for individuals who are 
already heat adapted, as most Finns are, sauna is very safe.  
The primary contention with passive heat stress is that it may increase risk of 
cardiac arrhythmias, and thus in Western medicine, it has been contraindicated for 
patients with cardiovascular diseases. However, in a study monitoring 98 acute 
myocardial infarction patients and age-matched control subjects, only 8% experienced 
arrhythmias during and after sauna bathing; whereas, 18% of subjects experienced 
  13 
arrhythmias during sub-maximal exercise [68]. Furthermore, of all sudden deaths that 
occurred in Finland in 1970, only 1.7% occurred within 24 h after sauna bathing (this 
includes those that may be related to sauna and those that definitely are not, e.g., motor 
vehicle accidents) [68]. Of the non-accidental deaths, the majority were caused by 
myocardial infarction related to alcohol consumption, which is known to increase risk of 
cardiac events even without hyperthermia [69]. 
There are some cardiovascular contraindications for heat therapy. Primarily, these 
include unstable conditions, for which exercise would also be contraindicated. Those 
such conditions which have been studied include severe aortic stenosis, unstable angina 
pectoris, recent myocardial infarction, recent stroke or transient ischemic attack, and 
elderly individuals prone to orthostatic hypotension [58,70].  
 
Similarities to exercise 
 In general, the cardiovascular effects of passive heat stress are similar to low-to-
moderate intensity aerobic exercise. Both increase body core temperature to similar 
extents. As described in more depth in the next section, elevated body core temperature 
increases the expression of HSPs which upregulate a variety of other proteins beneficial 
to the cardiovascular system, allowing for long-term cellular adaptation and protection 
against stressors. The increase in core temperature causes a subsequent increase in 
cardiac output, again similar to exercise. Although with passive heat exposure, the 
increased blood flow is routed to the skin for thermoregulation rather than to skeletal 
muscle, both exercise and passive heating result in similar increases in shear stress on the 
conduit arteries, which is essential for arterial adaptation. The mechanisms for how 
repeated increases in shear result in arterial adaption will be reviewed in a later section. 
 
HEAT SHOCK PROTEINS & THEIR ROLE IN VASCULAR FUNCTION  
 Heat shock proteins (HSPs) are a class of proteins synthesized by all organisms in 
response to heat or other stressors. They were first discovered in 1962 in drosophila by 
Ritossa [71]. Although HSPs were named for the observation that their expression is 
increased rapidly and intensely at the onset of heat shock, they are also expressed in 
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response to acute hypoxia [72], ultraviolet radiation [73], cytokines [74,75], cold stress 
[76], and exercise [8,77,78].  
It is believed that HSPs have two major roles. First, HSPs are thought to protect 
cells from the damaging effects of heat and other stressors. In support of this notion is the 
observation that HSP expression is increased rapidly and intensely at the onset of heat 
shock [79]. Upon exposure to milder doses of stressors, HSPs also confer tolerance 
against subsequent otherwise lethal stress. For example, thermotolerance refers to the 
ability of cells which have previously been exposed to non-lethal heat shock to survive a 
subsequent otherwise lethal shock. In addition to conferring thermotolerance, HSPs have 
been shown to also confer tolerance against a variety of other stressors, including 
ischemia [80,81], ultraviolet radiation [82], and toxicity from cytokines such as tumor 
necrosis factor (TNF)-α [83]. It is believed that much of this conferred tolerance stems 
from HSPs role in processing stress-denatured proteins [84] and preventing disruption of 
structural proteins [85], as described in more depth below.  
Secondly, HSPs are also expressed under non-stressed conditions and play 
important roles in cell function, namely in translocating proteins to other locations within 
the cell, chaperoning proteins across cell membranes, and stabilizing various proteins and 
receptors. Many of these processes involve unfolding and refolding of proteins. HSPs can 
be found, usually associated with other proteins, in the nucleus, cytosol, mitochondria, 
endoplasmic reticulum, and in close proximity to the plasma membrane [86].  
HSPs are named for their molecular weight. The different families of HSPs have 
been found to play different roles within the cells, although all aimed at stabilizing, 
chaperoning, and refolding of proteins.  
 
HSP90 family.  The HSP90 family consists of proteins which are constitutively expressed 
and abundant at normal temperatures, but which can be further induced by heat. Their 
primary role is to associate with other proteins. Through association, HSP90 proteins aid 
in translocation and stabilization of other proteins. In some such proteins (e.g., plasma 
membrane proteins and tyrosine kinases), Hsp90 associates immediately after the protein 
has been synthesized and, as soon as Hsp90 dissociates, the protein is phosphorylated and 
becomes active [87,88]. These observations led to the proposed role that Hsp90 aids with 
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transport of proteins from the nucleus to other locations in the cells, keeping these 
proteins stable and inactive until they are in their appropriate place. In other types of 
proteins (for example, nitric oxide synthase as described below), association with Hsp90 
allows for phosphorylation. Hsp90's third role is with stabilization of steroid hormone 
receptors. Hsp90 association with estrogen, progesterone, and glucocorticoid receptors 
(and likely others, although not yet specifically shown) ensures activation of the receptors 
only when the actual hormone is present [89,90].  
Although HSP90 proteins are constitutive expressed, they are also inducible. 
Hsp90 expression is increased in cells and intact animals following stressors, including 
following acute bouts of exercise [8]. Hsp90 has been shown to translocate into the 
cellular nucleus with heat shock [91], suggesting these proteins play a role in either gene 
transcription or chaperoning newly formed proteins out of the nucleus [79]. 
 
HSP70 family.  The HSP70 family consists of highly inducible proteins which are 
essential for cell growth and repair. For example, Escherichia coli cells cannot grow at 
temperatures of 42°C if they have a genetic deletion of one of the HSP70-related 
proteins, dnaK [92]. Within the HSP70 family, four have been identified in mammals: 
Hsp70, Hsp72, p72, and Grp78 [79]. Hsp70 and Hsp72 are the primary heat inducible 
proteins [93], although Hsp70 is also involved in regulating the cell cycle [94]. P72 
(Hsp73) is highly abundant in growing cells. Grp78 (glucose-related protein) is generally 
found in the endoplasmic reticulum [95], where it binds to a variety of transmembrane 
proteins, typically those that are unfolded or misfolded [79]. Grp78 protein content is 
increased with starvation, anoxia, viral infection, but typically not heat shock [96].  
HSP70 proteins are involved in a variety of cell processes, including DNA 
replication, post-translational transport of proteins across membranes in the endoplasmic 
reticulum and mitochondria [97], and binding proteins within the endoplasmic reticulum. 
Most of these processes involve hydrolysis of ATP [98] and HSP70 proteins are known 
to be able to bind ATP with high affinity [99,100]. Translocation of proteins also requires 
the protein to be unfolded to cross the membrane and then refolded on the other side 
[101].  
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These roles all work towards protecting the cell against damage. As such, it is 
thought that thermotolerance is most likely attributable to the processing of stress 
denatured proteins by HSP70s [84]. HSP70 proteins are highly inducible with heat shock 
and other stressors. With heat shock, Hsp70 concentrates mainly in the nucleus and in 
close proximity to cell membranes [102]. In the nucleus, Hsp70 and p72 associate with 
the nucleoli, which experiences severe structural changes with hyperthermia, aiding 
nucleolar recovery after heat shock [103]. In intact animals, Hsp70 protein content has 
been shown to be increased in rodent tissues following acute hyperthermia [104-108], 
ischemia [105,107], peripheral injection of pyrogens to simulate fever [109,110], local 
injections of neurotoxins [111], and exercise [112,113]. In humans, Hsp70 has been 
shown to be inducible by exercise [77,78] and exercise in the heat [114,115]. 
Interestingly, Hsp70 is also inducible in cultured endothelial cells by shear stress 
[116,117]. 
 
Small HSPs.  All other known HSPs smaller than ~30kDa have been grouped into the 
'small HSP' family. As such, they are a much more diverse group. They have been 
studied to a much lesser extent than the other families of HSPs and so much less is 
currently understood about their roles in the cell. They are expressed at different stages of 
cell development under normal temperatures and are inducible in response to heat shock 
and other stresses [118,119]. Hsp27 has been shown to prevent actin microfilament 
disruption under stress conditions [85], and so a role of small HSPs has been proposed in 
thermotolerance. Heat-induced cytokine production also independently signal increased 
Hsp27 expression, which is in turn involved in the signal transduction of these cytokines, 
including interleukin (IL)-1 and TNF-α, perhaps dampening their harmful effects on the 
cell [74].  
Besides heat, increases in fluid shear stress have also been shown to increase 
Hsp27 phosphorylation [116]. In isolated arteries, increased Hsp20 protein content is 
correlated with improved flow-mediated vasodilation [120] and nitroglycerine-induced 
vasodilation is associated with Hsp20 phosphorylation [121]. This link offers another 
mechanism for how repeated elevations in shear stress can improve vascular function 
(reviewed in depth below).  
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Magnitude and time course of HSP expression.  In general, the greater the duration of 
heat exposure and the higher the ambient temperature, the greater the magnitude of HSP 
expression. For example, Harris et al. [122] observed no change in Hsp70 protein 
following 1h of heat shock at 42°C in bovine aortic endothelial cells, but observed an 8-
fold increase in Hsp70 with 45°C heat shock of the same duration. Similarly, in rats, the 
longer the duration of heat stress (measured following 40, 60, and 90min) and the higher 
core temperature rose (37, 39, 42, and 45°C), the greater the induction of Hsp70 and 
Hsp27 mRNA [104]. Cultured cells often require higher ambient temperatures to observe 
increases in HSPs compared to intact organisms, or require extended periods of recovery 
time following heat exposure before peak expression of HSPs [79,123]. For example, 
Harris et al. [122] observed that 15min heat stress at 42°C in rats was sufficient to obtain 
a similar fold increase in Hsp70 in aortic tissue as what was obtained in cultured aortic 
cells following 1h at 45°C.   
Typically, HSP mRNA is increased immediately following heat exposure. Both 
Hsp70 and Hsp27 mRNA have been shown to peak within 1h following heat stress in 
rodents, returning to baseline levels by ~6h [104,107]. This has been shown across 
various tissue types, including brain, lung, liver, kidney, and skin tissue [104,107]. 
However, protein abundance generally does not peak for hours after heat stress. 
The time course of HSP induction may differ across species and tissue types. In 
skeletal muscle, Oishi et al. [124] showed that the timing for when Hsp72 protein 
abundance peaked following 1h heat stress (muscle temp reached 42°C) depended on the 
type of muscle fibers. In the soleus muscle of the rat, a predominantly slow-twitch 
muscle, Hsp72 protein content was elevated immediately following heat stress, with peak 
content at 4h; whereas, in the plantaris muscle, which is predominantly fast-twitch, 
Hsp72 protein content was not elevated until 24-48h following heat stress. Similar 
findings were observed in deep (more slow-twitch) and superficial (more fast-twitch) 
regions of the gastrocnemius [125]. In exercising humans, Hsp70 content in the vastus 
lateralis muscle does not increase until ~48h after exercise and is maintained elevated 
above baseline levels for up to 6-7 days [126,127]; however, the exercise stimulus may 
produce a different pattern of expression compared to passive heat stress. The one study 
that measured muscle HSP content in heat stressed humans observed no change in Hsp70 
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content [128], but they studied physically active men who may have had a blunted HSP 
response to acute stress. Interestingly, HSP content in heat stressed human peripheral 
blood mononuclear cells increases much more quickly, peaking following 1h after heat 
stress and returning back to baseline levels after ~5h [129].  
 
Roles of HSPs in vascular function 
 The primary signaling pathways that are altered with the progression of 
cardiovascular diseases and which have the greatest impact on vascular function are the 
nitric oxide pathway, oxidative stress, and vascular inflammation. HSPs can interact with 
all three, stabilizing proteins which result in a phenotype that has more bioavailable NO, 
is anti-oxidative, and is anti-inflammatory. The interactions of HSPs with these pathways 
are reviewed below and summarized in Figure 2.1 (page 20).  
 
Nitric oxide signaling.  NO is produced by the enzyme nitric oxide synthase (NOS), of 
which there are three primary isoforms: endothelial NOS (eNOS), neuronal NOS 
(nNOS), and inducible NOS (iNOS). When activated under coupled conditions, NOS 
catalyzes the conversion of L-arginine into L-citrulline and NO. Hsp90 is essential for the 
activation and stabilization of both eNOS [4] and nNOS [130]. When Hsp90 is inhibited 
with geldanamycin, eNOS activity in response to bradykinin, VEGF, histamine, and fluid 
shear stress is reduced by 50-90% [131,132]. eNOS binds to the middle region (residues 
259-615) of Hsp90 [131]. 
eNOS activation is dependent on the calcium state of the cell. While inactive, 
eNOS is bound to the caveolar cell membrane by caveolin-1. When bound with calcium, 
calmodulin can dissociate eNOS from caveolin-1, a process which is mediated by eNOS 
association with Hsp90 [133,134]. Once free in the cytoplasm, eNOS can then be 
activated, which can be achieved by various kinases, including mitogen-activated protein 
kinases (MAPK) and Akt (protein kinase B). Hsp90 is also important for activation. For 
example, Akt phosphorylation in endothelial cells is dependent on Hsp90 [135,136]. 
When activated, eNOS catalyzes the conversion of L-arginine to NO and L-citrulline. In 
order to enable proper flow of electrons during this conversion, several bound cofactors 
must be present, one of which is Hsp90. Another important and commonly studied one is 
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tetrahydrobiopterin. In the absence of one of these cofactors (termed 'uncoupling'), eNOS 
instead produces the damaging free radical superoxide (O2.-) [4].  
Through these extensive roles of Hsp90, eNOS activity and therefore NO 
production can be enhanced by increased Hsp90 protein independent of changes in total 
eNOS protein. For example, Harris et al. [137] observed increased eNOS activity in mice 
following 10 weeks of exercise training with no change in total eNOS protein. However, 
Hsp90 was increased following exercise training, as well as Hsp90 association with 
eNOS.  
 
Oxidative Stress.  Reactive oxygen species, such as superoxide and hydrogen peroxide, 
are produced as byproducts of oxidative metabolism in the mitochondria and by other 
intracellular enzymes, such as NADPH oxidases. Under normal, healthy conditions, the 
production of ROS is balanced by their reduction and removal from the cell by anti-
oxidative enzymes. However, when this balance is disrupted, either by excessive 
production of ROS or impaired anti-oxidative mechanisms, ROS build up and can have 
damaging effects on the cells, known as 'oxidative stress'. Oxidative stress occurs with 
normal aging and is thought to be involved in the pathogenesis of many other diseases. 
In the vasculature, NADPH oxidases are a primary source of ROS, which transfer 
electrons from NADPH to O2, forming superoxide [138]. Endothelial cells primarily 
express the NOX4 isoform of NADPH oxidase, which is found on intracellular 
organelles. NOX2, which spans cell membranes, is a major contributor to systemic ROS 
[138]. White blood cells, particularly peripheral blood mononuclear cells [139], are also a 
major source of ROS, especially in disease states. Many disease states are characterized 
by high levels of circulating angiotensin-II, which activates NADPH oxidases. While 
electron leakage at complexes I and III within the electron transport chain can 
substantially contribute to ROS production in other tissue types, this mechanism is not 
thought to play as large a role in the vasculature, where >96% of superoxide produced 
through the electron transport chain is rapidly reduced to water [140]. 
While transient increases in ROS can be beneficial (for example, ROS are 
transiently produced following acute exercise, which may help mediate adaptations such 
as exercise-induced angiogenesis [141]), chronically elevated levels of ROS are 
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Figure 2.1. Interactions of heat shock proteins (HSPs) in endothelial cells with three 
primary pathways associated with vascular function: the nitric oxide (NO) pathway, 
oxidative stress, and inflammation. 1. Hsp90 is essential for activation of endothelial NO 
synthase (eNOS) by calcium-calmodulin (Ca2+-CaM) and Akt (also known as protein 
kinase B). 2. Hsp70 upregulates superoxide dismutase (SOD), which reduces superoxide 
(O2.-) to hydrogen peroxide (H2O2), such that the damaging effects of O2.- are attenuated. 
These damaging effects include, a. scavenging of NO, b. upregulation of arginase, which 
then decreases available L-arginine for synthesis of NO, and c. scavenging of 
tetrahydrobiopterin (BH4), and thus uncoupling of eNOS. 3. Heat stress, most likely via 
Hsp70, suppresses nuclear factor kappa B (NFκB), a master regulator of pro-
inflammatory gene transcription, and its downstream effects mediated by pro-
inflammatory cytokines tumor necrosis factor (TNF)-α and interleukin (IL-6). Hsp70 also 
upregulates the anti-inflammatory cytokine IL-10, which can suppress NFκB activation. 
Other abbreviations: NADPH-O, NADPH oxidase; MAPK, mitogen-activated protein 
kinase; ONOO-, peroxynitrite; MCP-1, monocyte chemoattractant protein-1; ICAM-1, 
intercellular adhesion molecule-1; ECAM-1, endothelial cell adhesion molecule-1. 
 
associated with impairments in vascular function and disease progression [140]. 
Superoxide is especially damaging to endothelial cells. Superoxide can combine with NO 
to produce peroxynitrite, reducing the amount of bioavailable NO and therefore impairing 
the functional effects of NO, such as reducing NO-dependent vasodilation, impairing 
angiogenesis, and promoting the progression of atherosclerosis [142]. As mentioned, 
superoxide also impairs NO production by uncoupling eNOS. This is primarily achieved 
by the actions of peroxynitrite on tetrahydrobiopterin, one of the essential cofactors for 
eNOS [143]. Additionally, peroxynitrite upregulates arginase activity [144], which 
reduces the availability of L-arginine, the substrate used by eNOS for NO production. 
Therefore, the actions of superoxide on the NO pathway form a positive feedback loop 
promoting greater and greater impairments in vascular function.  
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ROS are reduced by anti-oxidative enzymes. For example, superoxide dismutase 
reduces superoxide into hydrogen peroxide, which is further reduced to water by catalase 
[145]. Glutathione peroxidase reduces glutathione, a byproduct of lipid peroxidation and 
another source of oxidative stress, to glutathione disulfide and water. The primary 
mechanism by which HSPs ameliorate oxidative stress is by upregulating expression of 
anti-oxidative enzymes. Hsp70 upregulates superoxide dismutase expression [146,147] 
and Hsp25/27 helps facilitate the actions of glutathione peroxidase [5]. As described, 
removal of superoxide by upregulation of superoxide dismutase can have profound 
effects on vascular function.  
 
Inflammation.  Vascular dysfunction and cardiovascular disease are strongly associated 
with chronic systemic and vascular inflammation [148]. Patients with cardiovascular 
diseases have elevated levels of circulating pro-inflammatory cytokines [149,150] and the 
pathogenesis of many diseases states is considered to be mediated by chronic low-grade 
inflammation [148].  
A mechanism that is thought to play a primary role in inflammation-mediated 
vascular dysfunction is activation of nuclear factor κ-B (NFκB) [151,152]. NFκB is a 
transcription factor which, when activated, regulates the production of various pro-
inflammatory molecules, such as TNFα, IL-6, monocyte chemoattractant protein 1 
(MCP-1), and adhesion molecules [151-154]. Some of these cytokines can in turn 
activate NFκB, contributing to another positive feedback loop [151].  
Several studies have shown that prior heat stress suppresses NFκB activation in 
response to various pro-inflammatory stimuli, including angiotensin-II, as shown in heart 
tissue in rats [155], induced pancreatitis in rat pancreatic cells [156], and TNFα in 
cultured bovine aortic endothelial cells [157]. Heat stress also suppresses TNFα release in 
response to pro-inflammatory stimuli in cultured macrophages [158,159] and in intact 
animals [156,160,161]. In the study by Snyder et al, the authors observed a reciprocal 
relationship between Hsp70 and TNFα [159]. Additionally, cells expressing elevated 
levels of Hsp70 are more resistant to the cytotoxic effects of TNFα [83,162]. Although 
not addressed in these studies, it is thought that heat stress suppresses TNFα production 
by suppressing NFκB.  
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Heat stress has also been shown to downregulate other pro-inflammatory 
molecules, many of which are downstream to NFκB and TNFα. For example, endotoxin-
induced release of IL-1 is suppressed in heat-treated cells [158,159]. IL-1- or TNFα-
mediated production of IL-6 can be suppressed by both prior heat stress and treatment 
with Hsp70, but not treatment with Hsp60 [6]. Heat stress also suppresses TNFα-
mediated expression of intracellular (ICAM-1) [163] and endothelial cell adhesion 
molecules (ECAM) [157], and pancreatitis-mediated production of ICAM-1 [156]. 
Adhesion molecule expression is known to be partially dependent on NFκB activation 
[164].   
Heat stress may also increase anti-inflammatory defenses. Treatment of arthritic 
mice with Hsp70 increased IL-10 levels and suppressed inflammatory responses in 
various immune cells that are key for promoting arthritis [165]. Interestingly, Hsp70 had 
no effect on suppressing arthritis in IL-10 knockout mice. Given that IL-10 is thought to 
be able to suppress NFκB activation, this offers a potential mechanism by which Hsp70 
elicited such profound effects on systemic inflammation.  
 
WHOLE-ORGANISM HEAT ACCLIMATION  
 The concept of heat acclimation is different from thermotolerance. While 
thermotolerance refers to the ability of cells to withstand otherwise lethal heat shock, heat 
adaptation refers to improved overall function of the organism following repeated 
exposures to mild heat stress. Furthermore, thermotolerance is only present while HSP 
expression remains elevated after initial milder stress, whereas, the benefits of heat 
adaptation can be maintained for prolonged periods of time. Heat acclimation is an 
evolutionarily conserved adaption and can be observed in a variety of species, from 
invertebrate worms [166] and insects [167] to fish [168], rodents [14], and humans [169]. 
The whole-organism heat acclimated phenotype results in decreased heat 
production, decreased core temperature and heart rate for any given ambient temperature 
or exercise intensity, decreased core temperature threshold for initiating heat loss 
mechanisms, and an increased capacity for heat loss, although some variations in the 
adaptive responses can be observed across species. For example, in humans, there is no 
evidence that heat production is decreased, but this is offset by a robust capacity for heat 
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loss, achieved via augmented skin blood flow and sweating responses. Other systemic 
effects of complete heat acclimation, as determined in rats chronically exposed to heat, 
include increased cardiac work efficiency through improved excitation-contraction 
coupling [170,171] and plasma volume expansion, resulting in increased stroke volume 
and a subsequent reduction in heart rate [172].  
Another important hallmark of whole-organism heat acclimation is enhancement 
of cytoprotective networks. These include upregulation of HSP-mediated pathways 
[173,174], upregulation of anti-oxidative and anti-apoptotic proteins, and earlier 
activation of these pathways during stressful conditions [173,175]. In animals who live in 
warm environments, HSP expression is elevated under non-stressed conditions (i.e., 
thermoneutral core temperature) [176,177]. This protects the animals against sudden 
increases in core temperature associated with bouts of physical activity in a hot 
environment. In fact, core temperature has to rise considerably higher in these animals 
before they exhibit a stress response. Upregulation of these pathways also protects 
organisms against novel stressors, termed "heat acclimation-mediated cross tolerance." In 
addition to heat stress, heat acclimated animals have conferred protection against 
stressors such as ischemia-reperfusion [178], traumatic brain injury [179], hyperoxia 
[180], hypohydration imposed on heat stress [181], and ionized irradiation [14]. While 
enhanced heat loss mechanisms associated with heat acclimation (e.g., increased sweat 
rates, increased skin blood flow, decreased core temperature) can be achieved within a 
relatively short period of time (e.g., in humans, these adaptations are achieved within 10-
14 days of 60-90 min per day exercise in the heat [22]), cross-tolerance involves 
reprogramming of a variety of genes and requires much longer periods of heat exposure.  
Dr. Michal Horowitz and colleagues have performed an elegant body of work 
investigating the genomic changes that occur with heat acclimation. To do so, they have 
primarily utilized a rat model in which they have investigated the protective effects of 4 
weeks of continuous heat exposure on ischemic insult in heart tissue. In the heart, they 
have shown that heat acclimation upregulates a variety of genes associated with: 1) anti-
apoptosis [182], 2) maintenance of DNA and chromatin integrity [183,184], 3) 
chaperones (e.g., HSPs) [175], and 4) reactive oxygen species scavengers [185]. These 
molecular pathways are common to the majority of stress responses, which are generally 
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characterized by high levels of oxidative stress and apoptosis. As such, Horowitz and 
colleagues have shown that heat acclimation protects heart tissue from apoptosis 
associated with ischemia reperfusion injury.  
A number of metabolic changes in heart tissue facilitate this protection. For 
example, the genomic changes associated with heat acclimation shift the cells towards a 
greater reliance on anaerobic metabolism. Intracellular glycogen reserves are increased 
[186], upregulation of GLUT-1 and GLUT-4 facilitates greater intake of glucose into the 
cell [186], 6-phosphfructo-2-kinase-2 expression is increased [186], and glyceraldehyde-
3-phosphate dehydrogenase activation is increased [186]. During ischemia, these changes 
favor anaerobic glycolysis. Additionally, the cell becomes more metabolically efficient 
and so rate of glycogen depletion is decreased [186]. The drop in pH that normally occurs 
rapidly with ischemia and CO2 build-up and which would inhibit glycolysis is prevented. 
Many of these metabolic changes are believed to be mediated through hypoxia inducible 
factor (HIF)-1α, which is essential for complete heat acclimation [166] and which is 
stabilized by Hsp72.  
 
SHEAR STRESS 
 Shear stress is the mechanical frictional force exerted by the blood on the arterial 
walls, determined by the velocity and viscosity of the blood. Importantly, shear stress and 
the adaptive effects of changes in shear stress are greatest in the conduit vessels. While 
some effects of shear stress can be observed in the microvasculature, this section will 
focus most on the conduit vessels.  
 With perfect forward laminar flow, shear stress will be completely anterograde. 
However, due to the pulsatile nature of blood flow in vivo (in conduit vessels), there are 
times in the cardiac cycle where blood flow will be halted or may move in a retrograde 
fashion back towards the heart. The shear patterns that occur as a result of alternating 
anterograde and retrograde flow is referred to as oscillatory shear. Stimuli that increase 
blood flow, such as exercise, typically increase anterograde shear. Stimuli or disease 
progression which result in increased peripheral vascular resistance will increase 
retrograde or oscillatory shear, as there will be greater resistance to the forward 
movement of blood. Many studies have investigated the effects of different shear patterns 
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(i.e., more or less retrograde or anterograde shear) on endothelial function and adaptation. 
In general, high retrograde or oscillatory shear (also referred to as "disturbed flow") is 
associated with endothelial dysfunction and a pro-atherogenic profile, and high 
anterograde shear improves endothelial function and is anti-atherogenic. The opposing 
effects of retrograde and anterograde shear stress on the vasculature are discussed below 
and summarized in Figure 2.2 (page 27).   
 
Detrimental effects of high retrograde/oscillatory shear 
 There is now a wealth of information that disturbed flow under resting conditions 
can promote unhealthy processes. Studies in cultured endothelial cells have indicated that 
high oscillatory shear upregulates a host of pro-atherogenic genes, including those that 
are pro-inflammatory, pro-apoptosis, and pro-coagulant [117,187,188]. This results in 
increased expression of pro-atherogenic factors, such as adhesion molecules 
[117,187,189], endothelin-1 [190], reactive oxygen species-producing enzymes like 
NADPH oxidase [191,192], and superoxide [192]. Expression of eNOS is also reduced 
[190,191], and leukocyte adhesion to endothelial cells [193] and endothelial cell turnover 
[194] are both increased. Expression of eNOS is also reduced in isolated arteries exposed 
to high oscillatory shear, resulting in impaired endothelium-dependent dilation [195]. 
In vivo rodent models of high oscillatory shear, induced either by carotid artery 
partial ligation [196] or casting of the carotid artery to cause partial stenosis [197], 
produces rapid and profound endothelial dysfunction [196] and vascular remodeling 
(intimal thickening, reduced number of smooth muscle cells, and greater lipid content) 
[197], upregulation of pro-atherogenic genes [196] and pro-inflammatory cytokine 
production [197], and downregulation of anti-atherogenic genes [196]. These rodents also 
quickly develop atherosclerotic plaques in regions of high retrograde shear; whereas, no 
plaques form in regions of normal or high anterograde shear [196,197].  
In humans, disturbed shear patterns and increases in retrograde shear may occur 
as a result of increased vascular tone in the downstream microvasculature in various 
patients populations, such as those with advanced age [198,199], obesity [200], and 
hypertension [201]. The extent of disturbance in flow has been shown to be related to 
reduced NO bioavailability [202] and alpha-adrenergic mediated vasoconstriction [203]. 
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Conduit vessel endothelial dysfunction, likely secondary to greater oscillatory shear, is 
also present in these patient populations [204-206] and there is a well-established link 
between endothelial dysfunction and the progression of atherosclerosis [207,208]. In 
support of a causal link between disturbed flow and endothelial dysfunction, acutely 
disturbing flow in young, healthy individuals by inflating a distal blood pressure cuff to 
increase retrograde shear (without affecting anterograde shear) in the brachial artery 
reduces flow-mediated dilation [209] and causes release of endothelial microparticles 
(EMPs) CD62E (E-selectin) and CD31 [210], biomarkers of pro-inflammatory 
endothelial activation and apoptosis, respectively [211]. EMPs, in turn, can release C-
reactive protein [212], carry regulatory microRNAs [213], reduce eNOS [214], and 
promote thrombosis, inflammation, and reactive oxygen species production [215]. Low 
mean shear rates are also associated with higher levels of circulating EMPs in patient 
populations [216]. 
 
Beneficial effects of increases in anterograde shear 
 On the contrary, repeated increases in anterograde shear, such as occurs during 
exercise or heat stress, have been shown to be anti-atherogenic and to improve 
endothelial function. In cultured endothelial cells, physiologically-relevant increases in 
shear stress (e.g., at levels that would be achieved in conduit vessels during exercise in 
humans) increase expression of eNOS [217-219], the essential eNOS cofactor 
tetrahydrobiopterin [220], and the anti-oxidative enzyme superoxide dismutase [217], and 
therefore increases NO production. Shear stress can also increase phosphorylation of 
eNOS through a few mechanisms, including through activating the receptor for vascular 
endothelial growth factor (VEGFR-2) [221] and activating phosphoinositide (PI)3-kinase, 
which in turn activates protein kinase A and then eNOS [222]. Additionally, shear stress 
(and VEGF and histamine) can increase association of Hsp90 with eNOS [132].  
Increases in shear stress also decrease endothelin-1 expression [223,224] and are 
anti-inflammatory, reducing expression of adhesion molecules [225,226] and protecting 
cells against TNFα-induced insult [225]. Importantly, these results have been confirmed 
in isolated arteries, in which physiological increases in shear stress have been shown to 
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increase eNOS and superoxide dismutase expression [227,228], resulting in improved 
endothelial-dependent dilation [228].  
 In humans, Dr. Daniel Green and colleagues have performed a series of 
studies indicating that increases in shear stress are essential for arterial adaptation to 
various stimuli. These authors have utilized a model in which they assess vascular 
function before and after an intervention in both arms. One arm is allowed to adapt 
normally; whereas, a blood pressure cuff is placed on the other arm and inflated to resting 
systolic pressure throughout the intervention sessions, such that blood flow, and therefore 
shear stress, is prevented from increasing above resting levels. Using this model, they 
have shown that arterial adaptation in both conduit vessels and the microvasculature, as 
measured by increases in brachial artery flow-mediated dilation, cutaneous microvascular 
endothelial function, or brachial artery diameter (i.e., arteriogenesis), is prevented in the 
cuffed arm following 8 weeks of local arm heating [229], whole-body heating [16,17], 
lower limb exercise training [230], and handgrip exercise training [18]. Reductions in 
brachial artery wall thickness with handgrip exercise training, a marker of structural 
remodeling, is also prevented in the cuffed arm [231]. These data argue for an obligatory 
role of shear stress in arterial adaptation, even in response to stimuli which should induce 
HSP expression, i.e., stimuli such as whole-body heating and exercise which increase 
body core temperature.  
 
 
Figure 2.2. Summary of opposing effects of retrograde and anterograde shear stress on 
the vasculature.  
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Based on these data and data from other laboratories, the general consensus in the 
field is that shear stress is the primary stimulus for inducing arterial adaptation to exercise 
training [232-234] Indeed, exercise training is well-known to improve endothelial 
function [235] and to be anti-atherogenic [113,236]. Additionally, exercise training can 
induce arteriogenesis (i.e., increases in diameter of the conduit vessels) [237,238], which 
is also thought to be shear-mediated. In contrast, it is important to note that angiogenesis, 
the growth of blood vessels in the microvasculature, is much less dependent on shear 
stress.  
Typically, eNOS protein is increased [234,235]. However, some studies have 
failed to observe increases in eNOS and endothelium-dependent dilation following 
exercise training [239-241]. The differential effects of exercise of conduit arteries 
throughout the body may help explain these differing results. For example, anterograde 
and total shear are increased and retrograde shear is decreased in the abdominal aorta 
during exercise [242], but depending on the mode and intensity of the exercise, 
oscillatory shear may be increased in peripheral conduit arteries [243,244]. It is also 
important to recognize that increases in flow can also increase arterial diameters, and so 
shear stress may not have increased in these studies if diameter increased proportionally 
with velocity.  
Increases in local temperature also seem to be important. Interestingly, in the 
same studies from Dr. Green's lab, adaptations to repeated whole-body heating [16] were 
prevented when local skin temperature was clamped to 30°C using a water bath, even 
though shear stress was allowed to increase. As such, it appears that the interactive 
effects of elevations in shear stress and temperature are necessary for adaptation. This 
evidence suggests that heat therapy may offer an even more powerful mode for inducing 
arterial adaptation.  
 
HEAT THERAPY STUDIES IN HUMANS 
 Although the acute effects of passive heat stress have been well characterized, 
very few studies have investigated the long-term benefits of heat therapy, with only 6 
studies investigating physiological effects beyond 4 weeks. As shown in animals, greater 
than 4 weeks of heat exposure are necessary in order to induce the full protective 
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phenotype [14]. While the available data is highly convincing of the benefits of heat 
therapy, further investigations are needed.  
 
Short-term studies: 2-4 weeks 
 The majority of shorter-term heat therapy studies have been conducted by a group 
in Japan utilizing Waon therapy, which consists of 15 min in a 60°C far infrared sauna 
followed by 30 min recovery in blankets to keep body core temperature elevated.  
Most studies from this research group have been conducted on heart disease 
patients. Waon therapy significantly reduces the severity of these diseases, greatly 
improving myocardial perfusion in chronically-occluded coronary artery-related ischemia 
patients [245] and improving cardiac function in left-sided heart failure. Improvements in 
the latter group include improved left-ventricular ejection fraction [23,246,247], 
improved cardiothoracic ratio [247], reduced incidence of arrhythmias [247], reduced 
atrial natriuretic peptide [247], and improved autonomic function, as measured by 
reduced low frequency (sympathetic) and increased high frequency (parasympathetic) 
components of heart rate variability [248]. In congestive heart failure, Waon therapy 
reduces mitral regurgitation and cardiothoracic ratio, and increases left ventricular 
ejection fraction [246].  
Waon therapy also improves biomarkers of vascular function. Flow-mediated 
dilation is improved in heart failure patients [23] and patients with chronically-occluded 
coronary artery-related ischemia [245]. Systemic vascular resistance is reduced acutely 
[24] following hot water immersion or sauna, and remains reduced chronically, measured 
24h following 2 weeks of heat therapy treatment [249]. Reductions in vascular resistance, 
along with improvements in angiogenesis that have been observed in rats undergoing 5 
weeks of Waon therapy [250], may underscore chronic improvements in blood pressure 
[251].  
Perhaps one of the most compelling arguments that passive heat therapy could be 
used as an alternative or adjunctive therapy to exercise is the observation that just 3 
weeks of Waon therapy improves VO2 peak [23] and exercise tolerance, measured using 
both 6-minute walk distance [23] and time-to-fatigue on a modified Bruce test [245]. In 
the study by Sobajima et al. [245], improvements were observed in every heart failure 
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patient studied, and 16 out of 20 patients improved in the study by Ohori et al. [23]. In 
both of these studies, improvements in exercise tolerance were correlated with 
improvements in FMD. Previous studies in animals have demonstrated that NOS 
inhibition reduces exercise tolerance, suggesting that improvements in vascular function 
are a primary mediator for heat therapy-induced improvements in exercise tolerance. 
 
Longer-term studies: 8-12 weeks 
 One study has investigated the effects of longer-term Waon therapy. Following 10 
weeks of therapy in peripheral artery disease patients, Tei et al. [252] reported improved 
pain scores, walking distance, ankle-to-brachial pressure index, and resting leg skin 
perfusion (laser-Doppler). Waon therapy was also successful at inducing the formation of 
new collateral vessels in the affected legs of these patients, as shown by angiography 
[252]. In one patient, Waon therapy greatly improved the rate of healing of a large skin 
ulcer, preventing amputation of his leg [253].   
With Finnish dry sauna, 12 weeks of biweekly sauna use has been shown to 
increase left-ventricular ejection fraction by 7-8% in heart failure patients [254] and to 
reduce blood pressure in heart failure patients [254] and hypertensives [254,255]. 
In young, healthy subjects, two studies from the same research group have been 
published investigating the effects of repeated hot water immersion on vascular function 
[16,17]. In these studies, subjects were immersed to the waist in 40°C hot water for 
30min per session, 3 times per week for 8 weeks. Following the 8 weeks, these authors 
observed an improvement in cutaneous microvascular function, measured using slow 
local skin heating to 42°C [16]. They also observed an improvement in brachial artery 
FMD after 4 weeks of leg heating; however, FMD returned to baseline values by 8 weeks 
[17]. However, the method of heating resulted in a fairly mild heat stress. Rectal 
temperature reached about 38.1°C during the first session, but by 8 weeks, only reached 
~37.5°C, which was only 0.4°C above resting core temperature. While these results 
indicate a beneficial effect of hot water immersion therapy on vascular function, due to 
limitations, these studies warrant further investigation.  
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Lifelong sauna use 
 While extensive studies have been performed in Finland characterizing the acute 
effects of sauna bathing, very few have prospectively (or cross-sectionally) studied 
individuals using sauna regularly. In acute studies, the main focus has been on disproving 
myths that sauna bathing is dangerous. There have been a few long-term studies, but none 
have systematically assessed cardiovascular health. For example, a ten-year follow-up 
study of patients who had suffered a myocardial infarction reported that although 60% of 
patients experienced symptoms of angina pectoris throughout their daily lives, only one 
patient experienced these symptoms associated with sauna bathing [58]. In another study, 
the authors followed patients with essential hypertension and coronary artery disease who 
used sauna regularly and reported a positive effect on blood pressure at 1 and 3 years of 
follow-up [251]. Several studies have also reported anecdotal evidence that regular sauna 
bathing improves symptoms associated with asthma [256], joint pain [38], rheumatoid 
arthritis [257], and chronic obstructive pulmonary disease [258], and the incidence of 
common colds and upper respiratory tract illnesses [259]. 
The most convincing study on the health benefits of sauna bathing was published 
recently by Laukkanen et al. [13]. These authors studied 2,315 Finnish men, aged 42-60 
years, who used sauna regularly. Subjects participated in baseline testing and completed a 
questionnaire on their sauna bathing habits. The authors then followed these subjects for 
30 years, or until time of death. Both the frequency and duration per session of sauna 
bathing significantly predicted incidence of sudden cardiac death, fatal cardiovascular 
disease, fatal coronary artery disease, and all-cause mortality. The risk of cardiovascular-
related mortality was 48-50% lower in subjects who used sauna 4-7 times per week 
compared to those who used it only once per week.   
 
CONCLUSIONS 
 It has been well established that exercise training improves vascular function and 
reduces risk of cardiovascular-related morbidity and mortality. Both increases in core 
temperature and the subsequent increases in shear stress are considered to be the primary 
mechanisms by which exercise induces arterial adaptation. The similarities in acute 
effects on the cardiovascular system between heat therapy and exercise argue strongly in 
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favor of heat therapy also inducing profound improvements in cardiovascular health. This 
argument is supported by the extensive data in animals that has shown long-term heat 
acclimation to be protective for the cardiovascular system, and the existing data in 
humans demonstrating improvements in vascular and cardiac function, as well as reduced 
incidence of all-cause mortality, with sauna therapy.  
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CHAPTER III 
OVERVIEW OF METHODOLOGY 
 
OVERVIEW 
 The overarching goal of this dissertation was to assess the effects of long-term 
heat therapy on vascular function and the underlying molecular mechanisms in young, 
healthy, sedentary humans. To investigate this goal, one large study was conducted in 
which 20 young, healthy, sedentary subjects were assigned to participate in one of the 
following 4-5x per week for 8 weeks (36 sessions total):  
 
 Group 1: Heat Therapy (hot water immersion; N=10) 
 Group 2: Sham (thermoneutral water immersion; N=10) 
 
Before, during, and after the 8 weeks, we performed the following experimental 
measures. A timeline of the human study is provided in Figure 3.1 (next page).   
1) We measured various well-established clinically relevant biomarkers of 
macrovascular health, including flow-mediated dilation, arterial stiffness, intima 
media thickness, and blood pressure. The results of these studies are detailed in 
Chapter V.  
2) We investigated the effects of heat therapy on microvascular function and the 
mechanisms behind improvements by performing a cutaneous microdialysis study. 
The skin serves as an ideal site to easily and effectively pharmacodissect the 
molecular pathways involved. The results of these studies are detailed in Chapter VI.  
3) We collected venous blood in order to measure circulating factors which are affected 
by heat therapy and for use in cell culture experiments in which we sought to 
elucidate the cellular mechanisms behind improvements in vascular health. The 
results of these studies are detailed in Chapter VII.  
4) In a subset of subjects, we measured blood volume, hemoglobin, and hematocrit in 
order to characterize whether passive heat therapy results in similar classical 
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adaptations to exercise heat acclimation. These results, along with other data that 
characterizes the overall physiological response to passive heat therapy (e.g., changes 
in core temperature, sweat rates, and heart rate) are detailed in Chapter IV.  	
	
Figure 3.1. A timeline of the human studies. Macrovascular and cutaneous studies were 
performed 36-48h after the previous hot tub session. Blood volume measurements were 
performed in a subset of subjects on the same day as macrovascular function studies. 
 
 
HUMAN SUBJECTS 
 All protocols in human subjects were approved by the Institutional Review Board 
at the University of Oregon (IRB #09272013.025, see Appendix pages 153-216 for 
informed consent documents). All subjects gave oral and written consent prior to 
participation as set forth by the Declaration of Helsinki. The study was registered as a 
clinical trial on clinicaltrials.gov. Identifier: NCT02518399; 
https://www.clinicaltrials.gov/ct2/show/NCT02518399?term=heat+therapy&rank=1.  
Figure 3.2 (next page) summarizes progression of subjects through the study. 
Seventy-six potential human subjects were assessed for qualification in the study. Subject 
inclusion criteria included age 18-40 years, healthy body mass index (BMI between 18-
25kg/m2), sedentary lifestyle (<2h aerobic exercise per week), not taking any prescription 
medications with the exception of hormonal contraceptives, no cigarette smoking, and no 
history of cardiovascular, metabolic, or other chronic diseases. Of these seventy-six 
subjects, thirty-eight met inclusion criteria. Eleven declined to participate. Thus, twenty-
seven (17 women, 10 men) young (age 21.5 ± 0.5 yrs old), healthy (BMI 22.4 ± 0.3 
kg/m2), sedentary individuals enrolled in the study. These subjects underwent an 
Heat therapy
Timing (weeks):   0                      2                       4                   6                       8  
*
= cutaneous microdialysis study
* * *  * 
* = macrovascular function study = venous blood collection before and after first and last hot tub/sham sessions
= blood volume measurement (N=12)
Thermoneutral water immersion
Group 1 (N=10): 
Group 2 (N=10): 
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additional health screening to further confirm they met all inclusion criteria and to ensure 
they were healthy enough to undergo heat therapy. Following the health screening, they 
were assigned to participate in either heat therapy or thermoneutral water immersion. 
Because of the relatively small cohort size, subjects were not randomly assigned to 
interventions, but were instead assigned by investigators to match for age, sex, BMI, and 
time of year across the two groups (Table 3.1 - next page). Of the 27 subjects who were 
initially enrolled, 24 subjects completed part or all of the 0-week testing, 23 initiated heat 
therapy or thermoneutral water immersion (sham), and 20 completed the full 8-week 
protocol. These numbers resulted in N=10 in each group. Data from subjects who 
dropped out of the study partway has been excluded, unless otherwise specified.    
 
Figure 3.2. Progression through the phases of the study. 
 
 Prior to all study days (at 0, 2, 4, 6, and 8 weeks), subjects abstained from food 
for 4h, caffeine and alcohol for 12h, over-the-counter medications, vitamins, and 
supplements for 24h, and exercise for 24h. No subjects were taking prescription 
Assessed for eligibility (n=76) 
Excluded (n=49) 
•  Not meeting inclusion criteria (n=38) 
•  Declined to participate (n=11) 
Analyzed (n=10) 
Discontinued intervention (scheduling) (n=3) 
Allocated to heat therapy group (n=13) 
•  Initiated heat therapy intervention (n=13) 
Discontinued intervention (n=0) 
Allocated to sham group (n=14) 
•  Initiated thermoneutral water immersion 
intervention (n=10) 
•  Did not initiate intervention (scheduling, 
n=3; started new medication, n=1) 
Analyzed (n=10)!
 
Allocation!
 
Analysis!
 
Intervention!
 
Assigned (n=27) 
Enrollment!
 
Figure 1 
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medications at the start of the study; however, one subject had to take antibiotics for a 7-
day period during the 8 weeks, which was discontinued 8 days prior to the next study 
day. Anther subject took amitriptyline for 3 days for migraine-like symptoms, which was 
discontinued 2 days prior to the next study day. All female subjects provided a negative 
pregnancy test within 24h of each study day. Women taking hormonal contraceptives 
(N=10) were always studied during the active (hormone) phase in order to control 
hormone status. Women who were naturally menstruating (N=2) were studied during the 
same phase of the menstrual cycle for 0, 4, and 8 weeks and at 2 and 6 weeks. Although 
women have been studied under low hormone conditions (i.e., in the early follicular 
phase of the menstrual cycle or during the placebo week if taking contraceptives) in the 
majority of recent investigations, it was not possible to do so in a study with such 
frequent experimental sessions. Studying women in the active phase of contraceptives 
provided more consistent hormonal conditions across all experimental days. Additionally, 
the magnitude of changes in vascular function we hoped to observe, which would 
indicate clinically relevant improvements in cardiovascular health, are of greater 
magnitude than the changes observed across the menstrual cycle or with the active vs. 
placebo phases of hormonal contraceptives [260,261].   
 
Table 3.1. Demographics of subjects who completed all 8 weeks of heat 
therapy or thermoneutral water immersion (sham). Data are mean ± S.E.  
 Heat Therapy (N=10) Sham (N=10) 
# of women 6 6 
Age (yrs) 22.0 ± 1.1 21.7 ± 1.3 
Height (cm) 173 ± 4 174 ± 3 
Weight (kg) 67 ± 3 67 ± 4 
BMI (kg/m2) 22.4 ± 0.6 21.9 ± 0.8 
# of subjects studied in 
Summer months 4 4 
 
HEAT THERAPY 
 Subjects in both groups reported to the Evonuk Environmental Physiology Core 
in Esslinger Hall on the University of Oregon campus 4-5 times per week for 8 weeks, 
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for a total of 36 sessions. Upon arrival, subjects were instrumented with a sterile rectal 
thermistor probe (YSI Series 400; Yellow Spring Instruments, Yellow Springs, OH) 
inserted ~10cm past the anal sphincter to monitor core temperature and a chest strap 
(Polar Electro Inc., Lake Success, NY) to monitor heart rate. Dry nude body weight was 
measured before and immediately after sessions in order to calculate mean whole-body 
sweat rate, after correcting for water intake.  
For heat therapy, subjects were immersed up to the shoulder in a 40.5°C hot tub 
until rectal temperature (Tre) reached 38.5°C, which took ~20-30 min (Figure 3.3). 
Subjects then sat up on a bench such that the water reached waist-level in order to 
maintain Tre between 38.5-39.0°C for another 60 min (up to 90 min total in the tub). 
Following hot water immersion, subjects were monitored for another 10 min, or until Tre 
had fallen below 38.5°C. Subjects in the sham group were immersed up to the shoulder in 
a 36°C tub for 30 min and then to waist-level for another 60 min in order to mimic the 
same hydrostatic pressures as were experienced by subjects in the heat therapy group, but 
without the heat exposure. This water temperature was selected to match reference values 
for mean body temperature (calculated at 0.2*Tsk + 0.8*Tc, where Tsk = mean skin 
temperature and Tc = body core temperature, using reference values of Tsk = 32.0°C and 
Tc = 37.0°C) in order to minimize core-to-skin temperature gradients [262], and was 
successful at avoiding any changes in rectal temperature >0.2°C across the 90 min in all 
subjects.  
 
Figure 3.3. Representative rectal temperature response to the heat therapy protocol from 
one subject. 
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The goal of heat therapy was to raise body core temperature to 38.5°C and 
maintain it at or above this threshold for 60 min. This threshold was selected as HSP 
expression is dependent upon time spent above a core temperature threshold, which in 
humans has most commonly been reported to be in the range of 38.0-38.5°C [22]. This 
protocol (>38.5°C for 60 min) has also been shown to be the ideal core temperature and 
length of time for attaining complete heat acclimation when using controlled passive 
hyperthermia [263]. A frequency of 4-5 sessions per week was selected to match exercise 
training regimens. There were no constraints on when sessions could be held so long as 
they were completed within the week (as in, all five sessions could be consecutive or 
could be spread out across the 7-day week). In general, subjects completed five sessions 
in odd weeks and four sessions in even weeks when a macrovascular function study was 
also held. However, schedules were customized to fit subjects’ needs. A time period of 8 
weeks was selected because periods of heat exposure greater than 4 weeks are required to 
induce many of the cellular adaptations [182], and the majority of exercise training 
studies are conducted over at least 8 weeks. Water immersion was selected as the 
preferred method of heating since it is difficult to achieve increases in core temperature 
solely in air. Water immersion is capable of increasing core temperature at a rate similar 
to moderate-intensity exercise [264] and it allows for core temperature to be continually 
elevated to a given threshold, even once individuals are adapted to the heat.  
Prior to all sessions, subjects provided a first-morning urine sample to confirm 
euhydration via urine specific gravity <1.02 (Analog Refractometer; Atago, Tokyo, 
Japan). If USG was >1.02, subjects drank 5ml/kg of water prior to entering the hot tub. 
While in the tub, subjects drank water ad libitum. If subjects did not drink enough water 
to compensate for sweat loss such that body weight loss was >1%, they drank additional 
fluids to make up the difference prior to leaving the laboratory. 
 
HEMODYNAMIC MONITORING 
 For vascular function studies, heart rate and rhythm were monitored using 3-lead 
electrocardiogram (CardioCap; Datex Ohmeda, Louisville, CO). Baseline blood pressure 
was measured in triplicate following at least 20 min of supine rest and periodically 
throughout the study via brachial oscillation. Beat-by-beat blood pressure was measured 
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using photopletysmography (Nexfin; BMEye, Amsterdam, the Netherlands), with a cuff 
placed around the middle finger of the left hand. Beat-by-beat blood pressure 
measurements were calibrated back to the brachial blood pressure. For cutaneous 
microvascular studies, brachial blood pressure was measured periodically throughout the 
study, timed with key points into the experimental measures.  
 
MACROVASCULAR FUNCTION  
 As the majority of cardiovascular diseases are associated with disorders of the 
arteries, we chose to focus this project on vascular function. The two primary 
components of vascular function are endothelium-dependent dilation and arterial 
stiffness. Endothelium-dependent dilation refers to the ability of the endothelial cells to 
synthesize and release vasodilators in response to a given stimulus; whereas, arterial 
stiffness refers to the distention of the arteries that occurs due to changes in pressure. 
Arterial stiffness can be impacted by endothelial-dependent dilation, but is also affected 
by elastic fiber composition, collagen content, vascular smooth muscle hypertrophy, and 
monocyte adherence. The structural properties and function of the conduit vessels can be 
non-invasively assessed using a combination of Doppler ultrasonography and applanation 
tonometry. The two techniques are described in depth below, whereas the specific 
measurements we made using these techniques are described in subsequent sections.  
 
Ultrasonography  
 An ultrasound transducer probe emits ultrasonic waves at a given frequency that 
penetrate through tissue. The lower the frequency, the deeper the waves can penetrate. 
For imaging the conduit arteries, which lie in the range of 1-6cm below the surface of the 
skin, transducer probes with a maximum pulsed frequency in the range of 10.0-12.0-MHz 
are most commonly used. As the ultrasound waves travel through a medium, they 
displace particles at their given frequency. When these waves meet a solid interface (e.g., 
soft tissue, muscle, blood cells), they are reflected back at an intensity equal to the 
acoustic impedence of the material. Modern ultrasounds have two modes. The first is B-
mode, or brightness mode, which is used to obtain an image of the vessel. Images are 
constructed by determining the amplitude of reflected energy at each depth through the 
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tissue. The beam of ultrasonic waves can be focused to a given depth (i.e., the depth 
where the vessel lies) to improve resolution within that focal zone. Secondly, the Doppler 
mode can be used to obtain blood velocity. In Doppler mode, ultrasound waves are 
transmitted at an angle of insonation. Velocity of the blood cells is determined based on 
the Doppler shift that occurs when waves are back-scattered. While an insonation angle 
of 0° provides maximal ability to detect a Doppler shift, this is not possible without being 
inside the body. Thus, an insonation angle of 60° is most commonly used [265].  
For the studies described in this dissertation, a high-resolution Doppler ultrasound 
(Terason t3000cv, Teratech, Burlington, MA) equipped with 10.0-MHz linear array 
ultrasound transducer probe was used to image the common carotid, superficial femoral, 
and brachial arteries 1-2 cm distal to the carotid bulb, 2-3 cm distal to the femoral 
bifurcation, and 3-10 cm proximal to the antecubital fossa, respectively. Probe placement 
(distances and angles) and subject position (including limb-trunk angles) were recorded 
to ensure consistency between experimental sessions. B-mode images were optimized 
using ultrasound contrast controls which were consistent across experimental days for 
each individual subject [266].  
Doppler blood velocity tracings were obtained using an insonation angle of 60° 
from a region of interest centered between the arterial walls in order to capture peak 
blood velocity, which occurs in the center of the vessel due to laminar flow. The gates of 
the region of interest were set to a width just less than the diameter of the vessel in order 
to prevent capturing the vessel walls, which can create artifacts and thus inaccuracies in 
the velocity tracing. Pulse repetition Doppler frequency was set to 6.0-10.0 MHz, 
depending on the depth of the vessel of interest (higher frequency pulsed Doppler was 
used for more shallow arteries and vice versa). 
 
Customized wall-tracking analysis software.  Ultrasound data were collected at 20 
frames/sec using a video recording software (Camtasia Studio, TechSmith, Okemos, MI). 
Videos were later transferred to a computer operating a custom-designed edge-detection 
and wall tracking analysis software (DICOM, Perth, Australia). The software tracks 
vessel walls and peak blood velocity within a region of interest set by the investigator 
(Figure 3.4 – next page), providing frame-by-frame average diameter and peak blood 
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velocity values. Data can then be used to calculate blood flow and shear rate. For 
calculations, mean blood velocity is estimated as half peak blood velocity. Peak blood 
velocity is typically used as it can be captured more accurately than mean blood velocity. 
In order to accurately measure mean blood velocity, velocity across the entire width of 
the vessel must be captured without capturing the vessel walls or regions outside the 
walls. This is technically challenging, particularly in arteries that are constantly pulsing 
across the cardiac cycle. However, this estimation that mean blood velocity is equivalent 
to half peak blood velocity assumes that flow is perfectly laminar, which may or may not 
be true across all vessels and conditions (e.g., close to arterial bifurcations or when 
cardiac output is increased).   
 
 
Figure 3.4. Ultrasound 2D image of the brachial artery (top panel) and Doppler blood 
velocity (bottom panel) from one representative subject approximately 1 min following 
release of a 5-min arterial occlusion. Wall tracking software was used to quantify changes 
in vessel diameter (yellow lines) and peak blood velocity (yellow dots). 
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Applanation tonometry 
 Applanation tonometry was used to obtain arterial pressure tracings of the 
common carotid, common femoral, posterior tibial/dorsal pedal, brachial, and radial 
arteries for measurements of arterial stiffness.  
Applanation tonometry was developed in conjunction with Millar Instruments as a 
simple, non-invasive technique for accurately obtaining intra-arterial pressure [267]. The 
probes consist of Millar strain gauge pressure transducer mounting on the tip of a pencil-
like probe. To measure intra-arterial pressure, the artery is flattened (applanated) over the 
point of maximal pulsation between the probe and an underlying rigid structure, ideally 
bone. Flattening of the artery allows for even force distribution across the pressure-
sensing surface of the probe - a curved wall would distort the pressure tracing due to 
circumferential forces. When performed properly (as described below), tonometry 
pressure tracings are equivalent to those obtained with intra-arterial pressure transducers 
[267]. 
In studies which verified accuracy between applanation tonometry and intra-
arterial pressure, the authors identified criteria that must be followed in order to obtain 
accurate pressure tracings (summarized in Figure 3.5 – next page). First, movement of the 
probe must be minimized. The site of measurement on the subject must be immobilized 
and the investigator holding the probe must prevent movement of their hand. Second, 
hold-down force should be optimized to achieve adequate applanation of the artery, but 
should not be excessive as this could impact arterial pressure. Kelly et al. [267] reported 
that excessive hold-down pressure most commonly results in a gradual increase in 
diastolic pressure, a sharp negative deflection immediately preceding the next systolic 
upstroke, or sometimes inversion of the systolic peak. Others have confirmed that when 
the artery is applanated with appropriate hold-down pressure, there is no effect on arterial 
pressure and in the carotid artery, there is no effect on the baroreceptors [268]. Third, the 
probe should ideally be held perpendicular to the artery. Inappropriate angling of the 
probe, particularly in the same direction as blood flow (i.e., pointing distally) can 
underestimate systolic pressure.  
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Figure 3.5. Applanation tonometry tracings from the brachial artery, applanated over the 
medial condyle of the humerus. A) Tracings with optimized hold-down force with the 
probe held perpendicular to the artery. B) Tracings with excessive hold-down force 
demonstrating a sharp negative deflection preceding the systolic upstroke. C) Tracings 
demonstrating distortion of the pressure tracing when the probe is angled distally. 
 
 To account for differences in hold-down force, pressure waves are commonly 
calibrated to brachial diastolic and mean arterial pressures, obtained via brachial 
auscultation or oscillation [268,269]. Mean arterial and diastolic pressures are used based 
on the assumption that mean pressure does not change along the large conduit arteries 
and the observation that diastolic pressure is the same across the carotid and femoral 
arteries [268]. In contrast, systolic pressure is affected by the elastic properties of the 
arteries and so can be different between different conduit arteries.  
 
Flow-mediated dilation 
 The most commonly used test of conduit vessel endothelial function is brachial 
artery flow-mediated dilation (FMD). FMD has been shown to be highly correlated with 
CV morbidity and mortality [270-272] and to parallel endothelial function in the coronary 
arteries [273].  
FMD is quantified as the percent change in brachial artery diameter following a 
distal arterial occlusion, achieved by inflating a blood pressure cuff placed just distal to 
the elbow to 250mmHg for 5 min. Upon release of the arterial occlusion, blood flow 
rapidly increases due to the downstream metabolic vasodilation, increasing shear stress 
on the brachial artery. Shear stress, which is the mechanical fluid force of the blood 
exerted on the blood vessel walls, activates mechanically-gated calcium channels on the 
endothelium, stimulating synthesis and release of NO [274,275] and endothelial-derived 
hyperpolarizing factors (EDHFs) [276], resulting in vasodilation. Peak brachial artery 
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dilation typically occurs approximately 40 to 90 sec post-cuff release [277,278] (Figure 
3.6).  
FMD measurements were made in accordance with previously published 
guidelines [279]. Subjects lay supine with their right arm extended to 80-90° at heart 
level. An inflatable occlusion cuff was placed 0-2 cm distal to the antecubital fossa and 
inflated to 250mmHg for 5 min (E20 Rapid Cuff Inflater, D. E. Hokanson, Bellevue, 
WA). Brachial artery diameter and blood velocity were measured via Doppler 
ultrasonography for 1 min of baseline prior to cuff inflation and for 3 min following 
release of the cuff. Immediately following the test, ultrasound scans were analyzed using 
the wall-tracking software and FMD was calculated as the percent change in diameter 
from baseline to peak dilation post-occlusion. Using this software, 2.5% changes in FMD 
can be detected with an N of 8 and power of 80% [280]. In the event that the first FMD 
was considered non-physiological (i.e., the tissue moved during occlusion and did not 
return to the same position post-release), the test was repeated at least 20 min after the 
first FMD. Subjects remained supine during this rest period.  
 
 
Figure 3.6. Taken from Thijssen et al. [278] (no permission needed from this publisher 
for reuse in a dissertation). Schematic presentation of diameter and shear rate responses 
following release of the 5-min arterial occlusion. The grey area represents the area under 
the curve (AUC) shear rate response that is believed to be the main stimulus for eliciting 
the peak dilation. 
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Shear rate was calculated frame-by-frame from diameter and velocity 
measurements. The shear stimulus responsible for eliciting dilation was calculated as area 
under the curve above baseline shear rate from the time of release to peak dilation 
(SRAUC). FMD was then normalized for shear stimulus by dividing FMD by SRAUC, as 
described and validated previously [281,282].   
(1) Shear rate = 4 x mean blood velocity / diameter 
(2) Shear corrected FMD (%/SRAUC) =  FMD (%) / SRAUC x 103 
 
Endothelium-independent dilation.  When measuring endothelial-dependent dilation, it is 
important to also measure endothelium-independent dilation (EIVD). Doing so allows for 
effects on the endothelium versus the underlying smooth muscle to be teased apart. For 
example, if FMD increases across an intervention, but EIVD remains unchanged, we can 
conclude that the intervention specifically improved endothelial-dependent dilation. 
Conduit vessel EIVD is most commonly assessed using sublingual nitroglycerine, which 
produces a maximal dilation of the conduit arteries. In solution (i.e., in the blood), 
nitroglycerine is rapidly converted to NO, which can then diffuse directly to the vascular 
smooth muscle, bypassing the endothelium.  For the measurement of EIVD, brachial 
artery diameter was measured for 1 min of baseline and for another 10 min following 
administration of 0.4 mg of sublingual nitroglycerine (Nitrolingual; Sciele Pharma, 
Atlanta, GA). EIVD was calculated as both the peak diameter and the percent change in 
diameter from baseline to peak dilation post-nitroglycerine administration.  
 
Reactive hyperemia 
 Reactive hyperemia refers to the large transient increase in blood flow that occurs 
following a period of ischemia secondary to profound vasodilation of the 
microvasculature distal to the site of arterial occlusion. Vasodilation occurs due to a 
combination of metabolic vasodilators, including NO, prostaglandins, adenosine, and 
ADP [283-285], and myogenic responses [284]. Reactive hyperemia has most commonly 
been studied in the forearm, where blood flow to the limb can be occluded safely and 
easily for a period time, as done with the FMD protocol described above. Forearm post-
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occlusive reactive hyperemia (PORH) has been established as a predictor of risk of CV 
disease and mortality [286-288].  
A peak rise in blood flow is observed within a few seconds of release of the 
occlusion, which is thought to be representative of maximal vasodilator capacity of the 
microvasculature, and thus changes in peak PORH are thought to reflect structural 
remodeling of the resistance vessels [289,290]. The theory that peak PORH represents 
maximal vasodilator capacity was based on observations that handgrip exercise 
performed during the arterial occlusion, which augments the metabolic stimulus for 
vasodilation, elicits no further increase in peak reactive hyperemia [291,292]. Blood flow 
then remains elevated for an extended period of time following release of the cuff, which 
is dependent on the ability of the resistance vessels to continue to vasodilate in response 
to the metabolic stimulus. Following a 5-min forearm occlusion, blood flow typically 
remains elevated for 2-3 min following release of the occlusion (Figure 3.7 – next page).  
It is important to note that PORH is not considered to be the gold-standard 
method for assessing microvascular function, but it is one that is used commonly due to 
being non-invasive and relatively easy to measure. Intra-arterial infusion of vasoactive 
agents allow for much better isolation of endothelial-dependent (e.g., acetylcholine) and -
independent (e.g., sodium nitroprusside) vasodilation. However, this technique is 
invasive and requires a skilled physician to place the intra-arterial catheter. Additionally, 
structural changes in the microvasculature can be quantified more accurately using other 
methods, such as taking skin or muscle biopsies to quantify vascularization. Again, these 
techniques are invasive and so we chose not to perform them in the present investigation. 
We additionally wanted to use techniques that are used clinically or have clinical 
relevance in order to be comparable to other studies that have determined cardiovascular 
risk.   
In this dissertation, PORH was measured following 5-min arterial occlusion at the 
same time as FMD by averaging blood flow measurements from ultrasound tracings and 
arterial pressure data (from Nexfin beat-by-beat measurements) over each cardiac cycle 
(R to R wave). Forearm vascular conductance (FVC) was calculated as blood flow / mean 
arterial pressure and zero-hold interpolated to 5Hz. As blood flow is dependent on 
changes in mean arterial pressure, conductance is more representative of the degree of 
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Figure 3.7. Representative post-occlusive forearm reactive hyperemia response from one 
heat therapy subject. 
 
vasodilation/vasoconstriction in the downstream resistance vessels. Peak PORH was 
identified as the cardiac cycle with the highest FVC value. Area under the curve (AUC) 
PORH was calculated as the integral of FVC values minus baseline FVC until FVC had 
returned to baseline values (range ~90-150 sec following release of the occlusion). Peak 
PORH and AUC PORH provide different information regarding microvascular function 
(i.e., structural versus functional changes, respectively) and so were treated as separate 
variables.  
 
Measures of arterial stiffness 
 Stiffening of the conduit arteries occurs with healthy aging, beginning as young as 
adolescence [293,294], and with disease progression due to a combination of elastic fiber 
degeneration, increased collagen content, impaired endothelial function, and structural 
changes to the arteries, including vascular smooth muscle cell hypertrophy [295]. As 
such, arterial stiffness is also an independent risk factor for cardiovascular disease [296-
298]. Pathological arterial stiffening, as in stiffening to a greater extent than what would 
occur with healthy aging, is also often accompanied by atherosclerosis, left ventricular 
hypertrophy, and increased incidence of vascular events [299].  
A variety of measures have been developed to measure arterial stiffness in 
humans. As all measures look at slightly different properties of the arterial walls, it is 
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important to measure more than just one [300]. Furthermore, as the various arteries 
themselves have different properties (e.g. elastic vs. muscular) and are subjected to 
different shear profiles, it is also important to make measurements at more than just one 
artery, in order to obtain a more complete view of arterial stiffness changes [300]. For 
this dissertation, we chose to assess three different measures, all of which have been 
validated for their abilities to predict CV morbidity and mortality [296-298,301,302]: 
pulse wave velocity, dynamic arterial compliance, and β-stiffness index. Compliance and 
β -stiffness were measured at the common carotid artery (a more elastic artery) and the 
superficial femoral artery (a more muscular artery). Pulse wave velocity was measured 
across the aorta (elastic) and across the leg and arm (peripheral muscular arteries).  
 
Dynamic arterial compliance. Arterial compliance is defined as the change in arterial 
volume that occurs for a given change in pressure, and is a direct measure of the elastic 
properties of the arteries. It has been previously shown to decrease progressively with age 
[303] and is predictive of cardiovascular risk.  
 As changes in the cross-sectional area of a cylinder (i.e., a blood vessel) are 
equivalent to changes in volume, cross-sectional compliance is most commonly used for 
calculating arterial compliance. Additionally, changes in cross-sectional area are 
proportional to changes in circumference of the artery. As elasticity is dependent on the 
square of initial arterial diameter, compliance is usually presented relative to diastolic or 
mean diameter.  
In this dissertation, dynamic cross-sectional arterial compliance relative to mean 
diameter was measured at the common carotid and superficial femoral arteries and 
calculated as, 
 
(3) Cross-sectional compliance = [(ΔD/D) / ΔP ] * π(D/2)2 
 
Where, ΔD = change in diameter across one cardiac cycle from diastolic trough to 
systolic peak measured using ultrasonography, D = diameter averaged across each 
cardiac cycle, ΔP = pulse pressure (systolic = diastolic blood pressure), measured 
beat-by-beat using finger photoplethysmography (Nexfin device). 
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 Changes in arterial diameter and pressure were related to one another on a beat-
by-beat basis (i.e., dynamically) as averaged over at least 20 cardiac cycles.  
 
β-stiffness index. While arterial compliance is a direct measure of arterial elasticity, there 
is a non-linear relationship between pressure and diameter and so compliance is heavily 
dependent on changes in arterial pressure [304]. With interventions that may alter blood 
pressure (e.g., heat therapy), it is impossible to distinguish whether changes in 
compliance are due to changes in arterial elasticity or pressure. β-stiffness index is also a 
direct measure of arterial stiffness, but is much less dependent of blood pressure. As 
such, it has become much more commonly used clinically [305]. It has also been 
validated for its ability to predict future cardiovascular morbidity and mortality 
[306,307]. As it is been more-widely measured than compliance, reference values have 
been determined. In young, healthy subjects, β-stiffness index is typically ~5±2 and it 
increases linearly with healthy aging up to ~8 by age 70 [308]. β-stiffness index is 
calculated as,  
(4)  β-stiffness index = Ln (SBP/DBP)*D/ΔD 
 
Where, SBP = systolic blood pressure, DBP = diastolic blood pressure, ΔD = change in 
diameter across one cardiac cycle from diastolic trough to systolic peak measured 
using ultrasonography, and D = diameter averaged across each cardiac cycle. 
 
Pulse wave velocity.  Pulse wave velocity (PWV) is an indirect measure of arterial 
stiffness, but one which has been shown to have greater predictive value than other 
available methods [296,302]. While compliance and β-stiffness index offer more direct 
measures, they provide characteristics of the arteries only at a specific point where the 
measurement is taken [304]. As the properties of different arterial segments can vary, 
indices of stiffness across entire arteries may provide a more complete view of arterial 
health.  
PWV is measured as the time delay between the arrival of the pressure wave at 
two arteries of interest (i.e., the systolic upstroke on tonometry tracings) divided by the 
distance traveled (Figure 3.8 – page 51). Mathematically, PWV is equivalent to arterial 
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impedance, as impedance = PWV x density of the blood, which is uniform within any 
given individual [309]. Arterial impedance is effectively the resistance the artery exhibits 
against pulsatile pressure and blood flow. It is directly proportional to Young's modulus 
of stiffness, the theoretical pressure required for maximal elongation.  
Most commonly, pulse wave velocity is measured at the carotid and femoral 
arteries, i.e., across the aorta. Aortic pulse wave velocity is considered to be the gold-
standard method for measuring arterial stiffness due to the relative ease of making 
measurements compared to other methods and due to its value in predicting 
cardiovascular morbidity and mortality [310-312].  
There are two approaches for determining distance travelled. One uses the linear 
distance between the two probes, and the other is the subtracted distance, the difference 
between the sternal notch of the femoral artery minus the distance between the sternal 
notch and the carotid artery. A study which compared measured distances between the 
carotid and femoral arteries to actual arterial distances determined with magnetic 
resonance imaging found that 80% of the time, the linear distance was an accurate 
estimate of the real distance traveled, whereas the subtracted distance underestimated the 
actual distance [313]. Therefore, linear distance was used in this dissertation. Normal 
values for aortic pulse wave velocity in young, healthy individuals ranges from 6.0-10.0 
m/s [314], and values >13.0 m/s are associated with significantly increased 
cardiovascular disease risk [302].  
In addition to being measured across the aorta, pulse wave velocity can be 
measured across any segment of conduit vessels where tonometry pressure tracings can 
be obtained. Some disease states are characterized by greater dysfunction in peripheral 
arteries compared to central arteries (e.g., peripheral artery disease), and so there has 
been interest in measuring stiffness in peripheral arteries, even though stiffness in the 
more muscular arteries tends to not be as predictive as that in the central arteries across 
the general population [315]. Leg and arm pulse wave velocity are most common, 
measured from the femoral to dorsal pedal or posterior tibial arteries and from the 
brachial to radial arteries, respectively. Arterial stiffness increases from the central aorta 
down through the peripheral arteries, and so normal values in healthy young individuals 
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range from 8.4 to 1.2 m/s for arm pulse wave velocity and 9.2 to 1.05 m/s for leg pulse 
wave velocity [314].  
 
 
Figure 3.8. Concurrent applanation tonometry tracings taken from the common femoral 
and dorsal pedal arteries. Pulse wave velocity is calculated as the time delay between the 
systolic upstrokes at each artery divided by the linear distance between the probes. 
Femoral-ankle pulse wave velocity measured from this tracing was 9.3 m/sec, which falls 
within what is considered to be a healthy range [314]. 
 
 In this dissertation, we measured leg and arm pulse wave velocity in addition to 
aortic primarily to be able to compare to spinal cord injured (SCI) subjects. We believed 
that the paralyzed limbs may respond differently to heat therapy due to loss of 
sympathetic innervation and due to much greater baseline impairment. Chapter VIII 
describes pilot work performed in SCI subjects. Leg and arm pulse wave velocity data 
from able-bodied young healthy subjects is included in that chapter for comparison. We 
hypothesized that we would observe no difference in leg or arm pulse wave velocity in 
able-bodied subjects; whereas, we would observe a robust improvement in leg pulse 
wave velocity in SCI subjects. Consistent with this hypothesis is the observation that 16 
weeks of exercise training, which significantly reduced aortic pulse wave velocity, had no 
effect on leg pulse wave velocity [316].  
 
Conduit vessel structure 
 In addition, we quantified structural changes in the arteries, namely vessel 
diameter, resting blood flow, and intima media thickness (IMT; also referred to as "wall 
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thickness"). IMT is another independent risk factor for cardiovascular disease as it is 
highly associated with the progression of atherosclerosis [297,301]. Thickening of the 
intimal lining of the arteries (the innermost layer consisting of endothelial cells, 
connective and elastic tissue, and sometimes other adhered cells) thickens with primary 
aging due to accumulation of collagen and adherence of white blood cells, primarily 
monocytes. Under pathogenic/pro-atherosclerotic conditions, monocytes that have 
differentiated into macrophages can accumulate cholesterol and become foam cells, 
resulting in atherosclerotic plaques. As these plaques grow, IMT becomes greater and 
greater. Although our subjects were young and healthy, some wall thickening can occur 
even in young subjects as a result of a sedentary lifestyle [310].  
To measure IMT, the common carotid artery was imaged 1-2cm distal to the 
carotid bulb in three planes: anterior, lateral, and posterior. The superficial femoral artery 
was imaged 2-3 cm distal to the femoral bifurcation in two planes: anterior and lateral.  
Clearly demarcated intimal-medial boundaries were obtained while focusing on the far 
wall. Ultrasound contrast settings remained constant across all experimental sessions 
[317]. Images were frozen in diastole, enlarged, and calipers were used to make three 
repeat measurements of the wall thickness from the lumen-intima interface to the media-
adventitia interface (Figure 3.9 – next page). All measurements (3 from each angle) were 
averaged.  
 When studying interventions which may change diameter and/or studying groups 
which may have different diameters (e.g., able-bodied versus spinal cord injured 
individuals), wall-to-lumen (W/L) ratio can be calculated to normalize for differences in 
diameter across groups and/or interventions [318]. For these measurements, average 
diameter was analyzed using the wall-tracking software (DICOM) over a period of 60 to 
90 sec immediately following wall thickness measurements.  
 
(5) W/L = wall thickness (mm) / average diameter (mm) 
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Figure 3.9. B-mode ultrasound image focusing on the distal wall of the common carotid 
artery, imaged from the posterior angle. A region of interest was magnified and calipers 
within the Terason software were used to measure from the lumen-intima interface to the 
media-adventitia interface in triplicate. 
 
 
CUTANEOUS MICROVASCULAR FUNCTION  
 There is now a wealth of evidence to suggest that cardiovascular disease begins in 
the microvasculature. In a variety of cardiovascular-related disease states, impairments in 
the microvasculature can be detected prior to that in the large conduit vessels. As such, 
any comprehensive assessment of vascular health must include measurement of 
microvascular function. Techniques now exist to measure blood flow to almost all 
regions of the body, and, in some, vasoactive stimuli can be delivered (e.g., 
pharmacological agents, ischemia, hypoxia) in order to assess the reactivity of the 
microvasculature, or microvascular function.  
In humans, the cutaneous circulation offers an ideal place to study microvascular 
function. Due to its accessibility, blood flow can be easily quantified using techniques 
such as laser-Doppler flowmetry and the underlying molecular mechanisms can be 
studied easily and relatively non-invasively using cutaneous microdialysis. 
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Microdialysis 
 The microdialysis technique allows for vasoactive substances to be delivered 
locally to a small area of skin with minimal systemic effects, thereby elucidating the 
molecular mechanisms behind vasodilator responses in vivo. Substances released from 
the tissue can also be collected from the distal end of the microdialysis fibers in the 
dialysate, although this was not performed as part of this dissertation. Microdialysis 
fibers consist of a hollow tube with a semi-permeable membrane in the center (Figure 
3.10). Vasoactive substances dissolved in a vehicle (most commonly Lactated Ringer's 
solution) can be infused through the fiber and will be delivered to an area of tissue 
approximately 1cm in diameter around the semi-permeable membrane.  
 Placement of microdialysis fibers is performed using aseptic technique. In this 
dissertation, fibers were placed in the dermal layer of skin on the ventral side of the non-
dominant forearm, although other locations can be used (the calf is also common). Before 
placement, a tourniquet should be used to identify superficial veins to be avoided in order 
to ensure fibers are placed within the microvasculature. Fibers are typically inserted at 
least 5cm apart by first introducing a 25-g needle ~1mm below the surface of the skin, 
with entry and exit points ~2.5cm apart (Figure 3.11 – next page). As pharmacological 
agents infused through the fibers typically reach an area of skin ~1 cm in diameter around 
the fiber, this placement ensures little to no interaction between drugs infused at different 
sites. Once the needle is placed, fibers are then threaded through the lumen of the needle 
 
 
Figure 3.10. Depiction of cutaneous microdialysis. Artwork by Bob Lorenz. 
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and the needle is removed leaving just the fiber in place under the skin, with the semi-
permeable membrane centered between entry and exit points. Fibers are typically infused 
with Lactated Ringer's solution at a rate of 2.0 µl/min (CMA 102 Syringe Pump; CMA 
Microdialysis AB, Solna, Sweden) until the start of study drugs. Since the needle trauma 
causes inflammation and a transient substantial increase in skin blood flow, a period of at 
least 60-90 min should be allowed prior to the start of experimental protocols.  
 
 
Figure 3.11. Placement of four intradermal microdialysis fibers in the ventral forearm 
using a 25-gauge needle. Photo by Brett Wong.  
 
Cutaneous thermal hyperemia 
 Using cutaneous microdialysis, the molecular mechanisms underlying 
vasodilation and vasoconstriction to a variety of stimuli have been extensively explored. 
Perhaps most widely assessed has been the vasodilator response to locally applied heat, 
known as "thermal hyperemia," in which the skin is typically heated to 42°C at a rate of 
0.1°C/sec. Local heating produces a biphasic vasodilator response consisting of an initial 
peak that occurs within ~3-5min into heating and a prolonged secondary plateau phases 
which stabilizes approximately 30-40 min into heating (Figure 3.13 – page 57). A brief 
nadir occurs between the two phases.  
Cutaneous thermal hyperemia has been shown to be impaired under a variety of 
disease states, including coronary artery disease [319], kidney disease [320], primary 
aging [321], and hypertension [322], as summarized in Figure 3.12 (next page). As these 
impairments mirror declines in microvascular function in other microvascular beds, the 
cutaneous microcirculation has often been proposed to be representative of globalized 
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microvascular health [323-325]. As a result, many studies have aimed at discovering the 
underlying mechanisms that contribute to the response. So doing helps to establish 
impairments in specific molecular pathways that are present in disease states, which then 
helps to identify potential targets for pharmacological and/or lifestyle treatments. 
 
Figure 3.12. Normalized plateau cutaneous vascular conductance across a variety of 
disease conditions. In general, the disease states which are characterized by the greatest 
impairments in cardiovascular function also exhibit the greatest impairments in cutaneous 
microvascular function. Data adapted from Van Duijnhoven et al. [2], Fujii et al. [326], 
Minson et al. [321], Kruger et al. [320], Hodges et al. [327], Smith et al. [322], Boignard 
et al. [328], Stewart et al. [329], Colberg et al. [330], and Agarwal et al. [319]. 
 
The initial peak is predominantly mediated by a sensory nerve axon reflex [331], 
most likely initiated via transient receptor potential vanilloid type-1 (TRPV-1) channels 
located on the sensory nerves [332]. The sensory nerves are thought to release calcitonin 
gene-related peptide and substance P, although this has not been confirmed 
experimentally [333].  
The plateau phase is approximately 60% dependent on nitric oxide (NO) 
[331,334]. Several other factors, including adenosine receptors [335], TRPV-1 receptors 
[332], and reactive oxygen species [336], have been shown to play a role, primarily 
through altering bioavailable NO. The cyclooxygenase pathway, a predominant 
vasodilatory pathway in response to other stimuli, does not appear to be involved [337]. 
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For a long time, the remaining ~40% of dilation was unexplained. However, in 2012 
[338], we showed that almost the entirety of the remaining vasodilation could be 
abolished by blocking the actions of endothelial-derived hyperpolarizing factors 
(EDHFs), a class of vasodilators that cause smooth muscle hyperpolarization and 
therefore relaxation primarily by stimulating calcium-activated potassium (KCa) channels 
(Figure 3.13). In this same study, we went on to elucidate which types of EDHFs may be 
involved. Of the various EDHFs, epoxyeicosatrienoic acids (EETs) have been most 
studied and have been shown to elicit vasodilation in humans in other vascular beds 
[276,339,340]. We showed that approximately half of the EDHF component was 
attributable to EETs [338].  
Despite how well the molecular underpinnings of this response have been teased 
out, some limitations do exist. For example, in young, healthy subjects, the plateau 
commonly reaches ~90–95% of maximal cutaneous vascular conductance (CVC), 
making it difficult to evaluate the effects of potentially beneficial interventions due to a 
 
Figure 3.13. Taken from Brunt & Minson, 2012 [338] with permission. A representative 
tracing from one subject during local heating of the skin at four microdialysis sites 
receiving: 1) Lactated Ringer's (control), 2) Tetraethylammonium (TEA), a calcium-
activated potassium (KCa) channel blocker, 3) NG-nitro-L-arginine methyl ester (L-
NAME), a nitric oxide synthase inhibitor, and 4) combined TEA + L-NAME. Data are 
presented as a percentage of maximal cutaneous vascular conductance (%CVCmax), as 
determined by infusion of 56mM sodium nitroprusside and max heating to 44°C. 
Combined blockade of KCa channels and nitric oxide synthase with TEA + L-NAME 
abolished the majority of thermal hyperemia and plateau CVC at this site was not 
different from baseline CVC. 
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ceiling effect. Furthermore, as the plateau is substantially dependent on both NO and 
EDHF, it is not possible to attribute impairments and/or improvements to either pathway 
without the use of pharmacological techniques, such as microdialysis. We therefore 
developed a new protocol for local heating in which the skin was rapidly heated to just  
39°C [341]. Using this protocol, we were successfully able to isolate the NO component 
of the response, creating a test of microvascular function that is more clinically relevant 
as vascular dysfunction in the majority of disease states is characterized by impaired NO. 
Additionally, plateau CVC reaches ~40-50% of max, allowing for the assessment of 
interventions, such as heat therapy, to improve the response (Figure 3.14).  For these 
reasons, and those described above in this section, we selected local heating to 39°C as 
the best approach for assessing the effects of heat therapy on microvascular function.  
 
 
Figure 3.14. Adapted from Choi et al. 2014 [341]. Representative response to local 
heating to 39°C at a rate of 0.1°C/sec at microdialysis sites receiving 1) Lactated Ringer's 
(Control), and 2) NG-nitro-L-arginine methyl ester (L-NAME), a non-specific nitric 
oxide synthase inhibitor. This local heating protocol results in vasodilation which is 
~80% dependent on nitric oxide and which reaches a plateau skin blood flow of ~40-50% 
of maximal. 
 
Pharmacological Interventions 
 In this dissertation, local heating to 39°C was assessed at three microdialysis sites 
randomly assigned to be infused with: 1) Lactated Ringer's solution (sham site), 2) 10mM 
Nω-nitro-L-arginine (L-NNA), or 3) 10µM Tempol. L-NNA is an analog of L-arginine, 
which non-specifically inhibits NO synthase. Inhibiting NOS, and therefore NO 
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production, allows us to investigate the contribution of NO to the overall vasodilator 
response and whether NO-dependent dilation is improved following heat therapy. 
Tempol is a superoxide dismutase mimetic. In the presence of Tempol, the free radical 
superoxide is converted to oxygen of hydrogen peroxide. Superoxide, which normally 
combines with NO to form peroxynitrite, is a primary contributor to oxidative stress and 
reduced NO bioavailability. Therefore, infusion of Tempol allows us to determine how 
oxidative stress limits the vasodilator response and how heat therapy may reduce 
oxidative stress. Drug concentrations were selected as the minimum doses for eliciting 
maximal inhibition, based on previous studies [336,342].  
All drugs obtained from manufactures at the highest chemical purity available. 
Solutions and dilutions to the appropriate concentration were made the day of the study 
by the primary investigator with sterile Lactated Ringer's solution in a fashion that yields 
sterile perfusates. Furthermore, perfusates were filtered through a 0.2µm filter prior to 
administration to the human subjects. An investigational new drug approval was obtained 
through the U.S. Food & Drug Administration in order to use these drugs in these studies 
(IND# 124,303; PI: Minson CT).  
 
Laser-Doppler flowmetry 
 As previously mentioned, skin blood flow can be easily quantified using laser-
Doppler flowmetry. These probes sit flush with the skin and can be seated in the center of 
local heaters (Figure 3.15 – next page). Laser-Doppler probes emit a single beam of 
infrared light which penetrates the skin and reflects off the red blood cells. Returning 
light is received by collecting fibers on the probe. The intensity of light received gives a 
measure of concentration of red blood cells, and the velocity of the red blood cells is 
determined using a Doppler shift analysis. Red blood cell flux is then calculated as the 
product of concentration and velocity.  
Flux is an arbitrary measure (versus absolute blood flow) and is dependent on 
probe placement, as the density of blood vessels will vary substantially across the skin. 
Therefore, it is important to normalize all flux measurements. Most commonly, flux is 
normalized to maximal flux, obtained by locally heating the skin to >43°C and/or 
microdialysis infusion of high doses of sodium nitroprusside, an endothelium-
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independent nitric oxide donor. In this dissertation, we used a combination of local 
heating to 43.5°C and infusion of 56mM sodium nitroprusside. Flux may also be 
presented as a percent change from baseline, although this approach is questionable when 
performing microdialysis studies as many pharmacological agents alter baseline. Since 
flux is dependent on changes in blood pressure, data are often converted to cutaneous 
vascular conductance (CVC = flux / mean arterial pressure) and then presented as a 
percentage of maximal CVC. CVC more closely reflects the vasodilator/constrictor state 
of the blood vessels.  
 
Figure 3.15. A subject instrumented with four laser-Doppler probes (MoorLab; Moor 
Instruments, Axminster, UK) seated in the center of local heaters (Skin Heater/ 
Temperature Monitor SH02; Moor Instruments) which cover ~0.78cm2 of tissue. Photo 
by Vienna Brunt. 
 
 
VENOUS BLOOD COLLECTION & ANALYSIS  
 During the first and last water immersion sessions, blood was collected from an 
antecubital vein prior to entering the hot tub and 1h after exiting the hot tub. Collection at 
1h after exiting the hot tub was chosen as pilot studies indicated this time frame was ideal 
for detecting peak changes in factors in the serum and peak increases in HSP content in 
peripheral blood mononuclear cells (PBMCs). Pilot data is presented in Chapter IV (page 
73).  
Venous blood was collected into three types of vacutainers: 1) EDTA 
(anticoagulant)-containing tubes for the measurement of hemoglobin and hematocrit, 2) 
serum-separating tubes (for cell culture experiments and other analyses described in 
Chapter VII), and 3) Ficoll Hypaque-containing cell preparation tubes with sodium citrate 
(CPT Vacutainer; BD, Franklin Lakes, NJ) for the separation of mononuclear cells from 
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whole blood. Whole blood samples in EDTA tubes were immediately analyzed in 
triplicate for hemoglobin (Hb 201 Hemoglobin Analyzer; HemoCue, Brea, CA) and 
hematocrit (microcapillary centrifugation). Serum-separating and CPT tubes were 
centrifuged 30 min post-collection, and serum or plasma containing PBMCs were 
separated, aliquoted, and stored at –80°C until later analysis.  
 
Blood volume  
 Plasma volume expansion is a hallmark of exercise heat acclimation [343]. It has 
been shown to also occur in animals following chronic heat exposure [172], but has not 
yet been measured in humans undergoing passive heat acclimation.  
Red cell and plasma volume were measured in a subset of subjects (N=4 in the 
heat therapy group and N=8 in the sham group) prior to the first hot tub session and 36-
48h after the last hot tub session using the optimized carbon monoxide rebreathing 
method developed by Schmidt & Prommer [344]. Due to the technical challenges of 
performing this technique, we were only able to begin using it part way through data 
collection (equipment had to be shipped from Germany and a technician had to come out 
to train us on the technique). Unfortunately, due to timing of when subjects in each of the 
groups began the 8-week intervention, this resulted in measurements being obtained in 
uneven numbers of subjects in each group. 
Subjects reported to the laboratory having abstained from food for at least 4h, 
caffeine and alcohol for at least 12h, and exercise and any medications, vitamins, or 
supplements for 24 h. Subjects provided a first-morning urine sample to confirm 
euhydration via urine specific gravity <1.02 (refractometer). If USG was >1.02, subjects 
drank 5ml/kg of water at least 30 min before blood volume measurements were obtained.  
Subjects rested seated for >20 min while an intravenous catheter was placed in an 
antecubital vein. A baseline venous blood sample was collected into an EDTA-containing 
vacutainer (BD, Franklin Lakes, NJ) and baseline end-tidal carbon monoxide (CO) was 
measured using a CO monitor (Dräger Pac 3500; Dräger, Lübeck, Germany).  
Red cell volume was then measured using the CO-rebreathing method developed by 
Schmidt & Prommer [344]. Briefly, at the end of a maximal exhalation, subjects fully 
inhaled a mixture of CO and oxygen (O2) through the spirometer device shown in Figure 
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3.16. A syringe (D) was pre-filled with 100% CO in a volume equivalent to 1ml/kg of the 
subject's body weight. A 3L anesthetic bag (I) was pre-filled with 100% O2 to a volume 
of approximately 2.5L (not necessary for it to be exact). After full inhalation, subjects 
held their breath for 10 seconds and then rebreathed through the device (with the syringe 
now closed off) for another minute and fifty seconds. At the end of the rebreathing 
period, subjects maximally exhaled and the air was captured in the anesthetic bag by 
closing the main two-way valve (C). End-tidal CO was again measured 2 min after 
subjects completed the rebreathing period (4 min after receiving the bolus of CO), and 
another venous blood sample was collected 5 min after subjects completed the 
rebreathing period (7 min after receiving the bolus of CO). HbCO in venous blood is 
equilibrated with arterial blood by this time [344]. CO concentration of the exhaled air in 
the bag was measured, and the volume of air in the bag was measured using a 3L 
calibration syringe (Hans Rudolph, Inc., Shawnee, KS). Baseline and post-CO blood 
samples were analyzed in triplicate for CO bound to hemoglobin (HbCO), O2 bound to 
hemoglobin (O2Hb), and total hemoglobin (Hb) (OSM3 Blood Gas Analyzer; 
Radiometer, Copenhagen, Denmark). Hematocrit was measured in triplicate by 
microcapillary tube centrifugation.  
 
Figure 3.16. Schematic of the carbon monoxide (CO)-rebreathing spirometer device, 
taken from Schmidt & Prommer [344] with permission. A: tube for filling bag with 
oxygen; B: oxygen port valve (closed during test); C: valve for oxygen reservoir (open 
during test); D: CO syringe; E: adapter to connect mouthpiece; F: anti-microbial filter 
and soda-lime to absorb carbon dioxide; G: connector to glass spirometer; H: 
mouthpiece; I: anesthetic bag filled with 100% oxygen. 
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Total hemoglobin mass (t-Hb-mass) was calculated using the below equations. 
Red cell volume was calculated from t-Hb-mass using the ratio of Hb concentration to 
hematocrit. Total blood volume and plasma volume were calculated from red cell mass 
using hematocrit. Two correction factors were applied to hematocrit values. A factor of 
0.96 was applied to account for plasma trapped between red cells as a result of 
centrifugation [345]. A factor of 0.91 was applied to account for differences in hematocrit 
in blood sampled from the venous periphery compared to whole-body hematocrit [346].  
 
(6) t-Hb-mass = K x MCO x 100 x (ΔHbCO% x 1.39)-1  
 
Where, ΔHbCO% = the difference in venous blood HbCO between baseline and post-CO 
administration   
 1.39 = Hüfner's number (ml CO x g Hb-1) 
 K = current barometric pressure x 760
-1
 x [1 + (0.003661 x current temperature)]
-1
 
 MCO = COadm - (COsys (at time of disconnection) + COexhaled (at 5 min)) 
COadm = volume of CO administered using syringe (equal to 1ml/kg body 
weight)  
COsys = concentration of CO in the bag x (bag volume + estimated lung residual 
volume) 
COexhaled = end-tidal CO concentration (change from baseline to post-CO 
administration) x estimated alveolar ventilation x time since delivery of 
bolus (i.e. 5 min) 
 Estimated residual volume (L) = (0.0275 x age) + (0.0189 x height) - 2.6139 
 Estimated alveolar ventilation (L) = (0.075 x height) - 7.75 
 
CELL CULTURE & IN VITRO TECHNIQUES  
 In addition to demonstrating functional vascular adaptations in human subjects are 
conferred with long-term heat therapy, a major goal of this dissertation was to identify 
some of the molecular mechanisms that potentiate functional improvements. While direct 
(acute) effects of HSPs have been extensively demonstrated, and intracellular genomic 
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changes in animal models of heat acclimation have been well-studied, the changes in 
these pathways that link back to changes in vascular function have not yet been 
elucidated, and these changes have not been investigated in humans.  
Furthermore, the majority of models in cells and animals have utilized what 
would be considered 'extreme' stressors in humans. For example, changes in protein 
abundance associated with heat shock to >42°C has been well-studied, but very few 
studies have investigated effects to more mild levels of heat stress that would match 
temperatures commonly reached by humans.  
Therefore, we utilized cell culture of human endothelial cells paired with 
collection of human sera and primary cells to elucidate the changes in the molecular 
pathways associated with our specific model of heat acclimation. In order to keep to 
techniques that could be performed feasibly for this dissertation, endothelial cells for 
culture were purchased and treated (as described below) to simulate physiological heat 
acclimation. A better approach would have been to collect primary endothelial cells from 
our human subject undergoing heat therapy; however, the techniques available to do this 
in humans result in very small yields of endothelial cells such that is it challenging to 
investigate changes in protein content and it is impossible to investigate stimulated 
responses (e.g., changes in protein activity). For all experiments, we focused on the 
molecular pathways that are associated with vascular function (i.e., the NO pathway, 
oxidative stress, and inflammation).  
 
We performed three types of experiments:  
 
1) We investigated changes in protein content in human umbilical vein endothelial cells 
(HUVECs) following 24h of incubation at 39°C. This temperature was matched to the 
rectal temperatures obtained by human subjects participating in heat therapy. An 
incubation period of 24h was selected to represent a chronic time frame in terms of 
the lifespan of the cells. In preliminary studies, we demonstrated that the magnitude 
of HSP induction was similar following 24h at 39°C (compared to shorter durations) 
to HSPs measured in primary mononuclear cells collected from human subjects, a cell 
line which can be isolated from venous blood, which is exposed to the same 
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temperature conditions as endothelial cells, and which has been shown to exhibit an 
HSP stress response to exercise heat stress [114].  
2) We investigated changes in protein content in HUVECs exposed to human sera 
collected from human subjects pre- and 1h post- the first session of heat therapy 
(acute response) and pre- and 1h post- the last session of heat therapy at 8wks 
(chronic response). Serum at 8wks was collected 24-48h after the penultimate heat 
therapy session. As demonstrated in animal models, heat acclimation results in 
widespread changes in gene activation and protein expression in a variety of tissues. 
Many of these changes include upregulation (or downregulation) of proteins that can 
traverse the cell membranes and enter the circulation (e.g., cytokines), thereby 
influencing endothelial cells1.  
3) We investigated the effects of heat acclimation on serum angiogenic balance, utilizing 
an endothelial tubule formation assay in which HUVECs were exposed to sera from 
human subjects collected at the four time points described above. Performing this 
assay allowed us to demonstrate the downstream effects of heat therapy on cellular 
processes, rather than just demonstrating changes in protein content.  
 
Specific techniques were performed as follows:  
 
Cell culture experiments 
 Primary human umbilical vein endothelial cells (HUVECs) were purchased from 
ATCC. Cells were cultured in 75 cm2 culture flasks under standard conditions (37°C, 5% 
CO2, 20% O2) in vascular cell basal medium that was supplemented with an endothelial 
growth kit containing growth factors, nutrients, and fetal bovine serum ("complete 
media"). Cells were grown until ~80% confluence and then passaged. For passaging, 
cells were washed in warm phosphate buffered saline (PBS), lifted from the flask with an 
enzymatic dissociation buffer (TrypLE Express, Gibco, Gaithersburg, MD), and 
                                                            
1 Besides direct heat and circulating factors, endothelial cells in vivo in our human subjects were 
also exposed to intermittent increases in shear stress. The effects of fluid shear stress on cultured 
endothelial cells have been well studied by others (as reviewed in Chapter 2) and so we chose not 
to repeat those experiments for this dissertation. 
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resuspended in complete media before being split between 2-3 new flasks. Cells were 
used for experiments after being passaged 3-4 times.  
For direct heat and serum exposure experiments, cells were plated in 6-well cell 
culture plates and incubated under standard conditions until ~40% confluence. Cells were 
then serum starved for 4h by replacing complete media with 1ml per well raw media (no 
endothelial growth kit). This step synchronizes the cell proliferation phase across all 
plates. After serum starve, media in plates used for direct heating experiments was 
replaced with 1ml complete media and plates were incubated at 39°C or 37°C (control) 
for 24h. For plates used for serum exposure experiments, 100µl human sera were added 
to each well and plates were incubated under standard conditions for 24h. Sera collected 
from human subjects in just the heat therapy group at each of the 4 time points were used 
(0wks preHT, 0wks postHT, 8wks preHT, 8wks postHT). Each sample was introduced to 
3 wells of cells, which were combined at collection.  
 For each condition (temperature or serum sample), samples from all 3 wells were 
combined. Cells were washed with warm PBS, lifted with TrypLE, and collected into 
sterile cryotubes. Cells were pelleted via centrifugation and washed again with PBS.  Cell 
pellets were combined with radioimmunoprecipitation assay buffer (RIPA) plus protease 
inhibitor and lysed via sonication.  
 
Peripheral blood mononuclear cell isolation  
 Venous blood was collected into Ficoll-Hypaque containing vacutainers (BD 
Vacutainer CPT Cell Preparation Tube; Becton Dickinson, Franklin Lakes, NJ) 
immediately prior to and 1h following the first and last hot tub sessions (4 time points). 
PBMCs were isolated in vacutainers by centrifugation (3,000rpm for 15 min at room 
temperature). PBMCs suspended in plasma were separated and stored frozen at –80°C 
until analysis. Prior to analysis, thawed PBMCs were separated from plasma by 
centrifugation and washed with PBS four times. Cell pellets were then combined with 
RIPA buffer plus protease inhibitor and lysed via sonication. Due to insufficient cell 
lysing in some samples, soluble protein was separated from any insoluble particles and 
transferred to clean cryotubes before protein analysis.  
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Western blotting  
 The concentration of total protein in HUVEC and PBMC lysates was quantified 
using a Bradford dye-binding protein assay (Bio-Rad Protein Assay; Bio-Rad, Hercules, 
CA). Samples were diluted with DI water to achieve a concentration of 20-50ug total 
protein in 20µl, and 4µl 2mM DTT + 2µl 4X LDS sample buffer (NuPAGE®, Invitrogen, 
Carlsbad, CA) was added to each sample. After being heated at 80°C for 20 min to 
facilitate unfolding of proteins, samples were loaded into each well of 4-20% SDS 
polyacrylamide separating gels (Life Technologies, Grand Island, NY) and separated by 
electrophoresis at 200V in MOPS or MES SDS running buffer (NuPage®). Proteins were 
then transferred onto nitrocellulose membranes (Bio-Rad, Hercules, CA) and Ponceau-
stained to access transfer across each gel. The images of the Ponceau-stained membranes 
were digitized using a flatbed scanner.  
 Nitrocellulose membranes were incubated for 1h in Odyssey Blocking Buffer (LI-
COR Biosciences, Lincoln, NE) and then incubated overnight at 4°C in blocking buffer 
containing primary antibodies (detailed below). Membranes were then washed and 
incubated with the appropriate secondary antibodies (LI-COR Biosciences) for 1h at 
room temperature. The fluorescent bands were digitized using a LI-COR Odyssey 
infrared imaging system (LI-COR Biosciences). Digitized images were quantified using 
LI-COR Image StudioTM software. Primary antibodies for one protein at a time were used 
and antibodies were stripped using NewBlotTM Nitro Stripping Buffer (LI-COR 
Biosciences) in between probing for other proteins of interest. For direct heating and 
serum exposure experiments, primary antibodies used were: 1) anti-endothelial NO 
synthase (eNOS)  (1:1,000; Cell Signaling Technology, Danvers, MA) 2) anti-superoxide 
dismutase-2 (MnSOD/SOD2) (1:1,000; Sigma-Aldrich, St. Louis, MO) 3) anti-Hsp90 
[S88] (1:200; Abcam, Cambridge, MA) and 4) anti-Hsp70 [BRM-22] (1:5,000; Abcam), 
and 5) anti-vinculin (loading control; 1:1,000; Cell Signaling Technology). For PBMCs, 
primary antibodies used were: 1) anti-Hsp70 [BRM-22] (1:5,000; Abcam) 2) anti-Hsp90 
[S88] (1:200; Abcam), or 3) anti- β actin (loading control; 1:1,000; Cell Signaling 
Technology). 
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Superoxide production assay 
In order to determine whether direct heat and exposure to serum from heat 
acclimated subjects reduces superoxide production, we used a cellular superoxide 
detection assay in live HUVECs (Cellular Superoxide Detection Assay Kit; Abcam). 
Since superoxide is generally only present in cells transiently (it is rapidly either reduced 
to hydrogen peroxide and then water or combined with NO to form peroxynitrite), assays 
must detect real-time superoxide production. The superoxide detection stain we used is 
cell permeable and reacts rapidly and specifically with superoxide, generating an orange 
fluorescent product.  
In separate experiments from the ones described above, HUVECs were plated in 
96-well culture plates at a concentration of 2 x 104 cells per well and exposed to the 
direct heat or serum exposure conditions as described in triplicate. After 24h, media was 
replaced with 20µl of 1µM superoxide detection stain diluted in either complete (for 
direct heating cells) or raw (for serum exposure cells) media.  Cells were incubated for 1h 
under the same conditions as before (37 or 39°C, or 37°C with 10% serum). Additional 
wells were left untreated (in complete media) and unstained (blank) or were treated with 
20µl of 500µM pyocyanin (reactive oxygen species inducer), which served as a positive 
control. Cell fluorescence was determined with a phase-contrasted fluorescent 
microscope with Cy3 filter at 10X optical zoom (Axio Observer.D1; Zeiss, Oberkochen, 
Germany). Total cell fluorescence per frame was determined using ImageJ analysis 
software (National Institutes of Health; Bethesda, MD). Total fluorescence of blank wells 
was subtracted from treated wells to obtain values of corrected total cell fluorescence and 
values from triplicate were averaged.  
 
Angiogenesis assay   
 An endothelial tubule formation assay was used as a marker of serum angiogenic 
balance. This assay was first developed by Kubota et al. in 1988 [347] and has been used 
widely since to quantify angiogenesis [348-350]. Briefly, endothelial cells are plated onto 
Matrigel, a gel comprised of extracellular matrix isolated from Engelbreth-Holm-Swarm 
mouse sarcoma cells and pro-angiogenic factors, which promotes the cells to proliferate, 
migrate, and form tubules and lumen-like structures. After a period of incubation 
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(commonly 6-12h), the cells resemble a cross-section of a capillary bed (Figure 3.17). 
Angiogenesis can be quantified by imaging the cells under a microscope. Number of 
tubules, number of lumen, and total tubule length are common methods of quantification.  
 
 
Figure 3.17. A representative phase-contrasted image at 2.5X magnification of HUVECs 
plated onto Matrigel following 10h of incubation with serum from a young, healthy 
human subject under standard conditions. 
 
The following were pipetted to each well of a 96-well cell culture plate, in this order:  
1) 40µl of phenol-red free growth factor reduced Matrigel (BD Biosciences, San Jose, 
CA) 
2) 100µl of HUVECs (American Type Culture Collection [ATCC], Manassas, VA), 
suspended in serum-free vascular cell growth media at a concentration of 1x106 
cells/ml 
3) 10µl of serum from human subjects (triplicate wells per sample) 
4) For a subset of experiments: 10µl of 12mM L-NNA (final concentration of 1mM; 
SigmaAldrich, St, Louis, MO) 
  
 Matrigel was incubated for at least 30min at 37°C prior to plating cells in order to 
allow time for the Matrigel to solidify and set. HUVECs used had undergone 2-3 
passages at the time experiments were conducted. To determine cell concentrations, a 
small sample of cells were stained with trypan blue to determine the concentration of live 
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cells with a CountessTM automated cell counter (Invitrogen; ThermoFisher Scientific, 
Inc., Grand Island, NY), and additional raw media was added to achieve a concentration 
of 1x106 cells/ml. Sera were collected from human subjects at 4 time points: immediately 
prior to their first heat therapy session (0wks pre), 1h following their first heat therapy 
session (0wks post), immediately prior to their last heat therapy session which was also at 
least 36h following their penultimate session (8wks pre), and 1h following their last heat 
therapy session (8wks post). Each serum sample was added to 3 wells on 2 separate 
experiments.  
In a subset of experiments, L-NNA was added to inhibit NO synthase and to 
determine whether the pro-angiogenic effects of heat therapy are mediated via NOS 
upregulation. A concentration of 1mM was selected based on pilot studies in order to 
reduce NOS activity without completely abolishing it (10mM is typically considered to 
produce complete inhibition), as NO is essential for angiogenesis [351].  
Cells were then incubated under standard conditions (37°C, 5% CO2, 20% O2) for 
10h. This time frame was determined in pilot studies to coincide with peak tubule 
formation (tubules began to dissociate shortly thereafter). Wells were then imaged with a 
phase-contrasted microscope at 2.5X magnification (Axio Observer.D1; Zeiss, 
Oberkochen, Germany). Images were cropped to 600x750 pixels to avoid edges of the 
wells where Matrigel became concave. Total tubule length was determined independently 
by two blinded investigators using ImageJ analysis software (National Institutes of 
Health, Bethesda, MD). Results were averaged first, for each well across investigators, 
second, across the 3 wells for each serum sample, and third, across the two experiments 
that used each serum sample.  
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CHAPTER IV 
HALLMARK ADAPTATONS TO HEAT ACCLIMATION CAN 
BE OBTAINED THROUGH EIGHT WEEKS OF PASSIVE 
HEAT THERAPY IN SEDENTARY HUMANS 
 
INTRODUCTION 
 This dissertation utilized passive heat exposure as a therapy for inducing 
cardiovascular adaptation over time. Although the physiological responses to acute 
passive heat exposure are well understood, few studies have investigated the effects of 
repeated bouts of passive heat exposure, and only two have done so for a time period >3 
weeks in humans [16,17].  
Exercise heat acclimation, which typically consists of 100 min of low-to-
moderate intensity exercise in a hot environment (35-50°C) for 7-14 consecutive days, 
has been extensively studied and shown to induce a number of "classical" adaptations. 
These include reductions in resting core temperature, improved thermoregulation (e.g., 
higher sweat rate and skin blood flow for a given core temperature), and increased 
plasma volume [22,343,352]. Additionally, basal expression of heat shock proteins 
(HSPs) have been demonstrated to increase, particularly Hsp70 which is highly inducible 
[169]. HSPs in turn upregulate a variety of proteins important for improved 
cardiovascular health [4-6]. This increased expression of HSPs is likely a key mechanism 
behind the chronic vascular adaptations observed with heat therapy.  
Prior to presenting data regarding the vascular adaptations observed in this 
dissertation (Chapters V-VII), we sought to characterize whether 8 weeks of passive heat 
therapy also results in a heat-acclimated phenotype, as does exercise heat acclimation. 
Specifically, we hypothesized that, compared to a sham group, heat therapy would result 
in reduced resting core temperature, increased sweat rate during heat exposure, plasma 
volume expansion, and elevated basal expression of HSPs.  
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METHODS 
Human Subjects 
 As described in Chapter III, twenty young, healthy subjects were assigned to 
participate in and completed either 8 weeks of heat therapy or thermoneutral water 
immersion (N=10 in each group; see Chapter III, pages 36-38 for descriptions of 
interventions). All subjects provided oral and written informed consent prior to 
participation in the study, as set forth by the Declaration of Helsinki. All experimental 
procedures were approved by the Institutional Review Board at the University of Oregon. 
 
Venous blood collection 
 During the first and last water immersion sessions, blood was collected from an 
antecubital vein prior to entering and 1h after exiting the hot tub. Collection at 1h after 
exiting the hot tub was chosen based on pilot data (Figure 4.1 – next page) in which we 
identified 1h post-hot water immersion as an ideal time point to observe increased HSP 
content in peripheral blood mononuclear cells (PBMCs) and improved anti-oxidative 
capacity in the serum. A previous study which conducted a more extensive time course 
analysis also showed that HSP protein content in PBMCs peaks at 1h following heat 
stress [129]. Additionally, Zuhl et al. [353] found Hsp70 protein in PBMCs to peak 2h 
after acute exercise in the heat, but observed no change from baseline immediately 
following or 4h after exercise.  
At the four time points, venous blood was collected into three types of 
vacutainers: 1) EDTA (anticoagulant)-containing tubes for the measurement of 
hemoglobin and hematocrit, 2) serum-separating tubes (for cell culture experiments and 
other analyses described in Chapter VII), and 3) Ficoll Hypaque-containing cell 
preparation tubes with sodium citrate (CPT Vacutainer; BD, Franklin Lakes, NJ) for the 
separation of mononuclear cells from whole blood. Whole blood samples in EDTA tubes 
were immediately analyzed in triplicate for hemoglobin (Hb 201 Hemoglobin Analyzer; 
HemoCue, Brea, CA) and hematocrit (microcapillary centrifugation). Serum-separating 
and CPT tubes were centrifuged 30 min post-collection, and serum or plasma containing 
peripheral blood mononuclear cells (PBMCs) were separated, aliquoted, and stored at     
–80°C until later analysis.  
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Figure 4.1. Pilot data from a subject who participated in one acute 90-min bout of hot 
water immersion. Venous blood was drawn before the session (pre), and immediately 
(post), 1h, and 24h after exiting the hot tub. A) Serum anti-oxidative capacity, measured 
as Trolox concentration using a commercially-available ELISA kit, peaked 1h after the 
hot water immersion session and had returned to baseline values by 24h. B) Heat shock 
protein (Hsp)90 content in primary peripheral blood mononuclear cells decreased 
immediately post-hot water immersion, but increased above baseline levels by 1h post 
hot water immersion. Data were obtained using Western blot and normalized to a β-actin 
loading control.  
 
Blood volume 
 Prior to the first hot tub session and 48-72h after the last hot tub session, a subset 
of subjects (N=4 in the heat therapy group and N=8 in the sham group) reported to the 
laboratory having abstained from food for at least 4h, caffeine and alcohol for at least 
12h, and exercise and any medications, vitamins, or supplements for 24h. Subjects 
provided a first-morning urine sample to confirm euhydration via urine specific gravity 
<1.02 (Analog Refractometer; Atago, Tokyo, Japan). If USG was >1.02, subjects drank 
5ml/kg of water at least 30 min before blood volume measurements were obtained.  
Subjects rested seated for >20 min while an intravenous catheter was placed in an 
antecubital vein. A baseline venous blood sample was collected into an EDTA-containing 
vacutainer (BD, Franklin Lakes, NJ) and baseline end-tidal carbon monoxide (CO) was 
measured using a CO monitor (Dräger Pac 3500; Dräger, Lübeck, Germany). 
Hemoglobin (Hb 201 Hemoglobin Analyzer; HemoCue), hematocrit by microcapillary 
centrifugation, and CO bound to hemoglobin (HbCO; OSM3 Blood Gas Analyzer; 
Radiometer, Copenhagen, Denmark) were immediately analyzed from the blood sample. 
Red cell mass was then measured using the CO-rebreathing method developed by 
pre post 1h post 24h post
Se
ru
m
 [T
ro
lo
x]
 (m
M
)
0.0
0.5
1.0
1.5
2.0
2.5
pre post 1h post
H
sp
90
 : 
be
ta
-a
ct
in
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
  74 
Schmidt & Prommer [344], and described in detail in Chapter III (pages 61-63). Total 
blood volume and plasma volume were calculated from red cell mass using hematocrit.  
 
Heat Shock Proteins  
 PBMCs from subjects in the heat therapy group were separated from plasma and 
washed with phosphate-buffered saline (PBS) four times.  Cell pellets were then 
combined with RIPA buffer plus protease inhibitor and lysed via sonication. Soluble 
protein (25-50ug – consistent within subjects) was separated by electrophoresis on 4-20% 
SDS polyacrylamide separating gels (Life Technologies, Grand Island, NY) and 
transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA). Membranes were 
Ponceau-stained to assess transfer. Membranes were incubated for 1h in Odyssey 
Blocking Buffer (LI-COR Biosciences, Lincoln, NE) and then incubated overnight at 4°C 
in blocking buffer containing either 1) anti-Hsp70 [BRM-22] (1:5,000; Abcam), 2) anti-
Hsp90 [S88] (1:200; Abcam), or 3) anti-β actin (loading control; 1:1,000; Cell Signaling 
Technology). Membranes were washed and incubated with the appropriate secondary 
antibodies (LI-COR) for 1h at room temperature. The fluorescent bands were digitized 
using a Odyssey infrared imaging system (LI-COR). Digitized images were quantified 
using LI-COR Image StudioTM software. Antibodies were stripped using NewBlotTM 
Nitro Stripping Buffer (LI-COR) in between probing for primary antibodies.  
 Due to increased variability in human PBMCs, we confirmed all results by 
running samples on duplicate blots. Data have been averaged.  
 
Statistics  
 Rectal temperature and heart rate during the first water immersion session were 
compared using two-way mixed design ANOVA with a between factor of group (heat 
therapy vs. sham) and a within factor of time into water immersion. Resting rectal 
temperature, resting heart rate, peak rectal temperature and sweat rate during water 
immersion sessions were compared using two-way mixed design ANOVA with a 
between factor of group and a within factor of weeks into the intervention. Time to reach 
a Tre of 38.5°C and HR at a Tre of 38.5°C were compared using one-way repeated 
measures ANOVA across weeks into heat therapy (0, 4, and 8 weeks), as these variables 
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were only measured for the heat therapy group. For all analyses, when significant main 
effects or interactions were detected, pairwise comparisons within group were made 
using Bonferroni's post-hoc text. Comparisons across groups were made using Student's 
unpaired t-test.  
Linear regression analysis was performed to compare HR and rectal temperature 
data that were pooled from one session at 0, 4, and 8 weeks from subjects in the heat 
therapy group.  
Due to the smaller sample sizes, fasted/resting hemoglobin and hematocrit and 
blood volume, plasma volume, and red cell volume were compared within groups across 
weeks into heat therapy (0 vs. 8wks) with Student's paired t-test. We were not powered to 
make across group comparisons for these variables. 
We were also underpowered for comparing changes in HSP protein content in 
PBMCs using ANOVA (power on two-way repeated measures ANOVA for Hsp90 in the 
heat therapy group was 0.21). Instead, differences were compared using Student’s paired 
t-test for 0wks pre vs. 0wks post, 0wks pre vs. 8wks pre, and 8wks pre vs. 8wks post.  
All data are presented at mean ± S.E., unless otherwise specified. Significance 
was set at α=0.05.  
 
RESULTS & DISCUSSION 
Core Temperature 
During the first hot water immersion session (0wks), Tre reached 38.5°C in 24 ± 2 
min with subjects immersed up to the shoulder (Table 4.1 – next page). After this 
threshold was obtained, subjects sat up such that the water reached approximately waist-
level and such that Tre was maintained between 38.5-39.0°C. At the end of the water 
immersion period, subjects exited the hot tub and Tre and HR were measured for another 
10 min, or until Tre had dropped to <38.5°C, whichever was longer. For subjects in the 
sham group, Tre was maintained within ±0.2°C of resting throughout the protocol, 
regardless of body position. Average Tre across the first session of heat therapy or 
thermoneutral water immersion is presented in Figure 4.2 (next page).  
By 4 weeks into heat therapy, subjects experienced a significant reduction in 
resting Tre (p=0.004), which stayed low through 8 weeks (Table 4.1 – next page); 
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whereas no significant difference in resting Tre was observed in sham subjects (p=0.15). 
Reduced resting core temperature is a hallmark sign of heat adaptation, indicating passive 
heat therapy is capable of eliciting similar thermoregulatory adaptations as classical 
exercise heat acclimation. 
 
Table 4.1. Rectal temperature (Tre) measurements during water immersion sessions 
 Heat Therapy (N=10)  Sham (N=10) 
 0wks 4wks 8wks  0wks 4wks 8wks 
Resting Tre (°C) 37.3±0.1 36.9±0.1*† 36.9±0.1*  37.3±0.1 37.4±0.1 37.2±0.1 
Time to reach 
38.5°C (min) 24±2 26 ± 2 27±1 
 - - - 
Peak Tre (°C) 39.0±0.03 38.8±0.05* 38.8±0.04*  37.5±0.1 37.4±0.1 37.4±0.1 
Data are mean ± S.E. * P<0.05 vs. 0wks (within group), † P<0.05 vs. sham at same time 
point. 
 
 
 
Figure 4.2. Average rectal temperature during the first water immersion session. Subjects 
were fully submerged for either 30 min (sham group) or until Tre reached 38.5°C (24±0.1 
min; heat therapy group), and then sat up so that the water reached approximately waist-
level for the remainder of the session (90 min for the sham group or until Tre had been at 
or above 38.5°C for 60 min for the heat therapy group). Data are mean ± S.E. *P<0.05 vs. 
resting (time 0) within group. † P<0.05 vs. sham group at same time point. 
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 Peak Tre obtained during heating was slightly higher during the first session 
compared to the sessions analyzed at 4 (p=0.008) and 8 weeks (p=0.003), but this was 
only a difference of 0.2°C (Table 4.1). This is likely attributable to improved heat loss 
mechanisms once the subjects became acclimated. Once they sat up out of the water 
(once Tre reached 38.5°C), they were more effective at losing heat through sweating and 
increased skin blood flow such that further increases in core temperature were limited. 
However, the time required to reach our target threshold of 38.5°C did not significantly 
differ across the 8 weeks (p=0.43) as subjects’ improved heat loss mechanisms were not 
effective while the majority of skin surface area was submerged. A major challenge with 
heat acclimation performed in a hot environment (i.e., in air instead of water) is that it 
becomes difficult to elevate core temperature to the same levels reached during a naive 
session as heat loss mechanisms become more robust as individuals acclimate. The 
conductive heat transfer in water is 24x that in air. Furthermore, evaporative cooling 
(which occurs with sweating) cannot take place in a 100% humid environment, leaving 
only a relatively small area of skin (e.g., the shoulders and head) from which heat could 
be lost via sweating. While some heat can be dissipated via respiratory water loss, it is 
minimal and this is not a mechanism that can be altered with heat acclimation. Therefore, 
despite presumably improved skin blood flow and sweating responses, the rate at which 
heat could be dissipated to the environment during the initial water immersion period 
changed minimally in our subjects across the 8 weeks. Thus, the target core temperature 
threshold could be attained within a similar amount of time across the 8 weeks. This 
further supports the appropriateness of using water immersion as the modality for 
inducing heat stress for long-term use. 
 
Heart rate 
 The initial full immersion during heat therapy resulted in a continual increase in 
HR as core temperature increased. Once subjects sat up, HR dropped partially and stayed 
relatively stable throughout the remainder of the heating period, although there was 
variability in HR during this time due to subject movement (subjects could freely adjust 
their sitting position in the tub for comfort so long as Tre was maintain within the desired 
range). In the sham group, HR was not different from initial HR (prior to getting in the 
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tub) at any time point. Average HR across the first water immersion session is presented 
in Figure 4.3. 
 
Figure 4.3. Average heart rate during the first water immersion session. Subjects were 
fully submerged for either 30 min (sham group) or until rectal temperature (Tre) reached 
38.5°C (24±0.1 min; heat therapy group), and then sat up so that the water reached 
approximately waist-level for the remainder of the session. Data are mean ± S.E.  
*P<0.05 vs. resting (time 0) within group. † P<0.05 vs. sham group at same time point. 
 
 One of our primary long-term research goals regarding heat therapy is for it to be 
translatable to clinical practice. As such, we were interested in investigating whether HR 
could be used as an accurate indicator for when core temperature reaches our chosen 
threshold for inducing adaptation. Rectal temperature measurements are not feasible for 
use outside the laboratory and non-invasive methods of measuring temperature (e.g., oral 
or tympanic) are generally not reflective of true body core temperature. Since cardiac 
output during heat stress is determined by thermoregulatory drive (i.e., core temperature 
since skin temperature is held constant at 40.5°C while submerged in water), we thought 
HR may provide a non-invasive and easy-to-measure surrogate for core temperature. 
We used several approaches for comparing HR and rectal temperature within the 
heat therapy group. For these analyses, we used HR and Tre data from one session at 0, 4, 
and 8 weeks. First, we investigated whether HR predicts Tre across all data pooled from 
these sessions. Overall (i.e., throughout the entire heating period and during all three 
sessions), there was only a weak, albeit significant, relationship between HR and Tre 
(p<0.001, r2=0.071). However, when we included data from just the initial 20-30 min of 
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full immersion (when subjects maintained a more consistent body positions), we 
observed a modest relationship between HR and Tre (p<0.001, r2=0.40; Figure 4.4).  
  
 
Figure 4.4. Relationship between heart rate and rectal temperature during the initial full 
immersion. Data are pooled from one session at 0, 4, and 8 weeks into heat therapy from 
all subjects in the heat therapy group (N=151 observations across 10 subjects). 
   
 We also investigated whether HR could be used as a predictor of when core 
temperature reached our target threshold. In our subjects, HR when Tre reached 38.5°C 
(while still fully submerged) was not significantly different across the 8 weeks (0wks: 
120 ± 3 beats/min, 4wks: 118 ± 3 beats/min, 8wks: 116 ± 2 beats/min; p=0.25). However, 
within individual subjects, HR at this time point was not very consistent (average range 
in HR at Tre=38.5°C across the 8 weeks: 9 ± 2 beats/min). 
A likely reason behind why we only observed a modest relationship between HR 
and Tre in our two analyses (both across the full immersion period and just at the point 
when Tre reached 38.5°C) is because HR and core temperature adaptations to the heat did 
not occur in tandem. We observed a reduction in resting Tre over the 8 weeks (Table 4.1 – 
page 76); whereas, we observed no change in initial HR (immediately prior to each hot 
tub session; p=0.16) or true resting HR (measured on a separate day after at least 30 min 
of supine rest; p=0.95) (Table 4.2 – next page). Furthermore, we assume the rate at which 
adaptations occur varies across individuals. Therefore, based on our data, we believe it is 
possible that HR could be used as a rough estimate for when Tre reaches 38.5°C, but 
further studies are needed to conclude whether the same vascular adaptations could be 
Rectal Temperature (oC)
36.0 36.5 37.0 37.5 38.0 38.5 39.0
H
ea
rt 
R
at
e 
(b
ea
ts
/m
in
)
0
60
80
100
120
140
160
r2 = 0.40
p<0.001
  80 
conferred by heat therapy if HR were used as a marker of when subjects should sit up out 
of the water instead of a Tre of 38.5°C. Future studies should also investigate whether 
non-invasive temperature measurements (e.g., oral or tympanic temperature) could be 
used to determine this threshold, allowing heat therapy to be translated to non-laboratory 
settings.  
 
Table 4.2. Initial heart rate (HR) taken immediately prior to water immersion 
sessions and HR measured on the vascular function day after at least 20 min 
supine rest.  
 Heat Therapy (N=10)  Sham (N=10) 
 0wks 4wks 8wks  0wks 4wks 8wks 
Initial HR (bpm) 83±1 86±3 79±3  80±5 92±4 81±3 
Supine resting 
HR (bpm) 59±3 57±4 59±3 
 62±3 64±3 61±2 
Data are mean ± S.E. * P<0.05 vs. 0wks (within group), † P<0.05 vs. sham at 
same time point. 
 
Sweat rate   
 Mean whole-body sweat loss was calculated during each session by measuring 
pre- and post- nude body weight, which was corrected for fluid intake (Table 4.3 – next 
page). During heat therapy sessions (up to 90 min immersion + 10 min recovery), 
subjects lost 0.84 ± 0.09 L to sweat during the first session (range 0.49 - 1.30 L). This 
corresponded to a 1.26 ± 0.12 % body weight loss (range 0.86-1.97%). Following 8 
weeks of heat therapy, these values more than doubled to 2.08 ± 0.20 L (p<0.001; range 
1.11-3.37 L) and 3.09 ± 0.25% body weight loss (p<0.001; range 1.96-4.75%). Subjects 
in the sham group experienced minimal sweat loss, which was not significantly different 
from 0L and did not change across the 8 weeks. In order to be comparable to previous 
studies, we also calculated mean whole-body sweat rate per hour, presented in Figure 4.5 
(next page).  
 Increased sweat rate is a classic and important adaptation to heat acclimation. 
Although we only measured mean whole-body sweat rate in the current study, others 
have shown that heat acclimation lowers the body core temperature threshold for 
initiation of sweating and increases the sensitivity and output of the sweat glands, such 
that sweat rate is increased for any given core temperature [354]. 
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Table 4.3. Sweat loss during water immersion sessions at 0, 4, and 8 weeks into heat 
therapy or sham, presented as absolute sweat loss in the 90 min period and as a 
percentage of body weight (BW).  
 Heat Therapy (N=10)  Sham (N=10) 
 0wks 4wks 8wks  0wks 4wks 8wks 
Sweat loss (L) 0.84±0.09 1.69±0.16* 2.08±0.20*‡  0.05±0.02 0.06±0.04 0.03±0.02 
Sweat Loss 
(%BW) 1.3±0.1 2.5±0.2* 3.1±0.3*‡ 
 0.1±0.03 0.1±0.03 0.0±0.03 
Data are mean ± S.E. * P<0.05 vs. 0wks (within group), ‡ P<0.05 vs. 4wks (within 
group). Sweat loss (both absolute and as a % BW) were significantly different between 
the groups at every time point. 
 
 
 
Figure 4.5. Mean whole-body sweat rate during the first (0wks) and last (8wks) water 
immersion sessions, and one mid-way session (4wks). *P<0.001 vs. 0wks (within group), 
‡ P<0.05 vs. 4wks (within group), † P<0.001 vs. sham group at the same time point. 
 
 
Tolerance   
 In general, subjects tolerated the heating protocol well. The most common side 
effects reported included light-headedness and slight headache (Table 4.4 – next page). 
These symptoms occurred most frequently during the first two weeks (26 out of the 43 
total reported cases occurred in the first 9 sessions). This suggests subjects adapt very 
rapidly to the heat stress. 
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Table 4.4. Symptoms of heat exposure reported by subjects throughout the 8 weeks of 
heat therapy. Ten subjects participated in 36 sessions each for a total of 360 sessions.  
Symptom Subjects reporting 
Times 
reported 
Median session 
reported during  
Light-headedness/dizziness 5 15 8 Subsided upon sitting up in 8 of 15 cases 
Slight headache 4 11 9  
Tingling sensation in hands 
and/or feet 2 7 5  
Nausea 3 4 13 Due to recent food intake in 3 of 4 cases 
Uncomfortable flushing of 
the face 1 2 1.5  
Moderate and persistent 
headache 1 1 5  
 
Hemoglobin/hematocrit  
 Venous blood was collected for hemoglobin and hematocrit measurements under 
resting fasted conditions for N=7 subjects in the heat therapy group and N=10 subjects in 
the sham group. Unfortunately, we did not perform these measurements on the first three 
subjects we studied (which were all in the heat therapy group). Subjects also abstained 
from caffeine and alcohol for at least 12h, all medications, vitamins, and supplements for 
at least 24h and heavy exercise for at least 4h. All subjects were assessed for euhydration 
via first-morning USG and drank 5ml/kg of water prior to when the blood sample was 
collected if USG was >1.02. These fasted blood draws occurred immediately prior to the 
first and last water immersion session (24-48h after the penultimate session) in N=3 
subjects in the heat therapy group and N=2 subjects in the sham group. In the remaining 
subjects (N=4 heat therapy and N=8 sham subjects), fasted blood draws were taken on a 
separate day prior to the blood volume measurement.  
In addition, venous blood was collected for hemoglobin and hematocrit 
measurements before and after the first and last hot tub sessions in order to assess the 
acute effects of heat stress/thermoneutral water immersion. The subjects who performed 
the blood volume measurement were not fasted for these sessions, but maintained time of 
day and approximate food and caffeine intake consistent between the two sessions. 
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Subjects tended to tolerate the first session of hot water immersion better when they were 
not fasted.  
There was no effect of heat therapy or sham on either fasted hemoglobin (p=0.35) 
or hematocrit (p=0.62) (Table 4.5). There was also no significant acute effect of heat 
therapy on hemoglobin or hematocrit at either 0 or 8 weeks. However, when considering 
individual subjects, we observed fairly large changes pre to post heat exposure on the 
very first heat therapy session (absolute change in hemoglobin from pre to post heat 
exposure averaged across heat therapy subjects: 1.5 ± 0.5 mg/dl); whereas, both 
hemoglobin and hematocrit remained relatively consistent pre to post heat exposure on 
the last heat therapy session (absolute change in hemoglobin: 0.6 ± 0.1 mg/dl, p=0.12 vs. 
change at 0wks), as shown by the individual data presented in Figure 4.6 (next page). As 
acute changes in hemoglobin and hematocrit are reflective of plasma volume shifts, these 
data suggest subjects became better able to gauge the volume and rate at which they 
needed to drink water in order to maintain hydration as they became heat adapted. 
 
Table 4.5. Resting fasted hemoglobin and hematocrit values. Venous blood 
for measurements was collected at the same time of day for each subject, 
following 4h fast, and after subjects abstained from caffeine and alcohol for 
12h, medications, vitamins, supplements, and heavy exercise for 24h. All 
subjects were euhydrated, measured by first-morning urine specific gravity.  
 Heat Therapy (N=7)  Sham (N=10) 
 0 wks 8 wks  0 wks 8 wks 
Hemoglobin (mg/dl) 14.8 ± 0.9 14.0 ± 0.6  14.1 ± 0.7 14.2 ± 0.6 
Hematocrit (%) 41.7 ± 1.4 41.4 ± 0.7  40.2 ± 1.7 40.7 ± 1.7 
 Data are mean ± S.E. 
 
Plasma volume   
In subjects undergoing heat therapy (N=4), blood volume increased significantly 
(p=0.05); whereas both plasma volume (p=0.12) and red cell volume (p=0.09) tended to 
increase (Table 4.6 – next page). Importantly, we observed increases in blood and plasma 
volume in all four heat therapy subjects. Red cell volume increased in three subjects, with 
one subject showing no change. No consistent changes were observed in the sham group. 
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Figure 4.6 Hemoglobin concentration measured immediately prior to (preHT) and 
following (postHT) the first (0 weeks) and last (8 weeks) heat therapy session. Bars are 
mean ± S.E. (N=7). Circles are data from individual subjects. 
 
Table 4.6. Changes in blood, plasma, and red cell volume following 8 weeks of heat 
therapy or thermoneutral water immersion (sham). *P<0.05 from 0wks (within group). 
First-morning urine specific gravity (USG) was measured on the days when blood 
volume measurements were made. Subjects with USG >1.020 drank 5ml/kg water 
≥30min before the first blood draw. 
 Heat Therapy (N=4)  Sham (N=8) 
 0 wks 8 wks  0 wks 8 wks 
Blood volume (L) 5.03 ± 0.30 5.45 ± 0.35 *  4.90 ± 0.23 4.64 ± 0.34 
Plasma volume (L) 3.15 ± 0.12 3.49 ± 0.20  3.22 ± 0.17 3.01 ± 0.21 
Red cell volume (L) 1.88 ± 0.19 1.96 ± 0.16  1.68 ± 0.11 1.63 ± 0.16 
USG  1.019 ±0.002 1.017 ± 0.002  1.020 ± 0.002 1.021 ± 0.001 
 
 Plasma volume expansion is another hallmark adaptation of heat acclimation. It 
allows for increases in blood flow to the skin for a given body core temperature to 
support increased sweating and heat loss. To our knowledge, no studies have investigated 
changes in plasma volume with heat acclimation in humans beyond 3 weeks. In exercise 
training studies, plasma volume increases fairly rapidly, but has been shown to return 
back to baseline levels after ~3-4 weeks [343]. This likely occurs because the stimulus 
for maintaining plasma volume expansion is reduced progressively as individuals adapt 
to exercise training, i.e., core temperature does not increase by as great an extent in later 
sessions. From our preliminary results, it seems plasma volume expansion with passive 
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heat acclimation is maintained for longer durations. This may have occurred in our study 
because we continued to raise core temperature to the same threshold throughout the 8 
weeks. However, further studies are needed to fully characterize this adaptation.  
Interestingly, red cell volume also tended to increase with heat therapy. This 
explains why we observed no change in hematocrit or hemoglobin. Red cell volume 
expansion is controlled by erythropoietin, which can be stimulated by long-term exercise 
training, ischemia, and hypoxia, among other stimuli [355]. Previous studies using short-
term exercise heat acclimation have failed to observe any change in red cell volume 
[356,357]; however, longer-term exposure is likely required to induce this phenotype 
[14]. Hypoxia increases red cell production via activation of hypoxia inducible factor-1 
(HIF-1)-α [355]. Interestingly, HIF-1-α is stabilized by Hsp70, providing a mechanism by 
which heat confers cross tolerance against hypoxia [15]. Although not tested 
experimentally in this study, it is possible increases in Hsp70 with heat therapy also 
activated HIF-1-α and therefore stimulated erythropoiesis.  
 
Heat Shock Proteins  
 HSP content was analyzed in primary PBMCs, isolated from venous blood using 
the Ficoll Hypaque method before and 1h following the first and last session of heat 
therapy. By collecting PBMCs at these times, we hoped to capture both the acute HSP 
responses to individual bouts of hot water immersion and the chronic effects of heat 
therapy. We chose to measure HSPs in PBMCs because they can be isolated easily and 
relatively non-invasively from human subjects, they are exposed to the same 
temperatures and circulating factors in vivo as endothelial cells, and they exhibit a stress 
response in humans during exercise hyperthermia [114] and exertional heat injury [115]. 
Hsp70 and Hsp90 have also been shown to be elevated basally in human primary PBMCs 
following 10 days of exercise heat acclimation [169].  
 Unfortunately, we observed considerable variability in responses, even when data 
were normalized as fold changes from baseline within individuals.  For example, the 
range in acute responses in Hsp70 following the last hot water immersion session was a 
0.5-fold reduction up to a 6.4-fold increase. Despite this variability, we did observe a 
significant elevation in basal Hsp70 following heat therapy (p=0.05). Additionally, we 
  86 
observed trends towards increases in Hsp70 with acute hot water immersion at 0wks 
(p=0.08) and 8wks (p=0.09). We observed a trend towards an increase in Hsp90 
following acute water immersion at 0wks (p=0.08), but Hsp90 only remained chronically 
elevated in half of the subjects at 8wks (p=0.25 vs. 0wks pre) (Figure 4.7).  
 
Figure 4.7. A) Heat shock protein (Hsp)-70 and B) Hsp90 protein content in peripheral 
blood mononuclear cells (PBMCs) collected from subjects before (pre) and 1h after 
(post) the first (0wks) and last (8wks) heat therapy sessions. Data are mean±S.E. (bars) 
and from individual subjects (black symbols), presented as fold changes from the 0wks 
pre condition within subjects. *P<0.05 vs. 0wks pre. C) Western blots performed with 
PBMC lysates from four representative subjects. Although we observed trends towards 
increases in HSPs across time into heat therapy, individual responses varied, as shown by 
individual data on graphs and Western blots.  
 
 It is possible variability in acute responses was due to the timing of blood 
collection. We selected to draw blood 1h post hot water immersion based on our (albeit 
limited) pilot data and previous reports of when HSP protein peaks in heat stressed 
PBMCs [129]. However, there may be individual variability in peak time for HSP 
abundance. For example, we observed a reduction in Hsp90 immediately post hot water 
immersion in our pilot subject (Figure 4.1, page 73). One hour may not have been long 
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enough for this transient reduction to recover in some subjects. Additionally, more time is 
often required for protein synthesis to occur. Had we measured HSP mRNA, we may 
have observed more robust responses. However, we chose to measure protein, as it is 
more indicative of functional effects.  
 We are not sure of the reason behind variability in the chronic responses, besides 
physiological inter-individual variability. All Western blots were run in duplicate and in 
general, responses were consistent across the two blots (e.g., reductions in HSP responses 
observed in some subjects were consistently observed across both blots), suggesting 
technical limitations were not the source of the variability. There were no trends in 
chronic HSP responses for sex or time since the second to last water immersion session 
(all within a 24-48h range).  
 Regardless of this variability, we did observe a significant increase in Hsp70 
following 8 weeks of heat therapy. This is consistent with findings in animals chronically 
exposed to heat [173] and humans following exercise heat acclimation [169,358]. 
Furthermore, the magnitude of basal change in Hsp70 that we observed was similar to 
changes reported following 10 days of exercise heat acclimation (60% increase vs. 67% 
increase observed by Amorim et al. [358] and a 21% increase observed by McClung et al. 
[169]). Of course, our study differed from exercise heat acclimation studies in a number 
of ways (e.g., passive heat stress, longer duration, increase in core temperature per 
session); however, the comparison of our data to theirs further supports the notion that 
passive heat acclimation results in the same hallmark adaptations as classic exercise heat 
acclimation.  
 Lastly, we observed increases in basal Hsp90 in only half of the heat therapy 
subjects. As Hsp90 is constitutively expressed (versus Hsp70 is highly inducible), 
increases in Hsp90 will be of smaller magnitude than increases in Hsp70, making it 
difficult to detect significant changes. For example, increases in Hsp90 abundance were 
lower than increases in Hsp70 in rats continuously exposed to passive heat for 5 days in 
all tissues harvested (e.g., brain: Hsp90 1.2-fold increase vs. Hsp70 3.5-fold increase; 
heart: Hsp90 1.9-fold increase vs. Hsp70 3.1-fold increase) [359]. Because of this 
difference, few studies have investigated changes in Hsp90 protein in humans following 
exercise or heat stress/acclimation [169,360]. The one study that has measured changes in 
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Hsp90 protein following 10 days of exercise heat acclimation demonstrated a similar 
increase (21%) to the average increase observed in our subjects (30%).  
 
CONCLUSIONS 
 Overall, eight weeks of passive heat acclimation results in reduced resting core 
temperature, increased sweat rate for a heat stress stimulus, and elevated basal HSP 
content, similarly to classical exercise heat acclimation [22], and similarly to what has 
been shown with long-term passive heat acclimation in animals [14]. Additionally, our 
preliminary data indicates that plasma volume is expanded. Differently from classical 
exercise heat acclimation, HR for a given heat stress stimulus was unchanged. We also 
observed a trend towards an increase in red cell volume with heat therapy, which has not 
previously been observed with short-term exercise heat acclimation [356,357], supporting 
the claim that longer term heat acclimation is required to induce the full phenotype [14].  
 Importantly, no changes were observed in the sham group. During thermoneutral 
water immersion sessions, there were no changes in rectal temperature >0.2°C from 
resting, no significant changes in HR, and no sweat loss. As a result, we observed no 
long-term adaptations in this group. This allows us to conclude that all adaptations 
observed in the heat therapy group were caused by the heat stress itself and not by 
hydrostatic or placebo effects.   
  The data included in this chapter demonstrates that the hyperthermic protocol 
and duration of time that we chose for performing passive heat therapy in humans is 
capable of inducing the hallmark adaptations associated with chronic heat exposure in 
animals and exercise heat acclimation in humans. As such, we expect heat therapy to 
have similar effects on vascular function as those that have been shown with exercise 
training, which itself confers long-term heat acclimation. Furthermore, we have shown 
that Hsp70 is chronically elevated in PBMCs following 8 weeks of heat therapy. 
Assuming HSP responses in PBMCs are similar to those in endothelial cells in vivo, this 
provides evidence that the pathways associated with improved vascular function which 
can be improved by HSPs (i.e., NO signaling, anti-oxidative stress, and anti-
inflammation, as discussed in Chapter II) will also be improved in vivo, leading to the 
improvements in vascular function that will be presented in the following chapters.  
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CHAPTER V 
PASSIVE HEAT THERAPY IMPROVES ENDOTHELIAL 
FUNCTION, ARTERIAL STIFFNESS, AND BLOOD              
PRESSURE IN SEDENTARY HUMANS 
 
 
Material contained in this chapter was published in the Journal of Physiology:  
Brunt VE, Howard MJ, Francisco MA, Ely BR, and Minson CT. Passive heat therapy 
improves endothelial function, arterial stiffness, and blood pressure in sedentary humans. 
J Physiol. 2016. In Press (accepted May 24, 2016).   
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INTRODUCTION 
 The majority of cardiovascular (CV) diseases are characterized by vascular 
dysfunction [1], including impaired endothelial-dependent dilation and arterial stiffening. 
To assess the progression of CV diseases, several biomarkers of conduit vessel function 
have been developed and verified to be independently predictive CV morbidity and 
mortality across a range of disease conditions.  
 Heat exposure increases core temperature, heart rate and contractility, 
redistribution of blood flow, and changes in conduit vessel endothelial shear stress [7], all 
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of which are believed to potentiate long-term improvements in vascular function. 
Additionally, heat exposure induces the expression of heat shock proteins (HSPs), which 
in turn stabilize a variety of other proteins important to the CV system. These include 
proteins which improve nitric oxide (NO) signaling [4], reduce oxidative stress [5], and 
reduce vascular inflammation [6], all of which greatly influence vascular function.  
Therefore, we investigated the effects of 8 weeks of heat therapy on well-
established biomarkers of macrovascular health, including endothelial-dependent 
dilation, arterial stiffness, intima media thickness, and blood pressure in young, sedentary 
(otherwise healthy) individuals. We hypothesized that, relative to thermoneutral water 
immersion (sham), heat therapy would improve endothelial-dependent dilation, arterial 
stiffness, blood pressure, and intima media thickness (also referred to as 'wall thickness'). 
This is the first clinical trial to comprehensively investigate the physiological benefits of 
long-term heat therapy in humans. 
 
METHODS 
Human subjects 
 As described in Chapter III, twenty young (18-30 yrs of age), sedentary (<2h of 
aerobic exercise per week), healthy subjects completed 8 weeks of heat therapy (N=10) 
or thermoneutral water immersion (N=10) (see Figure 3.2, page 35, for a flow chart of 
progression through the phases of the study; see Chapter III, pages 36-38 for descriptions 
of heat therapy and thermoneutral water immersion protocols). Subjects were well 
matched across groups for age, height, weight, BMI, and the distribution of males vs. 
females (see Table 3.1, page 36). Data from subjects who dropped out of the study 
partway have been excluded. 
 All subjects provided oral and written informed consent prior to participation in 
the study, as set forth by the Declaration of Helsinki. All experimental procedures were 
approved by the Institutional Review Board at the University of Oregon.  
 
Outcome measures 
 Subjects in both groups reported to a temperature-controlled laboratory before, 
every 2 weeks during, and immediately following the 8-week intervention for 
  91 
experimental testing. All experimental sessions took place 36-48h after the previous heat 
therapy session to ensure the chronic, rather than acute, effects of heat therapy were being 
investigated. Prior to all experimental days, subjects refrained from all over-the-counter 
medications, including vitamins and supplements, for 24h, alcohol and caffeine for 12h, 
food for 4h, and heavy exercise for 24h. Female subjects taking hormonal contraceptives 
were always studied during the active phase (N=10). Naturally menstruating females 
(N=2) were studied in the same menstrual phase during Weeks 0, 4, and 8 and during 
Weeks 2 and 6.  
Upon arrival at the laboratory, subjects voided their bladder and subjects' height 
and weight were measured. Subjects were instrumented with 3-lead electrocardiogram 
(CardioCap; Datex Ohmeda, Louisville, CO), a blood pressure cuff on the left brachium, 
and a finger cuff for measurement of beat-by-beat blood pressure via 
photoplethysmography (Nexfin; BMEye, Amsterdam, the Netherlands). Brachial blood 
pressure was measured in triplicate following at least 20 min of supine rest. Biomarkers 
of vascular function were then measured using a high-resolution Doppler ultrasound 
(Terason t3000cv; Teratech, Burlington, MA) equipped with 10.0-MHz linear array 
ultrasound transducer probe (Doppler insonation angle of 60°) and using applanation 
tonometry (PCU-2000; Millar, Inc., Houston, TX) to obtain arterial pressure tracings 
[361], as follows (in this order, and as described in more detail in Chapter III, pages 39-
53): 
Wall thickness (i.e., intima media thickness) was measured in diastole in the 
common carotid artery 1-2cm distal to the carotid bulb and in the superficial femoral 
artery 2-3cm distal to the femoral bifurcation. Concurrent ultrasound images and 
tonometry pressure tracings were obtained in the contralateral common carotid and 
superficial femoral arteries in order to calculate dynamic cross-sectional arterial 
compliance and β-stiffness index. Concurrent tonometry pressure tracings were obtained 
from the common carotid and common femoral arteries to calculate aortic pulse wave 
velocity [362]. Brachial artery flow-mediated dilation (FMD) and post-occlusive reactive 
hyperemia (PORH) were measured following 5-min arterial occlusion according to 
published guidelines [278,279]. Lastly, endothelium-independent dilation was measured 
as the percent change in brachial artery diameter following administration of 0.4 mg of 
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sublingual nitroglycerine (Nitrolingual; Sciele Pharma, Atlanta, GA), which elicits 
maximal dilation of the conduit arteries. 
FMD was calculated as the percent change in brachial diameter from baseline to 
peak dilation post-occlusion. The shear stimulus responsible for eliciting dilation was 
calculated as area under the curve above baseline shear rate from the time of release to 
peak dilation (SRAUC). FMD was then normalized for shear stimulus by dividing FMD by 
SRAUC, as described and validated previously [281,282]. PORH was characterized as the 
peak forearm vascular conductance (FVC = flow / mean arterial pressure) following 
release of the occlusion and as the area under the curve (AUC) PORH, calculated as the 
integral of FVC values above baseline FVC (average FVC across the 1-min baseline) 
until return to baseline. Due to higher variability in 0-week PORH values across subjects, 
data are presented as fold changes across the 8 weeks.  
 
Statistics 
 A priori, sample size analyses were conducted for each outcome variable using 
differences in mean values that would be considered clinically relevant and standard 
deviations from young, healthy subjects who have previously been studied in our lab. We 
determined a sample size of N=10 per group would ensure a power of 0.80 with α=0.05.  
 Outcome variables were compared across groups and time into heat therapy or 
thermoneutral water immersion using two-way 2x5 mixed design analysis of variance 
(ANOVA). When significant main effects or interactions were detected, significant 
differences between paired variables across time were determined using Bonferroni's 
post-hoc test. Statistical significance was set to α = 0.05. P-values given denote 
interaction between group x time, unless otherwise noted. Data are presented as 
mean±S.E.  
 
RESULTS 
Endothelial-dependent dilation 
 We observed a robust improvement in FMD with heat therapy (p=0.003), which 
was significantly elevated by 2 weeks (p=0.015 vs. 0wks within heat therapy group). 
FMD then decreased back down to baseline at 4 weeks (p=0.64 vs. 0wks), but continued 
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to increase afterwards through 6 and 8 weeks (Figure 5.1 – next page). No changes were 
observed in the sham group at any time point. FMD corrected for the shear rate stimulus 
continually increased across the 8 weeks of heat therapy (p=0.003), with no dip at the 4-
week time point (Table 5.1 – next page), and was significantly different from the sham 
group at all time points into the intervention (Weeks 2-8) We observed a significant 
difference in SRAUC between 4 and 6 weeks into heat therapy (p=0.04, 4 vs. 6wks within 
group; group x time: p=0.02). No changes were observed in baseline brachial artery 
diameter (p=0.43). There was no effect of heat therapy or thermoneutral water immersion 
on endothelium-independent dilation across the 8 weeks when data (p=0.24) (Table 5.1 – 
next page). 
 
Figure 5.1.  Changes in brachial artery flow-mediated dilation over 8 weeks of heat 
therapy (closed symbols) or thermoneutral water immersion (sham; open symbols). Data 
are mean ± S.E. Symbols denote results of post-hoc analyses when significant main 
effects were observed. *p<0.05 from 0wks (within group). ‡p<0.05 from 4wks (within 
group). †p<0.05 vs. sham group at the same time point. 
 
 
Post-occlusive reactive hyperemia  
 Heat therapy significantly increased AUC PORH by 6 weeks (p=0.004 vs. 0wks; 
group x time: p=0.047) (Table 5.1 – next page), while no changes were observed in the 
sham group. We observed no significant changes in Peak PORH (p=0.39).  
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Arterial stiffness 
 There was no effect of heat therapy or themoneutral water immersion on carotid 
artery dynamic arterial compliance (p=0.10) or β-stiffness index (p=0.41). However, in 
the superficial femoral artery, dynamic arterial compliance became significantly elevated 
from baseline by 4 weeks into heat therapy (p=0.02 vs. 0wks within heat therapy group), 
while β-stiffness index became significantly reduced from baseline by 8 weeks (p=0.03 
vs. 0wks).  Heat therapy also reduced carotid-femoral pulse wave velocity (p=0.03), but 
this effect only became significantly reduced from baseline at 8 weeks (p=0.046 vs. 
0wks). No changes were observed in the sham group. Data are summarized in Figure 5.2.  
 
 
Figure 5.2.  Changes in A) dynamic cross-sectional arterial compliance, B) β-stiffness 
index, and C) aortic pulse wave velocity over 8 weeks of heat therapy (closed symbols) 
or thermoneutral water immersion (sham; open symbols). Data are mean ± S.E. Symbols 
denote results of post-hoc analyses when significant main effects were observed. *p<0.05 
from 0wks (within group). †p<0.05 vs. sham group at the same time point. 
 
Vessel wall thickness & diameter   
 Heat therapy reduced carotid artery wall thickness significantly by 8 weeks 
(p=0.003 vs. 0wks within heat therapy group), but had no effect on superficial femoral 
artery wall thickness (p=0.26) (Figure 5.3 – next page). Heat therapy had no effect on 
resting superficial femoral artery diameter (p=0.73), although we observed a trend 
towards an increase in carotid artery diameter (p=0.09) (Table 5.1 – previous page).  
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Blood pressure & heart rate  
 We observed significant decreases in resting diastolic and mean arterial blood 
pressures across the 8 weeks (Table 5.1); whereas no changes were observed in systolic 
blood pressure (p=0.77) or resting heart rate (p=0.95).  
 
 
Figure 5.3.  Changes in arterial wall thickness in the A) common carotid and B) 
superficial femoral arteries over 8 weeks of heat therapy (closed symbols) or 
thermoneutral water immersion (sham; open symbols). Data are mean ± S.E. Symbols 
denote results of post-hoc analyses when significant main effects were observed. *p<0.05 
from 0wks (within group). †p<0.05 vs. sham group at the same time point. 
 
DISCUSSION 
 In the present study, we sought to determine the effects of 8 weeks of passive heat 
therapy in young, sedentary individuals. Our major findings were that passive heat 
therapy results in robust and clinically relevant improvements in endothelium-dependent 
dilation, arterial stiffness, wall thickness, and blood pressure, which continually improved 
across the 8 weeks. Furthermore, we observed no changes in any variables in response to 
8 weeks of thermoneutral water immersion.  This is the first study to comprehensibly 
investigate the physiological effects of long-term whole-body passive heat therapy in 
human subjects. Our results suggest that these improvements in vascular function likely 
underlie the reduced incidence of CV disease and all-cause mortality associated with 
lifelong heat therapy.  
 
 
C
om
m
on
 c
ar
ot
id
 a
rt
er
y
w
al
l t
hi
ck
ne
ss
 (m
m
)
0.00
0.35
0.40
0.45
Heat Therapy
Sham
Weeks into Heat Therapy
0 2 4 6 8
Su
pe
rf
ic
ia
l f
em
or
al
 a
rt
er
y 
w
al
l t
hi
ck
ne
ss
 (m
m
)
0.00
0.30
0.35
0.40
0.45
*
†
Figure 3igure 4
C
om
m
on
 c
ar
ot
id
 a
rt
er
y
w
al
l t
hi
ck
ne
ss
 (m
m
)
0.00
0.35
0.40
0.45
Heat Therapy
Sham
Weeks into Heat Therapy
0 2 4 6 8
Su
pe
rf
ic
ia
l f
em
or
al
 a
rt
er
y 
w
al
l t
hi
ck
ne
ss
 (m
m
)
0.00
0.30
0.35
0.40
0.45
*
†
Figure 3igure 4
C
om
m
on
 c
ar
ot
id
 a
rt
er
y
w
al
l t
hi
ck
ne
ss
 (m
m
)
0.00
0.35
0.40
0.45
Heat Therapy
Sham
Weeks into Heat Therapy
0 2 4 6 8
Su
pe
rf
ic
ia
l f
em
or
al
 a
rt
er
y 
w
al
l t
hi
ck
ne
ss
 (m
m
)
0.30
0.35
0.40
*
†
Figure 3igure 4
A B 
  97 
Endothelium-dependent dilation   
 FMD is a commonly used and clinically relevant test of endothelial function which 
is primarily dependent on NO [274] and highly correlated with CV morbidity and 
mortality [270-272]. Furthermore, endothelial function in the brachial artery has been 
shown to parallel that in the coronary arteries [273], adding to its prognostic value. In the 
present study, we observed a robust improvement in FMD by the first time-point into 
heat therapy (2 weeks), consistent with previous studies investigating the effects of 2 
weeks of infrared sauna therapy in patients with elevated CV risk [249,363]. By the end 
of the 8 weeks, FMD had increased by 5.31%, which represents a substantial 
improvement in vascular health, as improvements of just 2% have been correlated with a 
15% reduction in CV risk [364]. These findings are in contrast to those observed 
following 8 weeks of 3x per week leg heating, in which FMD was significantly improved 
by 4wks, but had returned back to baseline values by 8 weeks [17]. However, core 
temperature only reached ~38.0°C per session in that study, perhaps demonstrating the 
importance of reaching a higher threshold core temperature. Our findings also contrast 
with exercise training studies, in which early improvements in FMD typically resolve and 
return back towards baseline values by 8 weeks [365], suggesting heat therapy may offer 
a more robust stimulus for endothelial adaptation. However, exercise training is also 
known to increase conduit vessel diameter [237,238]. As such, it has been proposed that 
FMD presented as a percent change in diameter returns back towards baseline values due 
to this structural remodeling rather than because improvements in endothelial function 
have been reversed [366]. Interestingly, we did not observe a change in conduit vessel 
diameter with heat therapy, possibly due to hydrostatic effects or because increases in 
cardiac output and blood flow during hot water immersion were not as great as may be 
seen during dynamic exercise. The differential effects of heat therapy on exercise training 
on conduit vessel diameter may explain the difference in the pattern of FMD adaptations 
to the two interventions.    
Heat therapy results in repeated episodic elevations in core temperature and 
perfusion, both of which may upregulate NO-dependent dilation and therefore improve 
FMD. HSPs, which are activated by acute bouts of heat stress and chronically increased 
following heat acclimation [169], directly improve NO signaling. For example, 
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association of Hsp90 with eNOS is essential for eNOS activation and NO production [4]. 
Thus, increases in Hsp90 result in enhanced NOS activity independent of total eNOS 
protein [137]. Repeated episodes of increased shear rate, as occurs due to elevated blood 
flow during heat stress, has also been shown to increase FMD [18]. Furthermore, shear 
stress is known to upregulate transcription of HSPs, independently of elevations in 
temperature [117]. Importantly, limiting increases in shear with an arm cuff during 8wks 
of repeated leg heating prevented brachial artery FMD from improving over time [17], 
demonstrating elevations in shear, either alone or in combination with elevations in core 
temperature, is essential to arterial adaptation.  
We also evaluated the reactive hyperemia response, which is a common test of 
microvascular function and an independent predictor of future CV events [286,288]. 
Furthermore, the shear stimulus, and therefore FMD, are dependent on PORH and 
baseline diameter. Although we did not observe any significant change in baseline 
brachial artery diameter, heat therapy did improve AUC PORH at the 6- and 8-week time 
points. However, as we observed improvements in FMD as early as 2 weeks into heat 
therapy despite no changes in baseline diameter or PORH, we can conclude these 
improvements represent augmented vasodilator function of the brachial artery. The 
prolonged downstream vasodilation that occurs following release of arterial occlusion 
(measured as AUC PORH) is thought to be the combined result of myogenic responses 
and release of metabolic vasodilators, including adenosine, ADP, prostanoids, and NO 
[283-285]. Although we did not investigate the mechanisms in the present study, it is 
likely increases in AUC PORH with heat therapy were caused by HSP- and shear stress-
induced improvements in NO-dependent dilation, as described above.  
Although we observed a trend towards improved Peak PORH with heat therapy, 
this trend was not statistically significant when compared to the sham group. Peak PORH 
has been suggested to be representative of maximal vasodilator capacity [291,292], and 
so our findings suggest that there were no structural effects of heat therapy in the 
microvasculature, i.e., heat therapy did not induce angiogenesis. It is possible this is the 
case, despite pro-angiogenic effects of heat therapy [250,367], HSPs [368], and NO [351] 
that have been demonstrated in tissue culture and in animals. It is more likely that 8 
weeks was not long enough to detect angiogenesis in vivo using Peak PORH, which has 
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never been validated for this purpose. In fact, Peak PORH has only been validated to 
represent maximal vasodilator capacity using venous occlusion plethysmography to 
measure blood flow [291,292], which may underestimate Peak PORH. Therefore, other 
approaches are required to conclusively determine the effects of heat therapy on 
microvascular structure in vivo.  
 Lastly, we did not observe any changes in endothelium-independent dilation to 
nitroglycerine administration across the 8 weeks of heat therapy. Thus, improvements in 
FMD can be attributed to changes in the brachial artery endothelium rather than changes 
in the response of the underlying vascular smooth muscle to a NO stimulus.  
 
Arterial stiffness   
 Arterial stiffness is an independent risk factor for CV disease [296,298,301], and 
increased arterial stiffness is often accompanied by atherosclerosis, left ventricular 
hypertrophy, and increased incidence of vascular events [369]. We assessed three 
different measures, all validated for their abilities to predict CV morbidity and mortality 
[298,301,307]. With heat therapy, superficial femoral arterial compliance increased, 
femoral β-stiffness index decreased, and aortic pulse wave velocity decreased, all 
indicating reduced arterial stiffness. Furthermore, all of these improvements were of a 
great enough magnitude to be considered clinically relevant, which is compelling given 
we studied a young, healthy population, albeit a sedentary one. Consistent with our 
results, previous studies have demonstrated a reduction in arterial stiffness with acute 
passive heat stress [370] and following 8 weeks of Bikram (hot) yoga [371].  
Arterial stiffness can be impacted by a variety of factors, including elastic fiber 
degeneration, increased collagen content, structural changes to the arteries (e.g. vascular 
smooth muscle cell hypertrophy and hyperplasia), and impaired endothelial function 
[372], several of which were likely affected by heat therapy. HSPs are known to inhibit 
smooth muscle cell hyperplasia and hypertrophy [373,374], to reduce oxidative stress [5] 
and vascular inflammation [6]. Improved NO bioavailability and endothelial function (by 
the before-mentioned mechanisms) also reduce arterial stiffness [375]. Sympathetic 
nervous activity has been shown to increase stiffness [376]. Resting sympathetic activity 
is lower in the summer compared to winter despite no difference in body or room 
  100 
temperature at the time of testing [377], although it is unknown whether heat therapy 
would have similar effects.  
Lastly, blood pressure is well known to affect the visco-elastic properties of the 
arterial wall. As blood pressure is reduced, compliance increases. In the present study, we 
observed a reduction in diastolic and mean arterial blood pressure. For this reason, we 
chose to calculate β-stiffness index, which is less dependent on changes in blood 
pressure. In the carotid artery, we observed no change in β-stiffness index with heat 
therapy, suggesting that improvements in compliance were likely the result of reductions 
in blood pressure. However, both compliance and β-stiffness index were significantly 
improved in the superficial femoral artery. The superficial femoral artery is a more 
muscular artery than the carotid and, as such, may be more affected by nervous activity, 
hormones, or locally produced vasoactive substances, such as nitric oxide [378]. It is 
possible we were able to better observe the effects of heat therapy on the arteries in the 
superficial femoral compared to the more elastic carotid and aorta. Our results also 
demonstrate the importance of assessing arterial stiffness at more than one artery and 
using more than one method as each has limitations [314]. 
 
Blood Pressure   
 We observed significant reductions in diastolic and mean arterial blood pressure 
with heat therapy. Although the magnitude of these reductions were only ~4mmHg, 
increases of 10mmHg in diastolic pressure (or increases on 20mmHg in systolic) are 
associated with a two-fold increases in CV-related mortality, even in individuals as 
young as age 40 [379]. We expect the effects of heat therapy on blood pressure would be 
even greater in a (pre-)hypertensive population. Although exercise is considered a 
primary treatment for hypertension, exercise training generally has little or no effect on 
blood pressure in young individuals. Given that heat therapy is capable of lowering blood 
pressure even in young, normotensive individuals, heat therapy (or exercise combined 
with heat therapy) could prove more powerful than exercise alone as a treatment for 
hypertension.  
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Thermoneutral water immersion   
 Acute thermoneutral water immersion has previously been shown to induce 
changes in CV hemodynamics, such as increased cardiac output and mean arterial blood 
pressure [19], changes in conduit vessel diameter [20], and increased arterial compliance 
[380]. As such, we thought a true sham group which underwent chronic thermoneutral 
water immersion was necessary in order to isolate the effects of repeated rises in core 
temperature in the experimental group.  
We selected a water temperature of 36°C to match mean body temperature and 
therefore minimize core-to-skin temperature gradients. We were successful in preventing 
changes in core temperature in sham subjects, with no greater than +/-0.2°C changes in 
Tre from resting in any session. However, as mean skin temperature is typically closer to 
33°C, subjects may have experienced some cutaneous vasodilation during thermoneutral 
water immersion sessions, resulting in minor changes in blood flow and shear rate. 
Additionally, by having subjects in a seated position in the tub, we minimized hydrostatic 
effects on blood flow and cardiac output redistribution.  
Regardless of any acute changes, we observed no long-term adaptation in sham 
subjects.   
 
SUMMARY & BRIDGE 
 The data presented in this chapter demonstrates that passive heat therapy is capable 
of inducing robust improvements in macrovascular health, even in sedentary, young 
(otherwise healthy) individuals. Furthermore, the magnitude of improvements in vascular 
function and blood pressure observed in the present study was similar to what is typically 
observed in young, healthy, sedentary subjects with exercise training [365,381,382], and 
in some cases, even greater (e.g. FMD). As such, improved endothelial function and 
reduced arterial stiffness and blood pressure likely underlies the cardioprotective effects 
of lifelong heat therapy, similarly to exercise training.   
 In this chapter, we investigated the effects of passive heat therapy on well-
established biomarkers of macrovascular health. While these were all clinically relevant 
measures that have been validated in multiple large-cohort studies for their ability to 
predict CV morbidity and mortality, other evidence suggests CV disease progression 
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begins in the microvasculature [383]. Thus, in order to provide a comprehensive 
assessment of global vascular health, we also investigated the effects of passive heat 
therapy on microvascular function, presented in the next chapter.  
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CHAPTER VI 
PASSIVE HEAT THERAPY IMPROVES CUTANEOUS 
MICROVASCULAR FUNCTION IN SEDENTARY      
HUMANS VIA IMPROVED NITRIC OXIDE-           
DEPENDENT DILATION 
 
Material contained in this chapter was submitted for publication in the Journal of Applied 
Physiology (submitted May 5, 2016) and is currently under review:  
Brunt VE, Eymann TM, Francsico MA, Howard MJ, and Minson CT. Passive heat 
therapy improves cutaneous microvascular function in sedentary humans via improved 
nitric oxide-dependent dilation. J Appl Physiol. 2016.  
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INTRODUCTION 
 Dysfunction in the microvasculature often precedes dysfunction in the conduit 
vessels [383]. Therefore, developing novel strategies to specifically target this important 
vascular bed is of critical importance. Few studies to date have investigated the effects of 
heat therapy on microvascular function in humans and none have investigated the 
molecular mechanisms that underscore potential adaptions.  
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In humans, the cutaneous circulation offers an ideal site to study microvascular 
function. The accessibility of the skin allows the molecular pathways to be studied easily 
and relatively non-invasively using cutaneous microdialysis. A commonly-used test of 
cutaneous microvascular function is thermal hyperemia in which the skin is locally 
heated to 39-42°C, producing a biphasic vasodilator response [331,336,341,384]. 
Importantly, thermal hyperemia has been shown to be impaired under a variety of disease 
conditions [2,321,328,385] and to mirror microvascular dysfunction in other 
microvascular beds. For example, thermal hyperemia is substantially impaired in diseases 
such as end-stage renal disease [320], essential hypertension [322], type II diabetes 
mellitus [330], and coronary artery disease [319], all diseases which are characterized by 
impaired microvascular function independent of changes in the cutaneous circulation.  
Furthermore, the secondary plateau phase is primarily dependent on nitric oxide (NO) 
[331,334,341]. Given that the majority of disease states are characterized by impaired 
NO-dependent dilation and that the skin offers an accessible means of investigating the 
underlying mechanisms of microvascular function, thermal hyperemia is an ideal test for 
assessing the potential therapeutic effects of heat therapy on the microvasculature.  
Only one study has so far investigated the effects of chronic passive heating on 
cutaneous thermal hyperemia. Carter et al. [16] showed that 8 weeks of lower limb 
heating sufficient to raise body core temperature by 0.5-1.0°C increased the cutaneous 
forearm response to a local thermal stimulus. However, a few limitations to this study 
warrant further investigation. For example, maximal vasodilation at the skin sites were 
not obtained, a commonly performed practice to account for limitations in the laser-
Doppler flowmetry technique [386]. In this setting, recording maximal skin blood flow is 
necessary to determine whether any observed changes were due a structural or functional 
improvement. Additionally, to test microvascular function, a slow local heating protocol 
to 42°C was utilized, which has been shown in microdialysis studies to be only ~30% 
NO-dependent [341] and to be confounded by axon reflex involvement [387]. 
Furthermore, the underlying mechanisms were not investigated, so it is unknown whether 
the improvements in skin blood flow were due to improved NO bioavailability.  
NO bioavailability and cutaneous thermal hyperemia can also be limited by 
oxidative stress [336]. The effects of oxidative stress can by investigated via 
  105 
microdialysis using Tempol, a superoxide dismutase mimetic. While Tempol has been 
shown to have no effect in young, recreationally active subjects when locally heating to 
42°C [336], this protocol elicits vasodilation to ~85-95% of maximal, and so a ceiling 
effect may have been observed. The effects of Tempol have not yet been investigated 
using local heating to 39°C, which reaches a plateau of ~40-60% of maximal [341], 
allowing the effects of pharmacological agents and/or interventions which may increase 
vasodilation to be observed.  Additionally, Tempol has not been investigated in sedentary 
subjects, nor following long-term heat therapy. It has been reported that short-term heat 
acclimation (≤14 days) can increase total peroxide concentration and oxidative stress 
index [388]. However, heat shock proteins, which are elevated following heat acclimation 
[169], can increase expression of antioxidative enzymes, including superoxide dismutase 
[147].  
Therefore, we investigated the effects of eight weeks of passive heat therapy on 
cutaneous microvascular function, consisting of 4-5 sessions per week in which rectal 
temperature was maintained at ≥38.5°C for 60 min per session throughout the 8 weeks. 
The arm used for microdialysis studies was kept out of the water the entire time so that 
adaptations would be induced by systemic increases in body core temperature rather than 
increases in local skin temperature. To assess cutaneous microvascular function, we 
utilized rapid local heating to 39°C, a thermal hyperemia protocol which is ~80% 
dependent on NO [341]. Specifically, we hypothesized that, compared to a sham group 
(thermoneutral water immersion), eight weeks of heat therapy would improve the overall 
plateau response of 39°C cutaneous thermal hyperemia by improving NO-dependent 
dilation (investigated by delivering a NO synthase (NOS) inhibitor via microdialysis). 
Secondly, we hypothesized that Tempol would augment thermal hyperemia in sedentary 
subjects prior to heat therapy, and that Tempol-mediated dilation (the difference between 
Control and Tempol microdialysis sites, indicative of oxidative stress) would decrease 
with eight weeks of heat therapy.  
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METHODS 
Human subjects 
 Of the twenty-five young (18-30 yrs of age), sedentary (<2h of aerobic exercise 
per week), healthy subjects who were initially enrolled in the study, twenty-two 
completed the initial (0wk) cutaneous microdialysis study, and twenty completed the full 
8-wk intervention. However, data from eighteen who completed the intervention are 
included in this chapter (N=9 in each group). Microdialysis data was not collected on one 
of these subjects (heat therapy group) and data was excluded from one subject in the 
sham group due to technical difficulties. All experimental procedures were approved by 
the Institutional Review Board at the University of Oregon. All subjects provided oral 
and written informed consent prior to participation in the study, as set forth by the 
Declaration of Helsinki.  
 As before, subjects were assigned to participate in either 8 weeks of heat therapy 
or thermoneutral water immersion (sham) (see Chapter III, pages 36-38 for descriptions 
of intervention protocols), and were well matched by age, sex, height, weight, BMI, and 
time of year across groups (see Table 3.1, page 36).  
 
Experimental Measures 
 Prior to and following the eight weeks of heat therapy or thermoneutral water 
immersion, subjects reported to the lab having refrained from all over-the-counter 
medications, including vitamins and supplements for 24h, alcohol and caffeine for at least 
12h, food for at least 4h, and exercise for at least 24h. Female subjects provided a 
negative pregnancy test prior to studies, measured using urine hCG. Studies were held at 
the same time of day within subjects and the post study was held at least 48h after the last 
water immersion session in order to capture the chronic effects of heat therapy. Female 
subjects taking hormonal contraceptives (N=10) were studied during the active phase. We 
did not control for menstrual phase in naturally menstruating females (N=2), but the 
phase they were in was consistent between the pre and post studies. Studies were held on 
separate days from macrovascular function testing (described in Chapter V), separated by 
at least 24h. 
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Upon arrival at the laboratory, subject height and weight was obtained. Subjects 
then rested semi-supine and three microdialysis fibers (MD2000, 30-kDa cutoff 
membrane; Bioanalytical Systems, Inc., West Lafeyette, IN, or CMA 31 Linear Probe, 
55-kDa cutoff membrane; CMA Microdialysis AB, Kista, Sweden) were placed at least 5 
cm apart in the ventral skin of the non-dominant forearm. Fibers were introduced with a 
25-gauge needle, which was inserted ~1 mm below the surface of the skin with entry and 
exit sites ~2.5 cm apart. Fibers were then threaded through the lumen of the needle and 
the needle was removed, leaving the fiber in place under the skin. Fibers were secured 
with tape and infused with Lactated Ringer's solution at a rate of 2.0µl/min (CMA 102 
Microdialysis Pump; CMA Microdialysis AB) until the start of study drugs. Due to 
manufacturing issues, we had to switch to a different microdialysis fiber manufacturer 
mid-way through the study. However, the same fibers were used pre and post within each 
subject. All drugs delivered have molecular weights well below the membrane cutoffs, 
the concentrations of drugs delivered were great enough to cause maximal inhibition, and 
the infusion rate was low enough to allow for equilibration with the tissue. Therefore, this 
switch should not have impacted our results.  
A period of at least 60 min was allowed for the trauma associated with needle 
insertion to subside. During this time, subjects were instrumented with local heaters 
(SH02 Skin Heater/Temperature Monitor; Moor Instruments, Axminster, UK) over each 
microdialysis site. Laser-Doppler flowmeter probes (MoorLab; Moor Instruments) were 
seated in the center of each local heater flush with the skin in order to measure red blood 
cell flux, an index of skin blood flow. A fourth local heater with laser-Doppler probe was 
placed at a fourth site that did not have a microdilaysis fiber, which served as a control 
site. A blood pressure cuff was placed on the brachium of the opposite arm (Datex 
Ohmeda CardioCap; GE Medical Systems, Tampa, FL).  
After flux had returned to baseline values, local heaters were set to 33°C and a 5-
min baseline was recorded. After this, microdialysis fibers were randomly assigned to 
receive: 1) Lactated Ringer's (sham site), 2) 10mM Nω-nitro-L-arginine (L-NNA; Sigma-
Aldrich, St. Louis, MO), a non-specific NO synthase inhibitor, or 3) 10µM 4-hydroxy-
2,2,6,6-tetramethylpiperidine-1-oxyl (Tempol; EMD Millipore Chemicals, Billerica, 
MA), a superoxide dismutase mimetic to reduce oxidative stress. All drugs were 
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dissolved in Lactated Ringer's solution. Concentrations of drug were selected based on 
previous studies as the minimum concentrations capable of producing maximal inhibition 
[336,389]. Drugs were delivered for 60 min after which a second 'post-drug' 5-min 
baseline was recorded, immediately prior to the start of local heating.  
The local heaters were increased to a temperature of 39°C at a rate of 0.1°C/s and 
maintained at this temperature until skin blood flux reached a stable plateau for at least 5 
min, which took approximately 30-45 min. Once a stable plateau in skin blood flux was 
reached, the local heaters were furthered increased to 43.5°C at a rate of 0.1°C/s and all 
fibers were infused with 56mM sodium nitroprusside (US Pharmacopeia, Rockville, MD) 
in order to obtain maximal flux.  
 
Pilot Studies to Ensure Efficacy of Tempol 
 In order to ensure non-effects were real and not due to technical or drug 
limitations, we studied an additional two pilot subjects with chronic complete spinal cord 
injury (SCI) (sustained ASIA A complete injuries at T11 and T12, 7 and 8 years ago, 
respectively). SCI is known to result in elevated levels of oxidative stress [390], making 
them an ideal population in which to characterize the efficacy of Tempol. These two 
subjects underwent identical experimental testing to the able-bodied subjects, and were of 
similar age and BMI. Additionally, we have previously studied the effects of Tempol in 
young smokers in our laboratory using the same techniques and concentration of Tempol 
[326]. In these subjects, 10µM Tempol fully reversed impairments in thermal hyperemia.  
 
Data Analysis 
 Data were digitized and recorded to a computer using data acquisition software 
(Windaq; Dataq Instruments, Akron, OH). The local heating response was characterized 
by initial peak, nadir, and plateau. The initial peak was determined as the highest 30s 
period of flux values occurring within the first 5 min of local heating. Nadir was 
determined as the lowest 30s period of flux values occurring within 5 min following the 
initial peak. Plateau was averaged over the last 5 min of stable flux values prior to 
moving on to obtaining maximal flux. All flux values were then converted to cutaneous 
vascular conductance (CVC = flux/mean arterial pressure) and normalized to a 
  109 
percentage of maximal CVC (%CVCmax). There was no difference between CVC at the 
Lactated Ringer’s site and the site which had no fiber (paired t-test across all 0wk data: 
p=0.49) and so data were averaged (“Control”). NO-dependent dilation was calculated as 
the difference in normalized plateau CVC between the Control and L-NNA sites. 
Tempol-mediated dilation was calculated as the difference in normalized plateau CVC 
between the Tempol and Control sites.  
 
Statistics 
 Subject demographic data (age, height, weight, BMI) was compared across 
groups using Student’s unpaired t-test. Mean arterial blood pressure was compared across 
groups and across time (0 vs. 8 weeks) using two-way mixed design analysis of variance 
with a between factor of group and a within factor of week.  
 Effects of the drugs using data pooled across all subjects who completed 0wk 
testing.  Changes in normalized CVC were compared using two-way repeated measures 
(RM) analysis of variance (ANOVA) with factors of drug site (Control, L-NNA, and 
Tempol) and phase into local heating (baseline, peak, nadir, and plateau). Comparisons 
across paired variables were made with Bonferroni’s post-hoc test. Maximal CVC was 
compared across drug sites using one-way RM ANOVA. Pre- to post-drug baseline was 
compared at each site using Student’s paired two-tailed t-test. 
 Effects of the interventions.  Changes in normalized CVC at the Control site (e.g. 
the normal response) were compared using three-way mixed design ANOVA with a 
between factor of group and within/paired factors of week (0 vs. 8) and phase into local 
heating (baseline, peak, nadir, and plateau). Changes in NO-dependent dilation 
(difference in plateau between Control and L-NNA sites) and Tempol-mediated dilation 
(difference in plateau between Control and Tempol sites) were compared using two-way 
mixed design ANOVA with a between factor of group and a within/paired factor of 
week. Maximal CVC was compared using three-way mixed design ANOVA with 
between factors of group and drug site and a within factor of week. For all analyses, 
when significant main effects or interactions were detected, comparisons across paired 
variables (within group) were made with Bonferroni’s post-hoc test and comparisons 
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across groups were made using Student’s unpaired two-tailed t-test. For all analyses, the 
level of significance was set at α=0.05. Data are mean ± S.E.  
 
RESULTS 
 Subject demographic data is presented in Table 6.1. Subjects were well matched 
across the two groups for sex, age, height, weight, and BMI (p>0.64 between groups for 
all demongraphic variables).  
 
Table 6.1. Demographics of subjects who participated in cutaneous microdialysis studies 
 All subjects  
(N=22) 
Heat therapy group  
(N=9) 
Sham group  
(N=9) 
Females (N) 12 5 5 
Age (years) 22 ± 1 22 ± 1 22 ± 1 
Height (cm) 172 ± 2 174 ± 3 172 ± 3 
Weight (kg) 66 ± 2 68 ± 3 66 ± 4 
BMI (kg.m-2) 22.4 ± 0.4 22.6 ± 0.6 22.2 ± 0.6 
Mean arterial pressure (mmHg)2    
     0 weeks 84 ± 1 83 ± 2 83 ± 2 
     8 weeks - 81 ± 2 85 ± 2 
 
 Local heating of the skin elicited a biphasic vasodilator response, consisting of an 
initial peak and plateau with a brief nadir in between the two phases (Figure 6.1 – page 
111). When data were pooled across all subjects who completed the initial 0wk testing 
(N=22), average plateau in the Control site was 43±3%CVCmax, which is similar to what 
we have reported previously [341]. There was a significant interaction between drug site 
and phase into local heating (p<0.001). L-NNA significantly attenuated initial peak, 
nadir, and plateau compared to both the Control and Tempol sites (p<0.001 for all) 
(Figure 6.1 – next page), such that NO accounted for 78±4% of the overall plateau 
increase in CVC above baseline. There was no effect of Tempol on any phase of the local 
heating response compared to the Control site (p=0.53).  
 Heat therapy significantly improved the local heating response (group x week x 
phase of local heating: p=0.04). Within the heat therapy group, initial peak (p<0.001), 
                                                            
2 Blood pressure measurements included in Table 6.1 differ from those reported in Chapter V 
Table 5.1 as they were taken on different days, and in different positions. The semi-recumbent 
position may explain why we observed no significant reduction in these blood pressure 
measurements across heat therapy. 
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nadir (p=0.03), and plateau (p<0.001) were all significantly elevated after 8 weeks of heat 
therapy, whereas no changes were observed in the sham group (week x phase within 
group: p=0.22) (Figure 6.2A – next page, and Table 6.2). 
 
Table 6.2. Initial peak and nadir cutaneous vascular conductance (CVC) and Tempol-
mediated dilation 
 All Subjects Heat Therapy (N=9)  Sham (N=9) 
 (N=22) 0wks 8wks  0wks 8wks 
Initial peak (%CVCmax) 42 ± 3 44 ± 4  59 ± 4*  39 ± 4 45 ± 5 
Nadir (%CVCmax) 20 ± 2 21 ± 4  26 ± 4*  17 ± 3 19 ± 3 
       
Tempol-mediated dilation 4.0±3.3 0.2±6.1 -4.3±7.6  5.6±5.2 0.0±2.4 
Data are mean ± S.E. *p<0.05 vs. 0wks within group. L-NNA, Nω-nitro-L-arginine; 
Tempol-mediated dilation, difference in plateau CVC between Control and Tempol 
microdialysis sites.  
 
 
 
Figure 6.1. Average normalized cutaneous vascular conductance across time into local 
heating in all subjects who completed 0wk testing (N=22) at three microdialysis sites 
receiving 1) Control (Lactated Ringer’s), 2) Tempol, and 3) Nω-nitro-L-arginine (L-
NNA). Data over time were averaged across subjects at 4Hz (solid lines). Baseline, initial 
peak, nadir, and plateau were analyzed for each subject and presented as mean ± S.E. 
(symbols). Note, for initial peak, the symbols do not line up exactly with the solid lines 
since they were analyzed at the subject’s true peak CVC, rather than at a certain time 
point into local heating. *p<0.05 vs. Control. †p<0.05 vs. Tempol. 
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 Heat therapy significantly improved NO-dependent dilation, the difference between 
the Control and L-NNA sites (group x week: p=0.049; 0 vs. 8wks within heat therapy 
group: p<0.01), whereas no change in NO-dependent dilation was observed in the sham 
group (p=0.93) (Figure 6.2B – next page). No changes were observed in Tempol-
mediated dilation, the difference between the Tempol and Control sites, across heat 
therapy or thermoneutral water immersion (p=0.58) (Table 6.2 – previous page). Sample 
size analysis using the difference in Tempol-mediated dilation between 0 and 8wks of 
heat therapy and the standard deviation within the heat therapy group showed that we 
would have needed 260 subjects to show a significant difference with a power of 0.80 
and alpha level of 0.05. In the two SCI subjects (data averaged across the two), plateau 
reached 50.7%CVCmax in the Ringer’s site. Tempol increased plateau in both subjects to 
an average of 61.0%CVCmax. 
 
 
Figure 6.2. A) Local heating plateau and B) and nitric oxide (NO)-dependent dilation 
[difference in plateau between microdialysis sites receiving Lactated Ringer’s (Control) 
and Nω-nitro-L-arginine (L-NNA)] across 8 weeks of heat therapy or thermoneutral 
water immersion (sham). Heat therapy increased both plateau and NO-dependent dilation 
in every subject, as indicated by the individual data. Data are mean ± S.E. *p<0.05 0 vs. 
8wks within group. 
 
   
Maximal CVC and baseline 
 There were no significant effects of the drugs on maximal CVC within the pooled 
0wk data (p=0.20) (Table 6.3 – next page). Across the intervention, there was a 
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significant interaction between group, week, and drug site (p=0.02), but the only 
significant difference in paired variables that was found was the increase in maximal 
CVC at the Tempol site in the heat therapy group (p=0.01). L-NNA significantly 
decreased baseline CVC (p=0.02) and Tempol significantly increased baseline CVC 
(p=0.03) (Table 6.4).  
 
  Table 6.3. Maximal cutaneous vascular conductance (CVC) 
 All Subjects Heat Therapy (N=9)  Sham (N=9) 
 (N=22) 0wks 8wks  0wks 8wks 
       
Maximal CVC 
(mV/mmHg*100) 
      
    Control 253 ± 15 302 ± 26 285 ± 33  214 ± 14 271 ± 12 
    L-NNA 198 ± 14 185 ± 22 218 ± 41  197 ± 15 235 ± 31 
    Tempol 241 ± 32 199 ± 26  339 ± 46*  214 ± 18 180 ± 16 
   Data are mean ± S.E. *p<0.05 vs. 0wks within group. L-NNA, Nω-nitro-L-arginine 
 
 
 
     Table 6.4. Baseline drug effects 
 Pre-drug baseline Post-drug baseline P-value 
Control 5.5 ± 0.4 6.1 ± 0.5 0.13 
L-NNA 7.8 ± 0.9   6.2 ± 0.9* 0.02 
Tempol 7.4 ± 0.8   8.5 ± 1.1* 0.03 
Baseline data pooled across all subjects completed 0wk testing (N=22). 
Data are mean ± S.E. cutaneous vascular conductance (%max). *p<0.05 
from pre-drug baseline 
 
 
DISCUSSION 
 This is the first study to investigate the molecular mechanisms by which passive 
heat therapy improves microvascular function. Our major finding is that passive heat 
therapy improves cutaneous thermal hyperemia via improved NO bioavailability. We 
observed no change in NO-dependent dilation in our sham subjects and no change in the 
sites receiving Tempol in either group, demonstrating that the observed findings in the 
experimental group were due to the heat therapy intervention through improved NO-
dependent dilation.  
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 Local heating of the skin produces a biphasic vasodilator response, consisting of an 
initial peak occurring within the first 5 min into heating and a secondary plateau, which is 
achieved after approximately 20-40 min into heating. The initial peak is a sensory nerve 
axon reflex which elicits dilation via both NO and endothelial-derived hyperpolarizing 
factors (EDHFs) [331,338,387], most likely initiated via transient receptor potential 
vanilloid type-1 (TRPV-1) channels [332] located on the sensory nerves, which are 
thought to release calcitonin gene-related peptide and/or substance P [333]. The plateau 
phase is heavily dependent on NO [331,334] and also EDHFs to varying extent 
depending on the temperature used [338,341].   
 
Heat Therapy 
 Heat therapy increased all phases of the local heating response, indicating improved 
microvascular function. Furthermore, these effects were NO-dependent as no changes in 
the NOS inhibited site were observed. No changes were observed in the sham group, 
suggesting that improvements in microvascular function in the heat therapy group were 
the result of the heat exposure itself and not due to possible hemodynamic changes 
secondary to changes in hydrostatic pressure or visitation to the lab environment.  
 We believe the mechanisms behind this adaptation are two-fold. Heat stress induces 
elevations in core temperature and subsequent increases in blood flow, particularly to the 
skin. Elevations in core temperature upregulate expression of heat shock proteins. In 
particular, Hsp90 is an essential cofactor for endothelial NOS (eNOS) [4], meaning that 
changes in Hsp90 can alter eNOS activity and NO production independent of changes in 
total eNOS protein [137]. In the skin, inhibition of Hsp90 with geldanamycin attenuates 
thermal hyperemia [391], indicating Hsp90 is a primary player in the response. Secondly, 
increases in blood flow and shear stress are essential for cutaneous microvascular 
adaptation. For example, chronic localized arm heating in a water bath improves 
cutaneous microvascular function, but these improvements are prevented when a blood 
pressure cuff is used on the upper arm to prevent increases in blood flow above baseline 
during heating [229]. Shear stress can stimulate NO production via phosphorylation of 
eNOS through a few mechanisms, including through activating the receptor for vascular 
endothelial growth factor (VEGFR-2) [221] and activating phosphoinositide 3 (PI3)-
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kinase, which in turn activates protein kinase A and then eNOS [222]. Therefore, not 
only does heat therapy likely result in increased association of eNOS with Hsp90, but the 
pathways necessary for eNOS activation are also likely upregulated.   
 Importantly, we kept the arm used for microdialysis experiments out of the hot tub 
to better isolate the systemic effects of heat therapy rather than effects of chronic 
elevations in local skin temperature. By doing so, we believe our results may better 
reflect changes that occurred in other microvascular beds as the thermal hyperemia 
response has been shown to reflect globalized microvascular function [323-325]. In 
support of this, we also showed that forearm reactive hyperemia is improved following 8 
weeks of heat therapy (Brunt et al. 2016). Although we did not investigate this in the 
present study, the skin under the water (e.g. lower torso and legs) presumably received an 
even greater stimulus for adaptation as it would have been subject to both the systemic 
stimuli (e.g. elevated core temperature, exposure to circulating factors upregulated in the 
blood, and increased shear stress) and to elevations in local temperature. Shear stress may 
have been even greater in the legs as vasodilation would likely have been greater given 
the combined core temperature elevation and local skin temperature elevation. As such, 
heating the legs may be valuable for improving microvascular health in patient 
populations such as spinal cord injured and peripheral artery disease patients who suffer 
from a variety of complications secondary to poor circulation in their legs. However, it is 
important to recognize that we observed improved function in a microvascular bed which 
experienced large magnitude vasodilation during hot water immersion sessions. 
Microvascular beds that do not vasodilate during heat stress (e.g., skeletal muscle or 
kidneys) may not have experienced as great of improvements in microvascular function 
as did the skin (although, we did observe improved area under the curve forearm post-
occlusive reactive hyperemia, which is reflective of microvascular function 
predominantly in the skeletal muscle of the forearm, described in Chapter V).    
 
Effects of Tempol 
 Superoxide, a predominant reactive oxygen species, binds to NO to produce 
peroxynitrite, reducing NO bioavailability. Additionally, superoxide uncouples 
tetrahydrobiopterin, an essential cofactor for eNOS, causing eNOS to produce superoxide 
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instead of NO, further depleting NO bioavailability [142]. Tempol, a superoxide 
dismutase mimetic, reduces superoxide to hydrogen peroxide, thus improving NO 
bioavailability [392]. Oxidative stress, the accumulation of reactive oxygen species such 
as superoxide, occurs with aging and with the progression of vascular disease. In the skin, 
impairments in vasodilator responses with primary aging and hypertension can be 
reversed by administration of the antioxidant ascorbate [393,394], and by restoring 
tetrahydrobiopterin levels [395] or inhibiting arginase [393,396], which breaks down L-
arginine, the substrate necessary for conversion of NO by eNOS, and is upregulated by 
oxidative stress. However, the effects of Tempol, which targets oxidative stress more 
specifically than antioxidants such as ascorbate via its direct effects on superoxide, has 
been studied relatively little in the skin, despite being used extensively in other 
preparations.  
 When locally heating the skin to 42°C, Tempol has been shown to have no effect in 
young, recreationally active subjects [336], but to augment the plateau in young smokers 
[326], patients with chronic kidney disease [397], and young healthy subjects following 
angiotensin II infusion (a model of vascular disease) [336], restoring plateau back to the 
level of young, healthy individuals. However, in young, healthy subjects, plateau CVC 
when heating to 42°C reaches ~85-95% of CVCmax and so non-effects of Tempol may 
have been due to a ceiling effect. Heating to 39°C better isolates the NO-component 
compared to the more commonly used protocol heating to 42°C (~80% NO vs. ~50-60% 
NO with 42°C local heating), and it reaches a plateau of ~40-60%CVCmax allowing for 
the investigation of interventions which may improve NO-dependent dilation, such as 
heat therapy [341]. In the present study, our data show that Tempol also has no effect in 
young, sedentary but otherwise healthy subjects when using this local heating protocol, 
either across all subjects pooled at 0wks or following heat therapy or thermoneutral water 
immersion. As such, this establishes these methods for use in future studies in patient 
populations who have elevated oxidative stress in which heat therapy (or other 
interventions) may be able to alleviate oxidative stress-associated impairments in 
endothelial function.  
 In order to ensure non-effects of Tempol were truly because oxidative stress was 
minimal in our young, sedentary subjects and not because the drug didn’t work in our 
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hands, we studied two SCI subjects. SCI is associated with elevated oxidative stress 
[390], which is likely exacerbated due to increases in circulating angiotensin-II [398], 
which increases superoxide production via NADPH-oxidase [399]. This population was 
selected over other patient groups known to have high oxidative stress because they are 
young (matched to the mean age of our other subjects) and free of co-morbidities which 
might alter the effects of Tempol. For example, we have previously shown this 
concentration of Tempol was highly effective at reversing oxidative stress-associated 
impairments in young smokers [326]; however, oxidative stress is considerably higher in 
smokers than in any other disease state as multiple compounds in the cigarettes 
themselves induce oxidative stress [400]. By studying SCI subjects, we wanted to ensure 
the effects on vasodilation of more physiological levels of oxidative stress could also be 
detected using this concentration of Tempol via microdialysis.  
 Although our data suggest Tempol is having the effect we believe it is, some non-
specific effects of Tempol have been observed in animal studies. For example, Tempol 
has been shown to open ATP-sensitive potassium channels [401] and calcium-sensitive 
potassium channels [402], the latter of which is highly involved in the cutaneous thermal 
hyperemia response when heating to 42°C [338]. In our previous study in young smokers, 
we demonstrated no effect of Tempol when co-infused with L-NNA, indicating no NO-
independent effects [326]. 
 
Maximal CVC 
 Although we observed some trends in maximal CVC across drug sites and 
interventions, only the increase in maximal CVC in the Tempol site with heat therapy 
was statistically significant. Previous studies from our lab and others [326,397] have 
observed no effects of Tempol on maximal CVC, and since this effect was only observed 
in one site, we do not believe it was due to heat therapy. More likely, these differences 
are due to limitations in the laser Doppler flowmetry technique rather than physiological 
structural changes in the cutaneous microvasculature. For example, microvessel density 
can vary greatly from site to site, highlighting the importance of normalizing laser 
Doppler flux values [386]. 
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CONCLUSIONS, PERSPECTIVES & BRIDGE 
 In the present study, we have demonstrated that passive heat therapy improves 
cutaneous microvascular function via improved NO-dependent dilation. Many disease 
states are characterized by impaired endothelial function, particularly in the 
microvasculature, and the usual cause is impaired NO bioavailability secondary to 
chronic oxidative stress and inflammation. Although exercise is a potent means of 
improving vascular function, many patient populations are either unable or unwilling to 
exercise to an extent necessary for inducing protective adaptation. Our results 
demonstrate that passive heat therapy may offer a powerful alternative for improving 
microvascular function and NO bioavailability that could be implemented by a wide 
range of patient populations.   
 While we have demonstrated a role for NO in the adaptations to heat therapy in this 
chapter, the specific cellular mechanisms that result in improved NO bioavailability are 
still unknown. In the next chapter, we sought to discover the intracellular pathways 
associated improved NO bioavailability and vascular function in cultured endothelial 
cells.  
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CHAPTER VII 
BOTH DIRECT HEAT AND EXPOSURE TO SERUM FROM 
YOUNG, SEDENTARY HUMANS WHO HAVE UNDERGONE 
PASSIVE HEAT THERAPY IMPROVES NITRIC OXIDE 
SIGNALING, OXIDATIVE STRESS, AND        
ANGIOGENESIS IN CULTURED                            
ENDOTHELIAL CELLS 
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INTRODUCTION 
As detailed in Chapter V and VI, eight weeks of passive heat therapy improves 
biomarkers of conduit vessel and microvascular function in young, sedentary individuals. 
In particular, we observed robust improvements in brachial artery flow-mediated dilation 
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(FMD) (Chapter V), which is heavily dependent on nitric oxide (NO) [274], and 
cutaneous microvascular NO-dependent dilation (Chapter VI). As reviewed in Chapter II, 
we believe the mechanisms behind these improvements are two-fold. First, heat exposure 
increases cardiac output, blood flow, and therefore shear stress on the vasculature. Shear 
stress is well-known to upregualte eNOS activity and therefore NO bioavailability 
through several mechanisms. Secondly, elevations in body core temperature induce 
expression of heat shock proteins (HSPs), which in turn stabilize a variety of proteins 
important to the cardiovascular system. These include eNOS [4] and anti-oxidative 
enzymes such as superoxide dismutase (SOD) [147]. Together, these changes may 
explain the improvements in NO-dependent dilation we observed in humans. Therefore, 
the overall purpose of the experiments described in this chapter were to elucidate the 
molecular mechanisms by which heat therapy improves NO bioavailability and vascular 
function.  
The ideal way to investigate which molecular pathways are altered following heat 
therapy would be to collect endothelial cell biopsies from subjects before and after heat 
therapy. Although it is possible to collect endothelial cells from human subjects using a J-
wire technique [403], this technique yields a very small sample of cells, making it 
difficult to quantify changes in protein. We therefore utilized a cell culture model.  
Endothelial cells in vivo in subjects undergoing heat therapy are exposed to three 
different stimuli: 1) the direct intracellular effects of elevations in temperature, 2) the 
indirect effects of circulating factors upregulated elsewhere in the body, and 3) the effects 
of intermittent increases in shear stress. The effects of shear stress on cultured endothelial 
cells have been studied extensively, as reviewed in Chapter II, and so for these 
experiments, we focused on the effects of direct heat and of circulating factors.   
Therefore, in order to investigate the molecular mechanisms by which heat 
therapy functionally improves NO-dependent dilation, we utilized a cell culture model to 
isolate the direct effects of heat from the effects of upregulated circulating factors. We 
hypothesized that incubating cultured endothelial cells either 1) at 39°C (to match core 
temperatures reached by human subjects during heat therapy sessions) or 2) with sera 
collected from human subjects before and after 8 weeks of heat therapy, would increase 
HSP, eNOS and SOD protein abundance, and would reduce production of superoxide.  
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To support this purpose, we collected primary peripheral blood mononuclear cells 
(PBMCs) from human subjects before and 1h after the first and last water immersion 
sessions in order to compare the HSP response in cultured cells exposed to direct heat to 
intracellular HSP levels achieved in vivo in cells exposed to the same conditions as 
endothelial cells. We hypothesized that heating cultured endothelial cells at 39°C for 24h 
would induce a similar increase in Hsp70 and Hsp90 as observed in primary PBMCs 
following 8 weeks of heat therapy.  
As a second purpose, we utilized an endothelial tubule formation bioassay to 
investigate whether heat therapy improves serum angiogenic potential. In our human 
subjects, we observed a reduction in blood pressure, which is often associated with 
angiogenesis. As NO is essential for angiogenesis, endothelial tubule formation is also a 
functional test of improved NO bioavailability. Therefore, by performing this assay, we 
can relate changes in protein abundance observed in experiments performed for our first 
hypothesis to functional improvements in NO bioavailability. We hypothesized that 
incubating cultured endothelial cells with sera collected from human subjects before and 
after 8 weeks of heat therapy would increase endothelial tubule formation, and that this 
increase would be prevented by the addition of 1mM Nω-nitro-L-arginine (L-NNA; a 
non-specific NOS inhibitor) to the cell culture media. We additionally hypothesized that 
incubating cultured endothelial cells with sera from human subjects before and after 8 
weeks of thermoneutral water immersion (sham) would have no effect on endothelial 
tubule formation.  
Lastly, we compared changes in some of the variables obtained through cell 
culture to in vivo biomarkers of vascular function using regression analysis. We 
hypothesized that improvements in FMD and cutaneous NO-dependent dilation would be 
correlated with improvements in eNOS and SOD protein in serum-exposed cultured 
endothelial cells, and that improvements in blood pressure (particularly diastolic and 
mean arterial pressure) would be correlated with improvements in serum angiogenic 
potential (as measured by endothelial tubule formation). 
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METHODS 
Human Subjects 
All subjects provided oral and written informed consent prior to participation in 
the study, as set forth by the Declaration of Helsinki. All experimental procedures were 
approved by the Institutional Review Board at the University of Oregon. Twenty young 
(18-30 yrs of age), healthy (no history or cardiovascular-related diseases), sedentary (<2h 
aerobic exercise per week) subjects, who were non-smokers and were not taking any 
prescription medications except for contraceptives, completed 8 weeks of either heat 
therapy (N=10) or thermoneutral water immersion (sham; N=10), as described in Chapter 
III (pages 36-38).  
On the first (0wks) and last (8wks) water immersion sessions, venous blood was 
drawn into serum-separating vacutainers (BD, Franklin Lakes, NJ) and Ficoll Hypaque-
containing cell preparation tubes with sodium citrate (CPT Vacutainer; BD, Franklin 
Lakes, NJ) immediately before (pre hot tub [preHT]) and 1h after water immersion 
(postHT). This time frame was selected because based on pilot data (reported in Chapter 
IV, page 71) and previous reports [129]. The session at 8wks was held 36-48h after the 
penultimate water immersion session in order to capture the chronic rather than acute 
effects of heat therapy. Subjects reported to the laboratory fasted from food for at least 2h 
and having abstained from exercise for 24h. Sessions were held at the same time of day 
and subjects were asked to maintain food prior to 2h before and caffeine intake similarly 
between the two sessions. After collection, venous blood in serum-separating tubes was 
kept at room temperature for 30min and then separated by centrifugation. Serum was 
stored at –80°C until later use in cell culture experiments. PBMCs were isolated from 
whole blood in CPT vacutainers by centrifugation (3,000rpm for 15 min at room 
temperature).  
 
Direct heat & serum exposure experiments 
Following 4h serum starve, human umbilical vein endothelial cells (HUVECs; 
ATCC, Manassas, VA) were incubated for 24h under the following conditions: 1) 37°C 
in complete media, 2) 39°C in complete media, or 3) 37°C in non-supplemented media 
with 10% human sera collected at each of the 4 time points (0wks preHT, 0wks postHT, 
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8wks preHT, 8wks postHT) from all 10 subjects in the heat therapy group. Following the 
24h, cells were lifted with TrypLE, combined with radioimmunoprecipitation assay 
buffer (RIPA) plus protease inhibitor, and lysed via sonication. Cells used for 
experiments had undergone 2-3 passages.  
 
Western blotting 
Protein (20-50ug) from HUVEC and primary PBMC lysates was separated by 
electrophoresis on 4-20% SDS polyacrylamide separating gels (Life Technologies, Grand 
Island, NY) and then transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA). 
Membranes were Ponceau-stained to access transfer across each gel. Membranes were 
incubated for 1h in Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln, NE) and 
then incubated overnight at 4°C in blocking buffer containing primary antibodies. 
Membranes were then washed and incubated with the appropriate secondary antibodies 
(LI-COR Biosciences) for 1h at room temperature. The fluorescent bands were digitized 
using a LI-COR Odyssey infrared imaging system (LI-COR Biosciences). Digitized 
images were quantified using LI-COR Image StudioTM software. Antibodies were 
stripped using NewBlotTM Nitro Stripping Buffer (LI-COR Biosciences) in between 
probing for primary antibodies.  
Primary antibodies for HUVECs were: 1) anti-endothelial NO synthase (eNOS) 
(1:1,000; Cell Signaling Technology, Danvers, MA) 2) anti-superoxide dismutase-2 
(MnSOD/SOD2) (1:1,000; Sigma-Aldrich, St. Louis, MO) 3) anti-Hsp90 [S88] (1:200; 
Abcam, Cambridge, MA) and 4) anti-Hsp70 [BRM-22] (1:5,000; Abcam), and 5) anti-
vinculin (loading control; 1:1,000; Cell Signaling Technology).  
Primary antibodies for PBMCs were: 1) anti-Hsp70 [BRM-22] (1:5,000; Abcam) 
2) anti-Hsp90 [S88] (1:200; Abcam), or 3) anti-β-actin (loading control; 1:1,000; Cell 
Signaling Technology). 
 
Superoxide production 
HUVECs were plated in 96-well culture plates at 2 x 104 cells per well and 
exposed to the direct heat or serum exposure conditions as described in triplicate. After 
24h, media was replaced with 20µl of 1µM superoxide detection stain (Cellular 
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Superoxide Detection Assay Kit; Abcam), which permeates the cell membrane and reacts 
with specifically with superoxide. Cells were incubated for 1h under the same conditions 
as before (37 or 39°C, or 37°C with 10% serum). Additional wells were left untreated (in 
complete media) and unstained (blank) or were treated with 20µl of 500µM pyocyanin 
(reactive oxygen species inducer), which served as a positive control. Cell fluorescence 
was determined with a phase-contrasted fluorescent microscope with Cy3 filter at 10X 
optical zoom (Axio Observer.D1; Zeiss, Oberkochen, Germany). Total cell fluorescence 
per frame minus blank fluorescence was determined using ImageJ analysis software 
(National Institutes of Health; Bethesda, MD).  
 
Endothelial tubule formation assay 
As a functional test of improved NO bioavailability, serum angiogenic potential 
was quantified as previously described [348]. HUVECs were plated in 96-well cell 
culture plates onto solidified phenol-red free growth factor reduced Matrigel (BD 
Bioscience, San Jose, CA) at a concentration of 1 x 105 cells/ml in serum-free media. 
Cells were treated with 10% serum from human subjects collected at each of the four 
time points and from each of the two groups (in triplicate per sample), and incubated for 
10h. Wells were imaged with a phase-contrasted microscope at 2.5X optical zoom and 
total length of tubule formation per frame was assessed with ImageJ analysis software by 
two blinded investigators. Results were averaged across investigators and across two 
separate experiments for verification.  
In a subset of experiments, cells were additionally treated with 1mM Nω-nitro-L-
arginine (L-NNA; Sigma Aldrich, St. Louis, MO) to inhibit NOS and to determine 
whether the pro-angiogenic effects of heat therapy are mediated via NOS upregulation. A 
concentration of 1mM was selected based on pilot studies in order to reduce NOS activity 
without completing abolishing angiogenesis.   
 
Enzyme-linked immunosorbent assays 
To attempt to identify factors in the serum affected by heat therapy that could be 
responsible for inducing changes in endothelial cells, we measured serum concentrations 
of free vascular endothelial growth factor (VEGF) and soluble VEGF Receptor (sFlt)-1 
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using commercially-available enzyme linked immunosorbent assay kits (R&D Systems, 
Quantikine, Minneapolis, MD) according to manufacturer's instructions. The ratio of sFlt-
1 to VEGF was calculated as a marker of bioavailable VEGF.  
 
Statistical analyses  
Changes in protein abundance and superoxide production in direct heating 
experiments (37°C vs. 39°C) were compared using Student’s unpaired t-test. Changes in 
protein abundance and superoxide production in serum exposure experiments, serum 
[VEGF], [sFlt-1], and sFlt-1/VEGF, and endothelial tubule formation with heat therapy 
sera, sham group sera, and heat therapy sera + L-NNA, were compared using two-way 
repeated measures ANOVA with factors of week (0 vs. 8wks) and time (pre vs. post hot 
tub [HT]). When significant main effects were observed, pairwise comparisons were 
made using Tukey’s post hoc test. Comparisons in endothelial tubule formation across 
groups were made using Student’s paired (heat therapy with vs. without L-NNA) and 
unpaired (heat therapy vs. sham) t-tests. We were underpowered for comparing changes 
in HSP protein in PBMCs using ANOVA (power on two-way RM ANOVA for Hsp90 
was 0.21) and so differences were instead compared using Student’s paired t-test for 
0wks pre vs. 0wks post, 0wks pre vs. 8wks pre, and 8wks pre vs. 8wks post.  
Linear regression analysis was used to compare changes in molecular measures to 
changes in in vivo outcomes across the 8 weeks of intervention. Specifically, we 
compared changes in serum angiogenic potential (pooled across all 20 subjects) to 
changes in mean arterial, systolic, and diastolic pressure, and we compared changes in 
eNOS and SOD protein in serum exposed cells (heat therapy group only) to changes in 
FMD, cutaneous NO-dependent dilation.  
 
RESULTS 
Effects of direct heating on protein abundance & superoxide production  
 Exposing endothelial cells to 39°C for 24h significantly increased Hsp70 
(p<0.001), Hsp90 (p=0.02), and MnSOD (p=0.02) protein, but had no effect on eNOS 
protein (p=0.65), all relative to endothelial cells incubated at 37°C (Figure 7.1 – next 
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page).  Additionally, direct heating significantly reduced superoxide production (p=0.03) 
(Figure 7.3A – page 128). 
 
 
Figure 7.1. Heating endothelial cells to 39°C for 24h had no effect on endothelial nitric 
oxide synthase protein expression (eNOS) (A), but increased protein expression of 
manganese superoxide dismutase (MnSOD) (B), heat shock protein (Hsp)-70 (C) and 
Hsp90 (D). All data was normalized to a vinculin loading control and are presented as 
mean±S.E. fold changes from cells exposed to 37°C. N=9 across 4 separate experiments. 
*P<0.05 vs. 37°C (control). E) Western blots performed with HUVEC lysates incubated 
at 37°C or 39°C for 24h.  
 
Effects of serum exposure on protein abundance & superoxide production 
 Exposing endothelial cells to sera collected following the first hot water 
immersion session (0wks postHT) had no effect on eNOS (p=0.37) or MnSOD (p=0.58) 
protein, relative to cells exposed to sera collected prior to the same session (0wks preHT). 
However, sera collected following 8 weeks of heat therapy (chronic condition; 8wks 
preHT) induced significant increases in both eNOS (p=0.04) and MnSOD (p=0.02) 
protein in endothelial cells. These increases were maintained when endothelial cells were 
exposed to sera collected for the last hot water immersion session (8wks postHT vs. 8wks 
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preHT, eNOS: p= 0.57, MnSOD: p=0.99). These improvements occurred independent of 
intracellular changes in HSPs, as there was no effect of serum exposure on either Hsp70 
(p=0.50) or Hsp90 (p=0.45). Results are summarized in Figure 7.2.  
 Conversely, both sera collected following the first hot water immersion (p=0.001) 
and chronically following the 8 weeks of heat therapy (p=0.004) reduced superoxide 
production (Figure 7.3B – next page). 
 
 
 
Figure 7.2. A) Endothelial nitric oxide synthase (eNOS), B) manganese superoxide 
dismutase (MnSOD), C) heat shock protein (Hsp) 70, and D) Hsp90 protein abundance in 
endothelial cells exposed to sera from human subjects collected before (pre) and 1h after 
(post) the first (0wks) and last (8wks) heat therapy sessions. Data were normalized to a 
vinculin loading control and are presented as mean±S.E. fold changes from cells exposed 
to sera from the same human subjects prior to heat therapy (0wks pre). *P<0.05 vs. 0wks 
pre. E) Western blots performed with HUVEC lysates exposed to sera from two 
representative heat therapy subjects.   
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Figure 7.3. Superoxide production in cultured endothelial cells incubated for 24h at A) 
37°C or 39°C, or B) with 10% sera collected from human subjects pre (solid bars) and 1h 
post (dashed bars) the first (0wks) and last (8wks) heat therapy sessions. Data are 
mean±S.E., *p<0.05 from 37°C or 0wks pre conditions. C) Representative Cy3 
fluorescent images taken at 10X optical zoom of cultured endothelial cells stained for 
superoxide and exposed to 37°C, 39°C, or sera from one representative subject who 
underwent heat therapy.  
 
Heat shock proteins in primary mononuclear cells 
 As confirmation that changes we observed with direct heating experiments were 
comparable to changes that may occur in vivo, we measured HSP protein abundance in 
PBMCs collected from human subjects. Although not statistically significant, Hsp70 and 
Hsp90 were increased in PBMCs 1h following the first heat therapy session (Hsp70: 
p=0.12, Hsp90: p=0.09). Following 8 weeks of heat therapy, Hsp70 remained 
significantly elevated (p=0.05); whereas, Hsp90 tended to return back towards baseline  
(p=0.24). Importantly, fold changes in both Hsp70 and Hsp90 in PBMCs were similar to 
changes observed in cultured endothelial cells incubated at 39°C for 24h (Figure 7.4 – 
next page).  
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Figure 7.4. Heat shock protein (Hsp)-70 (A) and Hsp90 (B) protein abundance was 
similar between human umbilical vein endothelial cells (HUVECs) incubated at 39°C for 
24h and peripheral blood mononuclear cells collected from human subjects after the first 
hot water immersion session (0wks post) and chronically following 8 weeks of heat 
therapy (8wks pre). Data are mean±S.E. and presented as a fold change from control 
conditions (37°C or exposure to sera from subjects prior to heat therapy, 0wks pre), as 
indicated by the dashed lines.  
 
Endothelial Tubule Formation 
The effects of heat therapy and thermoneutral water immersion (sham) are 
summarized in Figure 7.5 (next page). Endothelial tubule formation was significantly 
improved in cells exposed to sera collected from subjects following one bout of hot water 
immersion (0wks postHT; p=0.04) and following 8 weeks of heat therapy (8wks preHT; 
p=0.03), relative to cells exposed to sera from the same subjects prior to heat therapy 
(0wks preHT). Although endothelial tubule formation in cells exposed to 8wks postHT 
sera trended to come back down towards baseline, this was not significantly reduced from 
8wks preHT (p=0.52). The addition of 1mM L-NNA to the culture media had no effect 
on baseline endothelial tubule formation (exposure to 0wks preHT sera from subjects in 
the heat therapy group; with vs. without L-NNA: p=0.41). However, L-NNA prevented 
the improvement in tubule formation associated with heat therapy (p=0.50). There were 
also no effects of sham on endothelial tubule formation (0wks preHT vs. 0wks postHT: 
p=0.39; vs. 8wks preHT: p=0.98; vs. 8wks postHT: p=0.15), however, we did observe a 
significant difference in tubule formation in cells exposed to sera from sham subjects 
between the 0wks postHT and 8wks postHT time points (p=0.004).  
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Figure 7.5. A) Changes in endothelial cell tubule formation following treatment with sera 
from heat therapy (with and without 1mM Nω-nitro-L-arginine [L-NNA]) and sham 
subjects collected pre (solid bars) and 1h post (dashed bars) the first (0wks) and last 
(8wks) water immersion sessions. Endothelial tubule formation was significantly 
improved following treatment with sera from subjects in the heat therapy group following 
acute and chronic hot water immersion. No other significant changes were observed. Data 
are mean±S.E., *p<0.05. B) Representative phase contrasted images at 2.5X 
magnification of endothelial cells exposed to sera collected from the same subject in the 
heat therapy group before and after 8wks of heat therapy, with and without L-NNA, and 
from a subject in the sham group (all pre-water immersion). 
 
 
Serum VEGF and sFlt-1 concentrations 
Heat therapy had no effect on serum concentration of VEGF (p=0.31) or sFlt-1 
(p=0.92), or on the ratio of sFlt-1/VEGF (p=0.68) (Figure 7.6 – next page).  
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Figure 7.6. Serum concentrations of A) vascular endothelial growth factor (VEGF) and 
B) soluble VEGF receptor (sFlt)-1, and C) the ratio of sFlt-1/VEGF, indicative of 
bioavailable VEGF, across time points into heat therapy. Serum was collected before 
(pre; solid bars) and 1h after (post; dashed bars) the first (0wks) and last (8wks) heat 
therapy session. Data are mean±S.E. No significant differences were observed. 
 
Correlations between cellular and in vivo vascular function data 
 Changes in serum angiogenic potential were significantly correlated with changes 
in mean arterial pressure (r2=0.28, p=0.02) (Figure 7.7), but not with changes in diastolic 
(r2=0.08, p=0.23) or systolic blood pressure (r2=0.05, p=0.34). We found no significant 
correlations between changes in eNOS or SOD protein with in vivo outcomes, 
presumably because the sample size was lower for these measures (performed in only 
heat therapy subjects). 
 
Figure 7.7. Changes in serum angiogenic balance across the 8 weeks of heat therapy or 
thermoneutral water immersion (sham), as measured by endothelial tubule formation in 
cells exposed to sera from human subjects, significantly predicted changes in mean 
arterial pressure.  
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DISCUSSION 
In the present study, we showed that 1) exposing endothelial cells to physiological 
levels of heat (39°C) increases SOD, Hsp70, and Hsp90 protein abundance, and reduces 
superoxde production, 2) exposing endothelial cells to serum collected from human 
subjects who have undergone 8 weeks of passive heat therapy increases eNOS and SOD 
protein abundance and reduces SO production, independent of changes in HSPs, and 3) 
serum from heat-acclimated human subjects increases endothelial tubule formation, a 
functional assay of NO bioavailability. Presumably in vivo, these effects are combined, 
offering multiple mechanisms by which passive heat therapy improves NO bioavailability 
and presumably overall vascular function. Additionally, we observed that circulating 
factors upregulated following acute hot water immersion were able to induce some 
changes in endothelial cells (e.g., reduced superoxide production and increased 
endothelial tubule formation), but not all, suggesting that repeated bouts of hyperthermia 
are required to acquire all cellular adaptations of interest.  
 
Direct effects of heat 
To our knowledge, this is the first study to investigate changes in endothelial cells 
in response to lower levels of heat (i.e., similar to temperatures that endothelial cells in 
vivo may commonly be exposed to). Many studies have investigated the effects of 
exposure to higher levels of heat (41-45°C). While these studies induce greater changes 
in protein abundance, they are less translatable to what occurs in vivo in humans.  
In the present study, physiological levels of heat were sufficient to induce 
increases in HSP abundance in cultured endothelial cells at magnitudes similar to what 
we observed in blood mononuclear cells in human subjects (approximately 1.5-fold). 
PBMCs were chosen as an in vivo marker for measuring HSPs because they are exposed 
to the same conditions in vivo as endothelial cells, they can be collected from human 
subjects easily and relatively non-invasively, they exhibit a stress response to exercise 
hyperthermia [114,115], and HSPs are upregulated under non-stressed conditions in 
human PBMCs following 10 days of exercise heat acclimation [169].  
Heating endothelial cells at 39°C for 24h increased MnSOD protein and reduced 
superoxide production. MnSOD has been previously shown to be increased in association 
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with Hsp70 in gerbil hippocampal neurons [146] and to be suppressed in Hsp70-knockout 
mice [147], as such, it is likely that MnSOD increased with direct heating in the present 
study as a direct result of increased Hsp70. HSPs are known to stabilize other anti-
oxidative enzymes, such as glutathione peroxidase [5]. However, we chose to focus on 
SOD for the current study as it is the most relevant for regulating NO bioavailability.  
Interestingly, we observed no effect of direct heat on eNOS protein, although we 
observed approximately a 1.5-fold increase in Hsp90. Hsp90 is an essential cofactor for 
eNOS activation, which controls the balance of NO and superoxide production [4]. 
Therefore, increased Hsp90 abundance can increase NO bioavailability, independent of 
changes in total eNOS protein. The predominant mechanism by which Hsp90 is thought 
to regulate eNOS activity is through enhancing Akt phosphorylation [136] and calcium-
calmodulin binding to eNOS [134]. In rats, Harris et al. [137] demonstrated that 10 weeks 
of exercise training had no effect on eNOS protein, but increased Hsp90 content and 
association of Hsp90 with eNOS, therefore increasing eNOS activity and NO production. 
Based on our results, the same may occur with physiological levels of direct heating.  
We did not investigate the effects of direct heat on tubule formation in the present 
study as it has previously been well established that Hsp90 regulates angiogenesis. Rattan 
et al. [404] showed that 24h exposure to 41°C improves tubule formation in HUVECs 
using the same assay as we used in the present study. Furthermore, inhibition of both 
NOS with 1mM L-NAME and Hsp90 with allyamino-17-demethoxygeldanamycin (17-
AAG) inhibits VEGF-stimulated endothelial tubule formation in HUVECs to similar 
extents [368]. In rats, inhibition of Hsp90 with 17-dimethylaminoethylamino-
17demethoxygeldanamycin (17-DMAG) prevents increases in eNOS protein content and 
phosphorylation and hindlimb angiogenesis induced by repeated sauna therapy [367].  
 
Effects of serum exposure 
Exposing endothelial cells to serum from heat-acclimated subjects increased 
eNOS and MnSOD protein, reduced superoxide production, and increased functional NO 
bioavailability (assessed by endothelial tubule formation), independent of changes in 
HSPs. Importantly, NOS inhibition with L-NNA prevented heat-therapy induced 
improvements in endothelial tubule formation, suggesting that these improvements were 
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due to the increases in eNOS and SOD protein that we observed (i.e., improved capacity 
to produce NO and anti-oxidative mechanisms to prevent NO from being scavenged by 
superoxide).  
This begs the question as to what did heat therapy upregulate in the serum that 
could have such profound effects on NO bioavailability? Interestingly, the well-
established pro-angiogenic factor VEGF, which induces angiogenesis by increasing 
eNOS protein and activation [405], was unchanged in serum following heat therapy. This 
finding is consistent with studies investigating the effects of repeated sauna therapy in 
rats [250] and humans [406]. In particular, Akasaki et al. [250] observed no change in 
serum VEGF in rats following 3 weeks of sauna therapy, despite NOS-dependent 
improvements in hindlimb angiogenesis.  
There are other known pro-angiogenic factors that can induce NOS-dependent 
angiogenesis independent of VEGF; however, whether they may be upregulated 
following heat stress is unclear. Both transforming growth factor (TGF)-β [407] and basic 
fibroblast growth factor (bFGF) [408] can induce angiogenesis independently of VEGF 
by upregulating eNOS protein content and activity. Genes involved in the TGF-β 
pathway have been shown to be upregulated following acute heat stress [409]; however, 
overexpression of Hsp70/72 has also been shown to inhibit TGF-β signaling [410,411]. 
Heat stress has been shown to increase bFGF mRNA in cancer cells via protein kinase C 
[412].  
Angiopoietin-1 (Ang-1) is a ligand for Tie-2 receptors expressed on the surface of 
endothelial cells. Although, Ang-1-induced angiogenesis generally occurs downstream to 
VEGF, Ang-1 enhances eNOS activity via the PI 3-kinase [413], Akt and MAP-kinase 
pathways [414], and so heat therapy-induced increases in Ang-I could promote 
angiogenesis independent of changes in VEGF. Recently, exogenous Ang-1 
administration has been shown to induce angiogenesis and muscle repair in injured 
skeletal muscle in mice [415]. Heat stress in cultured cells has been shown to increase 
Ang-1 mRNA [416], but it is presently unknown whether whole-body heat acclimation 
would do the same.  
Repeated sauna therapy has been shown to increase the number of circulating CD34+ 
cells in heart failure [23] and peripheral artery disease patients [406]. CD34+ cells are 
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endothelial progenitor cells which are thought to promote angiogenesis through the 
secretion of angiogenic growth factors and/or their incorporation into developing blood 
vessels [417]. However, the exact mechanisms for how these processes occur are 
presently unknown. Although CD34+ cells would not be present in the human sera with 
which we treated endothelial cells, it is possible mobilized CD34+ cells released 
signaling molecules that could have been present in the sera.  
 However, since investigating what specifically was upregulated in the sera was 
beyond the scope of this project, all we can conclude definitively from our data is that 
treating endothelial cells with sera from heat acclimated subjects increases NO 
bioavailability in a VEGF-independent manner.  
 
Considerations 
 As discussed, we observed no changes in circulating VEGF, and so improvements 
in NO bioavailability in serum exposed endothelial cells were VEGF-independent. 
However, we cannot rule out VEGF as a mediator of improvements in vascular function 
in vivo. Acute hyperthermia [418] and repeated sauna therapy [419,420] have been shown 
to increase VEGF expression in myocardial tissue, although these changes have not been 
observed in skeletal muscle [250].  
We chose to study HUVECs in the present study, which are venous cells and so 
are habituated to lower levels of oxygen and shear stress than arterial endothelial cells. 
However, many of the other commercially available cell lines are harvested from patients 
who all have some level of disease progression. In order to be more similar to endothelial 
cells in our young, healthy subjects, we wanted to avoid cell lines harvested from patient 
populations.   
Relevant to the cardiovascular system and vascular function, HSPs are known to 
suppress oxidative stress and inflammation. In the present study, we chose to focus on the 
effects of heat therapy on NO signaling because both healthy subjects and healthy cells 
have minimal levels of oxidative stress and inflammation, and because we observed the 
greatest improvements in our human subjects in measures of vascular function which 
were the most dependent on NO. In pilot studies, we observed no effects of either direct 
heat or serum exposure on expression of markers oxidative stress (e.g., nitrotyrosine) or 
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inflammation (e.g., nuclear factor kappa-B) (data not shown). However, given the known 
effects of HSPs, heat therapy may be capable of reducing oxidative stress and 
inflammation in patient populations who have elevated levels of these markers to begin 
with.  
We only performed experiments measuring changes in protein abundance using 
sera from human subjects in the heat therapy group. This prevents us from being able to 
isolate the effects of whole-body heat exposure from hydrostatic and placebo effects by 
comparing changes with serum from heat therapy vs. sham subjects. However, we 
observed no effects of serum from sham subjects on endothelial tubule formation, 
suggesting that we also would not have observed any changes in protein abundance with 
serum from these subjects.  
 
Perspectives: Potential combined effects in vivo 
During heat therapy sessions, endothelial cells in vivo are exposed to direct heat, 
increases in shear stress, and factors upregulated elsewhere in the body. These circulating 
factors, which may be upregulated due to HSPs, increases in shear, or by unknown 
mechanisms, are then released into the blood and may have acute and prolonged effects 
on endothelial cells. In our direct heating experiments, we were able to determine the 
intracellular effects of heat exposure. In our serum exposure experiments, we investigated 
the effects of circulating factors in the blood released both acutely following hot water 
immersion and chronically following 8 weeks of heat therapy. The mechanisms that 
underscore improvements in vascular function in vivo will be a combination of these 
effects, along with the effects of repeated elevations in shear stress, which is also known 
to upregulate eNOS expression. Combining data from our two sets of experiments, we 
believe that, in vivo, heat therapy results in upregulation of eNOS and SOD protein. 
Increased Hsp90 further increases eNOS activity. This provides three separates 
mechanisms by which increases in NO bioavailability are achieved, which likely explains 
why we were able to induce such robust improvements in NO-dependent dilation in vivo.  
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CHAPTER VIII 
PILOT STUDY IN SPINAL CORD INJURED INDIVIDUALS 
 
 
INTRODUCTION 
 In the previous chapters, I have presented data that strongly argues heat therapy can 
be used to drive robust arterial adaptation. The motivation behind conducting studies in 
this line of research is to establish heat therapy as an effective alternative means for 
improving cardiovascular health, particularly for use by patients with limited exercise 
capabilities. Patients who have sustained spinal cord injury (SCI) are one such 
population. Just in the United States, an estimated 276,000 individuals are living with a 
SCI, with an estimated 12,500 new cases per year [421]. SCI results in an estimated 
lifetime healthcare cost of up to $4.7 million per individual [421]. Despite advancements 
in medical treatment following SCI, these patients experience significantly higher rates of 
mortality than the general population [422], with cardiovascular (CV) diseases 
accounting for >40% of deaths beyond the first year post-injury [423]. The incidence and 
severity of ischemic cardiovascular events is exceptionally high, leading to 2-3x higher 
risk of stroke [424] and 2x higher risk of heart attack [425,426] compared to their able-
bodied peers. Although SCI is characterized by an amplification of risk of CV disease, 
this increased risk cannot be explained by traditional risk factors [427]. Instead, the 
increased CV risk may relate to the direct effects of SCI on arterial health. SCI is 
associated with rapid vascular remodeling including decreased conduit-artery diameters 
[428,429] and increased wall thickness [430], increased arterial stiffness [431,432], and 
increased peripheral vascular resistance [433]. Oxidative stress is also greater [390,434] 
and circulating levels of vasoconstrictors, such as angiotensin-II [398] and endothelin-I 
[435], are increased. These changes result in impairments in vasodilator ability, including 
impaired lower limb reactive hyperemia [436] and cutaneous endothelial-dependent 
dilation [2,437].  
 Although some modalities of exercise are available to SCI patients (e.g. arm 
exercise and functional electrical stimulation [FES]), they do not confer the same benefits 
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as dynamic whole- body exercise. For example, FES, in which denervated muscles are 
electrically stimulated to produce rhythmic contractions, is able to partially reverse the 
conduit vessel remodeling [290], but has been unsuccessful at improving endothelium-
dependent dilation in conduit and resistance vessels [2,3]. A potential explanation is that 
FES is not accompanied by the normal changes in cardiovascular hemodynamics that are 
observed during voluntary exercise (e.g. increases in HR, cardiac output, and stroke 
volume, and decreases in peripheral vascular resistance [438]), which are key stimuli for 
arteries to adapt [18]. Similarly, upper body exercise in SCI only results in minimal 
increases in cardiac output since complete SCIs lack the ability to redistribute blood from 
the inactive lower body [439], severely limiting exercise intensities that can be reached. 
Thus, there is high demand for new therapies to better manage CV risk in these patients.  
 Therefore, we performed pilot data in two subjects who had sustained complete 
SCI, with one completing 8 weeks of heat therapy and the other serving as a time control. 
By doing so, we hoped to gain insight into whether heat therapy could successfully be 
translated into a clinical population. We hypothesized that we would observe 
improvements in all primary outcome variables assessed in young, sedentary, able-bodied 
subjects. Specifically, we hypothesized that we would observe increased brachial artery 
flow-mediated dilation, reduced arterial stiffness, reduced intima media thickness, 
reduced blood pressure, increased cutaneous microvascular function and nitric oxide-
dependent dilation, and increased serum angiogenic potential.  
 
METHODS 
 Two young, otherwise healthy (non-smokers and no overt cardiovascular-related 
diseases), paraplegic subjects participated in the study. Subject demographics are 
provided in Table 8.1 – next page. A physician familiar with treating SCI patients 
screened subjects prior to participation in order to ensure they would tolerate heat 
therapy. Subjects provided oral and written informed consent prior to participation in the 
study, as set forth by the Declaration of Helsinki. All experimental procedures were 
approved by the Institutional Review Board at the University of Oregon.  
 Subject 1 participated in 8 weeks of heat therapy, exactly as performed by able-
bodied subjects, as described in Chapter III (pages 36-38). Subject 2 served as a time  
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Table 8.1. Characteristics of spinal cord injured (SCI) pilot subjects 
 SCI subject 1 SCI subject 2 
Sex Male Female 
Age 23 25 
Body mass (kg) 66 59 
BMI (kg/m2) 20.8 25.4 
SCI level T11 (ASIA A/complete) T12 (ASIA A) 
Years since injury 7 8 
ASIA, American Spinal Injury Association classification system 
 
 
control and reported to the laboratory for all experimental days every 2 weeks but did not 
participate in thermoneutral water immersion sessions. Since we observed no differences 
in any of our outcome variables over the 8 weeks of sham in able-bodied subjects, we 
believed it would suffice to perform just a time control in SCI subjects. This helped to 
compensate for the higher difficulty of recruiting and retaining SCI subjects.  
 Both subjects reported to the laboratory every 2 weeks for macrovascular function 
studies, which were performed exactly as described in Chapter V, and pre- and post-the 
8-week intervention for cutaneous microdialysis studies, as described in Chapter VI. 
Additionally, venous blood was drawn from both subjects at the 0 and 8-week time 
points. After collection, blood was serum separated and stored at -80°C until later use in 
serum angiogenic potential experiments, as described in Chapter VII.  
 
RESULTS 
Macrovascular function 
 We observed clinically relevant improvements in biomarkers of macrovascular 
function in our pilot SCI subject who underwent 8 weeks of heat therapy (Figure 8.1 – 
next page), including improved brachial artery flow-mediated dilation (FMD), improved 
superficial femoral arterial compliance, reduced intima media thickness of both the 
carotid and superficial femoral arteries (presented as wall-to-lumen ratio in Figure 8.1, 
which normalizes for differences in diameter across SCI and able-bodied subjects [318]), 
and reduced mean arterial pressure. No changes were observed in the SCI time control 
subject in any of these variables beyond fluctuations that would be expected with 
hormonal variations across the menstrual cycle.  
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Figure 8.1. A) Brachial artery flow-mediated dilation, mean arterial blood pressure, B) 
carotid and superficial femoral dynamic arterial compliance, and C) carotid and femoral 
wall-to-lumen ratio in pilot spinal cord injury (SCI) subjects who underwent 8 weeks of 
heat therapy or time control. Data (mean±S.E.) from able-bodied (AB) subjects are 
included for comparison (also reported in Chapter V). *P<0.05 vs. 0wks within AB 
group.  
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 Additionally, we observed a reduction in leg pulse wave velocity in the SCI heat 
therapy subject, measured from the femoral to dorsal pedal arteries, whereas we observed 
no changes in leg PWV in able-bodied subjects who underwent heat therapy (Figure 8.2) 
(this measure was not reported in Chapter V since it was included purely for comparison 
to SCI subjects). 
 
Figure 8.2. Aortic and leg pulse wave velocity in spinal cord injury (SCI) subjects who 
underwent 8 weeks of heat therapy or time control. Data (mean±S.E.) from able-bodied 
(AB) subjects are included for comparison. There was no effect of heat therapy on leg 
pulse wave velocity in able-bodied subjects, but we observed a robust improvement in the 
SCI pilot subject. *P<0.05 vs. 0wks within AB group. 
 
Microvascular function 
Interestingly, we observed no change in overall plateau cutaneous vascular 
conductance (CVC) during local skin heating in the subject who underwent heat therapy. 
However, we observed a substantial reduction in plateau CVC at the microdialysis site 
receiving L-NNA (NO synthase inhibition) and thus a large improvement in NO-
dependent dilation (the difference between Control and L-NNA microdialysis sites) 
(Figure 8.3 – next page). We observed no changes in plateau in the SCI time control 
subject (change in plateau CVC across 8 weeks of time control at the Ringer’s/Control 
site: +2.3%CVCmax, and at the L-NNA site: –1.4%CVCmax).  
In both SCI pilot subjects, Tempol increased plateau CVC at the 0-week time 
point (Tempol-mediated dilation, Subject 1: 9.0%CVCmax, Subject 2: 11.7%CVCmax), 
indicating baseline oxidative stress. In the SCI subject who underwent heat therapy, 
Tempol-mediated dilation was effectively abolished (Figure 8.3C). However, we 
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observed a similar reduction in Tempol-mediated dilation in the SCI time control subject, 
and so we cannot conclude an exclusive effect of heat therapy on this variable.  
 
 
Figure 8.3. A) Cutaneous vascular conductance (CVC) at the four phases into local skin 
heating in our pilot spinal cord injury (SCI) subject who underwent heat therapy in 
microdialysis sites receiving Lactated Ringer’s (control) and Nω-nitro-L-arginine (L-
NNA). B) Nitric oxide (NO)-dependent dilation, the difference between microdialysis 
sites receiving Lactated Ringer’s and L-NNA, and C) Tempol-mediated dilation, the 
difference between microdialysis sites receiving Lactated Ringer’s and Tempol, in our 
SCI pilot subject who underwent heat therapy. 
 
Serum angiogenic potential 
Endothelial tubule formation was impaired in cells exposed to baseline 0-week 
sera from SCI subjects compared to cells exposed to 0-week sera from able-bodied 
subjects (average total tubule length per frame: 61.0 vs. 69.3±1.9 mm). Heat therapy 
resulted in a robust improvement in serum angiogenic potential, whereas no change was 
observed in the SCI time control subject (Figure 8.4 – next page). 
 
 
DISCUSSION 
In a young, otherwise healthy SCI pilot subject, we observed clinically relevant 
improvements in conduit vessel and microvascular endothelial function, reductions in 
arterial stiffness, intima media thickness, and blood pressure, and improvements in serum 
angiogenic potential, while minimal changes were observed in the SCI time control 
subject. The magnitude of many of the improvements we observed was on par with 
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Figure 8.4. Total tubule formation in cultured endothelial cells exposed to sera from 
spinal cord injury subjects collected before and after heat therapy or time control 
interventions.  
 
improvements observed in AB subjects; however, some were of considerably greater 
magnitude and warrant discussion.  
First, the reduction in mean arterial blood pressure with heat therapy was 
approximately double in the SCI subject compared to the AB subjects. Hypertension is a 
major problem with chronic SCI, particularly for paraplegics. Despite a loss of 
sympathetic control below the level of the injury and a period of profound hypotension 
that accompanies acute SCI, prevalence of hypertension among individuals with chronic 
SCI [440] is on par with prevalence in the general population [1]. SCI results in rapid and 
extensive remodeling of the vasculature to smaller and stiffer arteries [428]. Additionally, 
circulating levels of angiotensin-II [398] and endothelin-1 [435] are upregulated soon 
after the initial injury, which is thought to occur to combat the loss of sympathetic 
vasoconstrictor tone. These adverse changes in the vasculature predispose SCIs to 
developing hypertension. Our data indicate that heat therapy may useful in combatting 
hypertension in the SCI population.  
Secondly, heat therapy improved some biomarkers of vascular function in the 
lower limb to a greater extent in our SCI subject than we observed in AB subjects, 
including superficial femoral wall-to-lumen ratio and leg pulse wave velocity. Vascular 
impairments are often more extensive in the lower limbs compared to the rest of the body 
following SCI due to complete lower body inactivity (although systemic impairments are 
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also present). For example, remodeling of vessel diameters occurs to a greater extent in 
the lower body compared to upper body [428] and impairments in cutaneous 
microvascular function are worse in the lower body compared to the upper body [437]. 
As SCIs are prone to complications secondary to poor circulation in their legs, such as 
pressure ulcers [441,442] and deep vein thrombosis [443,444], interventions that can 
target improvement in the lower legs is particularly helpful for this population. 
Unfortunately, exercise training modalities that are available to SCIs have very little 
effect on the lower body, likely because these forms of exercise do not sufficiently 
increase shear rate in the legs of SCIs [2,445]. 
In contrast to AB subjects, both of the SCI subjects were physically active, 
engaging in aerobic and resistance exercise 2-5x per week. Despite them participating in 
regular exercise and being young and otherwise healthy, we observed baseline 
impairments in these subjects in many of the biomarkers of vascular function we 
measured compared to our young, able-bodied, sedentary subjects (e.g., arterial 
compliance, intima media thickness, pulse wave velocity, and serum angiogenic 
potential). This finding stresses the important of developing novel therapies to improve 
cardiovascular health in this population. Also importantly, both subjects maintained their 
exercise programs throughout the 8-week interventions. Heat therapy induced additional 
changes in vascular function in our SCI subject beyond what exercise training was 
capable of doing.  
By collecting pilot data in SCI subjects, we have demonstrated the feasibility and 
effectiveness of using heat therapy to improve cardiovascular health in an at-risk clinical 
population. Our SCI subject tolerated heat therapy well, reporting no adverse effects 
besides slight light-headedness on the first day, which was also reported by several AB 
subjects. Heat therapy was also successful at driving profound vascular adaptations, 
providing strong evidence for its utility for treating cardiovascular risk in patient 
populations.   
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CHAPTER IX 
CONCLUSIONS 
 
MAIN FINDINGS 
 The overall purpose of this dissertation was to comprehensively assess the effects 
of passive heat therapy on vascular function and the associated molecular pathways. To 
address this goal, we performed one large study in which subjects participated in eight 
weeks of 4-5x per week heat therapy or thermoneutral water immersion, which served as 
a sham. Importantly, heat therapy resulted in hallmark adaptations of heat acclimation, 
including reduced resting core temperature, increased sweating responses to heat stress, 
plasma volume expansion, and elevated heat shock protein (HSP) expression under non-
stressed conditions, as discussed in Chapter IV. Furthermore, no changes were observed 
in the subjects in the sham group. These observations allow us to conclude that the 
improvements in vascular function we observed were the result of adaptation to the heat 
itself (i.e., HSP- and shear stress-mediated).  
 In Chapter V, we investigated the effects of heat therapy on well-established 
biomarkers of conduit vessel (macrovascular) function. We observed that passive heat 
therapy resulted in robust improvements in flow-mediated dilation, arterial stiffness 
(including superficial femoral dynamic arterial compliance and β-stiffness index, and 
aortic pulse wave velocity), carotid intima media thickness, and diastolic and mean 
arterial blood pressure. The magnitude of all of these improvements was on par with 
improvements typically observed in exercise training studies of similar duration, in some 
cases greater (e.g., flow-mediated dilation). Furthermore, all of these improvements were 
great enough to be considered clinically relevant. Based on studies that have correlated 
these biomarkers with risk of cardiovascular disease and mortality, our subjects were 
considerably more ‘healthy’ at the end of the 8 weeks.   
 In Chapter VI, we investigated the effects of heat therapy on microvascular 
function. To do so, we used the cutaneous circulation as a model of globalized 
microvascular health and the cutaneous microdialysis technique to pharmacodissect some 
of the molecular pathways involved with microvascular adaptation to heat therapy. We 
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observed that heat therapy improved cutaneous thermal hyperemia, a well-established 
marker of endothelial-dependent microvascular function. Furthermore, we observed that 
improvements in thermal hyperemia were due to improved nitric oxide (NO)-dependent 
dilation, as determined by infusing the NO synthase inhibitor L-NNA via microdialysis.  
 In Chapter VII, we sought to further elucidate the molecular mechanisms behind 
improvements in vascular function, particularly those associated with the NO pathway. 
Of the functional improvements we measured in our human subjects, those that showed 
the most robust improvements were markers of NO-dependent dilation. To do so, we 
utilized a cell culture model of heat therapy in which we exposed cultured endothelial 
cells to either 24h of direct heating at the same temperature reached by subjects during 
heat therapy sessions or to sera collected from human subjects pre- and post-heat therapy 
in order to isolate the effects of upregulated circulating factors in the blood. We found 
that heating cells to 39°C increased abundance of Hsp70 and Hsp90 and the anti-
oxidative enzyme superoxide dismutase (SOD), and reduced superoxide production, but 
had no effect on endothelial NO synthase (eNOS). Conversely, we found that exposing 
cells to sera from heat acclimated subjects increased both eNOS and SOD protein 
abundance and reduced superoxide production, independent of changes in intracellular 
HSPs. Additionally, sera from heat acclimated subjects increased endothelial tubule 
formation, a marker of angiogenesis, in an NO-dependent, but vascular endothelial 
growth factor (VEGF)-independent manner.  
 
INTEGRATION OF STUDIES 
 The molecular studies performed in Chapter VII were intended to elucidate the 
mechanisms behind functional in vivo improvements in vascular function observed in 
Chapters V-VII. In Chapter VII, we isolated the effects of direct heat and circulating 
factors in the sera. However, in vivo, these stimuli act in tandem to improve endothelial 
function, along with the beneficial effects of intermittent increases in anterograde shear 
stress, which were reviewed in Chapter II. Based on our molecular data and the known 
effects of shear stress on endothelial cells, we have developed the working model 
summarized in Figure 9.1 (next page).  
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Figure 9.1. Working model of how heat therapy affects the nitric oxide (NO) pathway in 
endothelial cells, as determined in Chapter VII, resulting in the functional improvements 
in vascular health observed in human subjects in Chapters V-VII. See text for details. 
Abbreviations include: Hsp, heat shock protein; eNOS, endothelial NO synthase; SOD, 
superoxide dismutase; O2.-, superoxide; ONOO-, peroxynitrite; FMD, flow-mediated 
dilation. 
 
 Intermittent increases in body core temperature result in elevated HSP abundance. 
Hsp70 upregulates SOD [146,147], while Hsp90 stabilizes eNOS [4], playing an 
important role in all steps necessary for eNOS activation [133,135,136]. Elevated HSP 
abundance likely had many other cellular effects (e.g., suppression of pro-inflammatory 
pathways [157,160,165]); however, we chose to focus on the NO pathway for this 
investigation. Repeated intermittent increases in anterograde shear stress also increases 
eNOS activation [217,218]. Additionally, shear stress is known to upregulate HSPs 
[116,117], and thus their effects act in tandem to improve eNOS signaling. Heat therapy 
also upregulated circulating factors in the blood which increased both eNOS and SOD 
protein abundance. While determining which circulating factors associated with 
improved vascular function were upregulated by heat therapy was outside the scope of 
this investigation, we did determine that vascular endothelial growth factor (VEGF) was 
unchanged. VEGF concentration is increased in serum following exercise [446,447] and 
is thought to mediate exercise training-induced angiogenesis [448]. The fact that we 
observed no change in serum VEGF concentrations suggest that there are some 
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mechanistic differences between how heat therapy and exercise training improve vascular 
function. Specifically what these differences are should be investigated in future studies.  
 The combined effects of direct heat, shear stress, and circulating factors is an 
increased capacity for NO production (due to increased eNOS protein and presumably 
increased eNOS activity) and a reduction in superoxide production (due to increased 
SOD protein). Therefore, not only is NO production increased, but scavenging of NO by 
superoxide is also reduced, resulting in increased NO bioavailability. Additionally, the 
damaging effects of superoxide on eNOS activity (uncoupling of eNOS by depletion of 
tetrahydrobiopterin [143] and reduction in L-arginine by upregulation of arginase activity 
[144]) will be reduced, further improving eNOS activity and NO bioavailability.  
 Functionally, this improved NO bioavailability results in angiogenesis, and 
improved NO-dependent dilation, which we measured in vivo both in the cutaneous 
microvasculature and in the brachial artery using flow-mediated dilation. While we only 
demonstrated an effect of simulated heat therapy and improved NO bioavailability on 
serum angiogenic balance, we assume exposure to this pro-angiogenic serum in vivo 
would have also resulted in increased vascularization. Supportive of this, we found that 
reductions in mean arterial blood pressure were correlated with improvements in serum 
angiogenic balance, although reductions in blood pressure were likely the result of a 
combination of factors, including improved endothelial-dependent dilation and reduced 
vascular resistance [249,250]. Additionally, we did not definitely assess whether 
angiogenesis occurred in vivo in this investigation. Lastly, our observed reductions in 
arterial stiffness were likely predominantly caused by improved NO-dependent dilation in 
our disease-free population. However, we did observe some structural improvements in 
the conduit vessels (e.g., decreased intima media thickness), which may have contributed 
to the reduction arterial stiffness. The overall result of all of these changes in significantly 
improved vascular health and reduced risk of cardiovascular disease and mortality.  
 
PASSIVE HEAT THERAPY AS A VIABLE ALTERNATIVE TO EXERCISE 
FOR PATIENTS WITH LIMTED EXERCISE CAPABILITES 
 The long-term goal of this line of research is to develop heat therapy as a feasible 
and effective means of improving cardiovascular health that could be used as an 
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alternative or adjunctive therapy to exercise training. Many disease states are 
characterized by impaired vascular function. While exercise is arguably the best 
'medicine' for these patients, many of them are unable or unwilling to exercise to an 
extent great enough to induce protective adaptations (e.g., spinal cord injured, heart 
failure, and diabetic patients). In the present study, we have demonstrated that heat 
therapy is capable of inducing robust improvements in vascular function. To confirm that 
adaptations would also occur in a patient population, we conducted a pilot study in spinal 
cord injured patients (Chapter VIII), and demonstrated that heat therapy was capable of 
inducing even greater changes in this population. Our data, combined with the data 
demonstrating the effectiveness of Waon sauna therapy for treating heart failure and 
peripheral artery disease [247,252,253], suggest that heat therapy could be used feasibly 
and effectively for reducing cardiovascular risk across a broad range of patient 
populations. Additionally, as heat therapy can improve exercise tolerance [23,245], it 
could be used in some patient populations (e.g., heart failure and peripheral artery 
disease) to improve health in the meantime before these patients are able to engage in an 
exercise training program, or as an adjunctive therapy to gain even greater protective 
benefits.  
 
FUTURE DIRECTIONS 
 This dissertation comprehensively demonstrated that vascular function is improved 
in sedentary humans following eight weeks of heat therapy and provided some insight 
into the cellular mechanisms underlying adaptations. However, the studies described 
herein are just the beginning. Given the relatively limited research that has been 
performed thus far, heat therapy is essentially an untapped field.   
 Just within the realm of vascular function, there is still much to answer. First, there 
are many more molecular aspects to vascular function than what we investigated in this 
dissertation. We chose to focus on the NO pathway and oxidative stress as they related 
more closely with the in vivo measures we observed, and because we were able to 
actually detect changes in these pathways in generally healthy subjects and in healthy 
cultured cells. We did not investigate inflammation, which is a major contributor to 
cardiovascular disease progression. The primary reason why was because, in pilot data, 
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we failed to observe any changes in inflammatory markers under non-stressed conditions 
in young, healthy humans/cells. There are two options to better investigate these 
pathways: 1) study a population which has elevated baseline inflammation (e.g., older 
adults, obese/metabolic disease, coronary artery disease patients, etc.) such that it is 
possible to improve their inflammatory profile with an intervention, or 2) study healthy 
humans/cells under stimulated pro-inflammatory conditions (e.g., with hypoxia/ischemia, 
TNFα, lipopolysaccharide). Both options address important, but different, questions 
related to cardiovascular health. The former option addresses whether a patient could be 
healthier on a day-to-day basis, hopefully slowing disease progression; whereas, the latter 
option addresses whether heat therapy confers protection against novel stressors (i.e., is 
the patient’s heart or brain tissue better protected against tissue death when they have a 
heart attack or stroke?).  
 Even within the NO and oxidative stress pathways, studying a patient population 
with elevated oxidative stress would better elucidate the extent of cellular improvements 
that can be attained with heat therapy. For example, we infused the superoxide dismutase 
mimetic Tempol via microdialysis, but observed no effects in healthy subjects. We did 
observe an effect in pilot spinal cord injured patients, but studying patient populations 
with even greater oxidative stress (e.g., older adults, hypertensives) may yield different 
results. It will also be interesting to determine whether patients with greater vascular 
dysfunction can still attain the same benefits - when is it too late to reverse their disease 
progression? Based on the data in heart failure and end-stage peripheral artery disease 
patients [247,252,449], it seems that heat therapy could be effective at treating even very 
advanced pathological conditions, but future studies are required to determine if this is 
the case before heat therapy could be translated to clinical practice. 
 An interesting disease state to investigate would be atherosclerosis. Many of the 
biomarkers we measured are supposed to be predictive of the development of 
atherosclerosis (e.g., intima media thickness [369]). Furthermore, many of the molecular 
pathways affected by heat therapy are considered to be anti-atherogenic (e.g., shear stress 
and the anti-inflammatory effects of heat shock proteins). However, while we can 
conjecture based on our data that heat therapy should be protective against the 
development of atherosclerosis, we cannot conclude that it would improve symptoms and 
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risk of mortality in patients who already have clinically-diagnosed atherosclerosis 
without studying the disease state itself. Several rodent models have been developed to 
accurately simulate the pathological conditions of atherosclerosis [196,197,450]. Given 
the potential contraindications of heat therapy for patients with unstable coronary artery 
disease and angina pectoris [58], performing studies in rodents would be a good place to 
start, particularly for pairing mechanistic and functional measures.  
 Another important question to address is dosing – how much heat therapy do you 
need in order to attain (and maintain) the benefits? In this dissertation, we used a very 
high ‘dose’ of heat therapy in order to ensure we would at least see some effect. 
However, 90 min 4-5x per week is likely an unrealistic time commitment for the majority 
of patients. Can the same benefits be obtained if the duration, frequency, and/or core 
temperature reached is reduced?  
 Furthermore, how long do the benefits last if someone stops or reduces the 
frequency of sessions? We began to investigate the decay of benefits by performing 
follow-up studies in some subjects for up to 8 weeks after they finished the 8-week heat 
therapy intervention. In these very preliminary studies, we observed that the FMD 
response decayed at approximately the same rate at which it improved during heat 
therapy. Future studies should investigate this decay further. In the real world, patients 
will not continue to perform heat therapy consistently for the rest of their lives. If they 
stop for a period of time, how long will they still have benefits and can these benefits 
return more quickly if they start again? In animal studies, it appears heat acclimation is a 
‘remembered’ phenotype, in that cellular adaptations can be gained more quickly the 
second time around [451].  
 Lastly, we only investigated the effects of heat therapy on vascular function. While 
vascular dysfunction is the primary cause of cardiovascular diseases, there are many 
other pathological processes that fall under the umbrella of cardiovascular-related 
diseases, and many other non-cardiovascular-related diseases that could be improved by 
heat acclimation. In animals, and in some limited studies in humans, there is evidence 
that heat acclimation could be used to protect against a variety of other pathologies, 
including myocardial infarction [186], ischemia-reperfusion injury [452], stroke and 
traumatic brain injury [179], diabetes mellitus [453,454], and metabolic disease [455]. 
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Therefore, future studies should be aimed to undercover the multitude of benefits that 
could be gleaned from heat therapy.  
 With any luck, these questions (and many more!) will keep those of us in the heat 
therapy field busy for a very long time…  
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APPENDIX 
INFORMED CONSENT DOCUMENTS 
 
Group 1: Able-bodied Heat Therapy 
TITLE: “Chronic heat exposure and cardiovascular health”   
INVESTIGATORS: Vienna E Brunt, M.S., Dr. Christopher T Minson, and colleagues 
APPROVED BY INSTITUTIONAL REVIEW BOARD:  February 5, 2014 
This is an important form.  Please read it carefully.  It tells you what you need to know 
about this study.  If you agree to take part in this research study, you need to sign this 
form.  Your signature means that you have been told about the study and what the risks 
are.  Your signature on this form also means that you want to take part in this study. 
Why is this study being done? 
Cardiovascular disease is the number one cause of death in the United States. Exercise is 
a potent means of improving cardiovascular health, but not all patient populations are 
able to exercise effectively. There is high demand for novel therapies to better manage 
cardiovascular risk in these patients. Heat exposure can have many beneficial effects on 
the cardiovascular system. As such, long-term heat exposure (i.e. sitting in a hot tub 4-5x 
per week) may provide an alternative means to exercise for improving cardiovascular 
health. This project will assess the benefits of long-term heat exposure on the health of 
the vasculature and on the cellular pathways that improve vascular health, which is 
important as the majority of cardiovascular diseases affect the arteries. We will measure 
various biomarkers of vascular health before and after 8 weeks of heat exposure in able-
bodied individuals and patients with spinal cord injury. SCI patients are a population with 
elevated cardiovascular risk who have limited exercise capabilities, and who may be able 
to utilize chronic heat exposure as an alternative to exercise training for improving 
cardiovascular health. Additionally, prehypertensives represent another patient 
population with elevated cardiovascular risk whose cardiovascular health may be affected 
by chronic heat exposure.  
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We will address the following questions in this study:   
• How does 8 weeks of passive heat exposure affect cardiovascular health, as measured 
by various biomarkers of cardiovascular function? 
• How does 8 weeks of passive heat exposure affect levels of factors circulating in the 
blood and located within muscle tissue that are important for cardiovascular health? 
• Do effects differ between healthy normotensive able-bodied individuals and spinal 
cord injury patients? 
What will happen in the study? 
1. If you are interested in participating in the study, we will schedule an appointment 
with you to meet with one of the investigators of the study to discuss the project, to 
see the laboratory, and to read this form. If we have scheduled this appointment, it 
means you meet all initial subject criteria (based on initial phone and/or email 
conversations).  
2. Additionally during this initial session, you will fill out a health history form and may 
meet with a physician, so that we can ensure you are healthy enough to participate in 
the study. In addition, the physician will be available to you to answer any medical 
questions or concerns you may have throughout the duration of your participation in 
the study. This visit should last about 60 minutes.  
3. We will assign you to a subject group. If you are reading this form, you are in the 
able-bodied heating group.  
4. Throughout the study, you will report to the laboratory 4-5 times per week for 8 
weeks for hot tub sessions. Additionally, you will participate in 7 experimental days 
over the course of 8-11 weeks. Experimental Days 1-2 will occur prior to the 8 weeks 
hot tub sessions, and Days 6-7 will occur immediately following the 8 weeks of hot 
tub sessions. Days 3, 4, and 5 will occur at Weeks 2, 4, and 6 into hot tub sessions. 
We will perform the same procedures in Experimental Days 1 and 7, and in Days 3-6. 
All procedures are explained in detail below.  
5. During the screening session, we will schedule your initial experimental days (2 
sessions), the start of your hot tub sessions, and tentatively schedule all other 
sessions. We will give you a hard copy of your schedule to take home with you.  
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Heating (hot tub) Sessions: 
1. You will report to the laboratory 4-5 times per week for 8 weeks, for a total of 36 
sessions. Each session will take approximately 2-2.5 hours. You will be asked to 
bring a swimsuit to wear during the session. If you do not have one, we will provide 
one for you to use for the duration of the 8 weeks. No other subjects will use the same 
swimsuit.  
2. You will be asked to provide a urine sample so that we can ensure you are properly 
hydrated before undergoing heat stress. If you are dehydrated, we will give you 
5mL/kg body weight (about half a normal sized 20oz bottle of Gatorade®) of fluids 
to drink prior to getting in the hot tub.  
3. Your nude body weight will be measured by a member of the same sex prior to 
getting in the hot tub. You will stand behind a privacy screen while this measurement 
is taken. Your nude body weight will also be measured following heat stress. This 
will be done so that we can quantify the volume of sweat you lose while in the tub.  
4. You will be instrumented with a Polar® heart rate monitor chest strap so that we can 
continuously monitor your heart rate throughout the procedure.  
5. We will give you a rectal probe labeled with your subject number. It is made of a thin 
rubber (flexible) material that is inserted 10 cm (approximately 4 inches) past the anal 
sphincter. The probe will remain in place throughout the entire study session (up to 
2.5 hours). The probe has a “tail” that will be connected to an external apparatus. The 
procedure may be a little uncomfortable at first (during insertion) but it should not be 
painful at anytime. You will be instructed how to self-insert the rectal probe, as well 
as how to remove it and clean it. If you needed assistance, a lab researcher of the 
same sex will help you. Once in place, you may not even feel the probe at all. This 
technique is widely used and it’s considered the “gold standard” procedure for 
measuring body (“core”) temperature. 
6. On the very first and very last heating session (and possibly during one session at 
about 4wks), we will place 1 small flexible needle (these are called “intravenous 
catheters”, and are smaller than the lead of a pencil) into a vein near your elbow. The 
skin will be cleaned before this procedure. This catheter will remain in your vein 
throughout the heating session. We will take about 40ml of blood, about 2.7 
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tablespoons, prior to getting into the bathtub, and another 25ml of blood at the end of 
the heating period so that we can measure various factors in your blood that are 
affected by the heat exposure. We will remove the catheter after the second blood 
draw and place a sterile bandage over the site. The vials in which we collect the blood 
will be coded such that the investigators can determine all samples came from the 
same subject and the time the sample was taken. No one will be able to determine 
your identity from the sample.    
7. You will then be transferred to a bathtub that will be filled with water at 40°C 
(104.0°F). The tub is hooked up to a water pump and heater such that water can be 
circulated and maintained at a desired temperature. You will lay down in the bath tub 
such that the water level comes up to the level of your collar bone (to the top of your 
shoulders). You will lay down in this position until your core temperature has reached 
38.5°C (101.3°F). This takes approximately 25-35 minutes. At this point, you will sit 
up such that the water level reaches the middle of your chest (with your shoulders and 
arms out of the water). You will remain sitting up for another 60 minutes, or until the 
total time in the hot tub reaches 90 minutes, whichever comes first.  
8. We will continuously check in with you throughout the hot tub session. You will be 
instructed to inform an investigator if you feel any of the following symptoms: light-
headedness, dizziness, nausea, headache, or if you feel unbearably warm. If you feel 
these symptoms, we will have you sit up if you were previously laying down in the 
bath, or we will have you get out of the bath if you were previously sitting up. If your 
body temperature gets too high (above 39.5°C, 103°F), we will have you get out of 
the bath, even if you feel fine.  
9. You will be allowed to drink fluids while in the hot tub. 
10. At the end of the heating period, you will get out of the hot tub and sit in a recovery 
chair. We will continue to monitor your body temperature until your core temperature 
begins to return back to normal. If your body temperature remains high for too long, 
or if you feel too hot, dizzy, or nauseous, we will cool you down more quickly with 
cold packs. We will provide you with a towel to dry off during this time.  
11. Once you feel fine, you will remove the rectal probe, clean it, and place it in a 
location allocated to you.  
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12. If you lost >1% of your body weight while in the hot tub due to sweating, we will ask 
you to drink fluids prior to leaving the lab in an amount necessary to return you to no 
more than a 1% loss of body weight.    
13. We will also offer you a light snack before leaving the lab.  
 
Experimental Days 1 and 7 (Skin Studies):  
1. You will arrive at Dr. Minson’s laboratory in Esslinger Hall at the University of 
Oregon to participate in the experimental protocol. The testing will take 
approximately 4-5 hours. The day before the study, we will contact you (either by 
phone or email depending on your preference) to remind you to refrain from all over-
the-counter medications, including vitamins and supplements, for 24 hours, alcohol 
and caffeine for 12 hours, food for 4 hours, and heavy exercise for 24 hours. 
Additionally, you will be asked to wear a short-sleeved shirt. 
2. Upon arrival at the laboratory, your height and weight and resting blood pressure will 
be measured. Female subjects will be asked to take a urine pregnancy test. You 
cannot participate in the study if the pregnancy test is positive, as the study 
procedures could be harmful to an unborn child. 
6. We will place 3 small tubes (these are called “microdialysis fibers”, and are about the 
size of sewing thread) in the skin of your forearm. A small needle will be placed just 
under the surface of your skin and will exit back out about 1½ inches from where it 
entered your skin.  The small tubes will be placed inside the needle, and the needle 
will be withdrawn, leaving the small tubes under your skin.  These will remain in 
your skin throughout the rest of the study.  
7. We need to wait about 1-2 hours after the small tubes are placed in your skin to let the 
insertion trauma (redness of your skin around the small tubes) to go away.  During 
this time, a small probe (laser-Doppler probe) will be placed over each area of skin 
where the small tubes are so that we can measure skin blood flow over the small tube.   
8. During the study, we may periodically inflate a small cuff that is placed on your 
middle finger of one of your hands to measure your blood pressure (Portapres 
device).  We will only inflate this cuff for about 10 minutes at a time.  If the cuff 
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becomes uncomfortable, let the investigator know and they will turn it off for a few 
minutes. 
9. Blood pressure will also be measured periodically throughout the study using an 
inflation cuff on your upper arm.  
10. During the protocol we will put some very small doses of drugs through the small 
tubes in your skin.  These drugs will cause the vessels of your skin to either widen or 
become narrow.  You should not feel anything when the drugs are going into your 
skin.  However, it is possible you may feel a slight tingling in the skin where the 
probe is. You will receive the following drugs:  
a. L-NNA:  this stops nitric oxide from being produced and causes the skin vessels 
to narrow 
b. Tempol: This is a substance that may cause your blood vessels to open.  
c. Sodium nitroprusside:  this is a substance that is used to lower blood pressure in 
patients and causes the skin vessels to open 
11. We will heat a small area of your skin with a small heater up to 43.5° Celsius (110 
degrees Fahrenheit) to open the vessels in your skin.  This is below the temperature 
where heating becomes painful (about 113 degrees Fahrenheit) and well below the 
temperature that may burn your skin (about 117 degrees Fahrenheit).  If you think the 
heater is becoming painful, you need to tell the investigator and the temperature will 
be lowered. 
12. After the study, we will remove the small tubes in your skin and a bandage will be 
placed over the area of skin where the tubes were placed. 
13. Although you will not be allowed food or beverages during the study, you will be 
given a light snack and fluids to drink before you leave. 
 
Experimental Days 2-6 (Vascular Function): 
1. You will arrive at Dr. Minson’s laboratory in Esslinger Hall at the University of 
Oregon to participate in the experimental protocol. This testing will take 
approximately 3-4 hours. The day before the study, we will contact you (either by 
phone or email depending on your preference) to remind you to refrain from all over-
the-counter medications, including vitamins and supplements, for 24 hours, alcohol 
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and caffeine for 12 hours, food for 4 hours, and heavy exercise for 24 hours. 
Additionally, you will be asked to wear a short-sleeved shirt and shorts that can be 
easily pushed up.  
2. Upon arrival at the laboratory, your height and weight and resting blood pressure will 
be measured. Female subjects will be asked to take a urine pregnancy test. You 
cannot participate in the study if the pregnancy test is positive, as the study 
procedures could be harmful to an unborn child.  
3. We will prep you for the study by placing 5 sticky electrodes on your skin and 
attaching a small wire or lead to each electrode.  These leads will be attached to a 
monitor that will allow us to measure your heart rate and heart rhythm. These 
electrodes will be placed on your skin by a member of the same sex. The electrodes 
will be placed on your body in the following locations: 2 electrodes are placed on 
your upper chest close to your shoulder (one on the left and one on the right); 2 
electrodes will be placed on your stomach just above your hip bones (just above 
where your pants line is) on the left and right side; and one will be placed on your 
lower ribcage on the left side.  
4. After these electrodes are in place, you will lay down on a padded exam table for the 
remainder of the study.  
5. During the study, blood pressure will be measured periodically throughout the study 
using an inflation cuff on your upper arm.  
6. We may also periodically inflate a small cuff that is placed on your middle finger of 
one of your hands to measure your blood pressure.  We will only inflate this cuff for 
about 10 minutes at a time.  If the cuff becomes uncomfortable, let the investigator 
know and they will turn it off for a few minutes. 
7. We will use an ultrasound probe to image the large arteries in your neck (carotid) and 
thigh (femoral). We will be measuring the diameter of the arteries, the thickness of 
the artery walls, and the resting blood flow.  
8. You will undergo carotid arterial tonometry with ultrasound. An ultrasound probe 
will be placed on one carotid artery while a non-invasive tonometer device (looks like 
a blunt pencil) is placed on the opposite carotid artery which non-invasively measures 
blood pressure using pressure sensors pressed against the skin over the artery. The 
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ultrasound probe measures carotid artery diameter and blood velocity, while the 
tonometer measures the blood pressure wave traveling down the vessel. The two 
values are compared to give an index of the stiffness of the arteries. This is a non-
invasive procedure and should not be uncomfortable, other than some minor pressure 
of the measurement sites.  
9. Your pulse wave will be measured using tonometry. Two tonometers that measure 
blood pressure waves will be placed on the skin over arteries on your neck and thigh 
(carotid and femoral) and your arm and foot (brachial and posterior tibial or dorsal 
pedal). The time between the onset of the pulse waves from the two locations will be 
measured and compared. This is a non-invasive procedure and should not be 
uncomfortable, other than some minor pressure at the measurement sites.  
10. You will have a blood pressure cuff placed around your forearm, just below your 
elbow. We will position an ultrasound transducer probe on your upper arm (above 
your elbow) at the brachial artery.  We will occlude blood flow to your arm by 
inflating the blood pressure cuff on your lower arm to 250 mmHg for 5 min.  There is 
possible risk of discomfort due to the occlusion of the forearm. This discomfort 
should be mild, and only comparable to the lower portion of the arm falling asleep. 
This discomfort should subside immediately following deflation of the cuff. 
However, if this discomfort exceeds a tolerable level, please alert the investigator so 
that the cuff can be deflated early. We will use the ultrasound transducer probe to 
image your brachial artery before and after the blood pressure cuff is inflated and 
released.  This test may be repeated 1-2 times. If it is repeated, we will allow a rest 
period of at least 20 min in between each blood flow occlusion.  
11. Next, we will administer one spray of nitroglycerin below your tongue and continue 
to image your brachial artery for 10 more minutes. This will cause your blood vessels 
to relax, and will slightly lower your blood pressure. This test causes the smooth 
muscle of your brachial artery blood vessel to relax and dilate allowing an increase in 
blood flow, and we call this test ‘endothelium-independent vasodilation’. You will 
continue to lie supine for at least 15 minutes after nitroglycerin administration to 
ensure your blood pressure has returned to normal.  
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12. At the end of the study, we will estimate your total blood volume using a carbon 
monoxide (CO) uptake test. For this test, you will breathe 100% oxygen for 4 minutes 
to remove nitrogen from your lungs (this naturally exists). Then, you will start to 
breathe on a rebreathing system. This essentially means you will inhale and exhale 
into a bag. The air in this rebreathing system is pre-filled with 100% oxygen. After 
several minutes you will expire all of the air out that you possibly can through your 
nose. When you cannot get any more air out, your nose will be closed with noseclips. 
A dose of CO (1.0 mL CO/kg of body mass) will then be injected into the breathing 
system and you will inhale deeply to make sure you inhale as much CO as possible. 
CO is a gas that quickly moves from the air in your lungs to your blood. To further 
help this you will hold your breath for ~10 seconds after you deeply inhale. You will 
then breathe 100% oxygen normally for another several minutes. Small blood 
samples (~5ml) will be taken before you start breathing on the rebreathing system and 
immediately after you stop breathing on the rebreathing system.  These blood samples 
will be taken from the catheter in your arm.  
13. Although you will not be allowed food or beverages during the study, you will be 
given a light snack and fluids to drink before you leave. 
 
Optional Follow-Up Testing:  
If you are interested and if you continue to qualify, you may be asked by the investigators 
to return to the laboratory after you have completed the 8 weeks of hot water immersion. 
This is so that we can assess how long any changes in your cardiovascular health last. 
Follow-up testing would take place 2, 4, 6, and/ 8 weeks after your last hot tub session. If 
you are interested in participating in follow-up testing, you will be asked to give consent 
and will sign an additional consent form closer to the end of your 8 weeks of hot water 
immersion. Importantly, if you are not interested in participating in follow-up testing, it 
does not affect your participation in the primary study, the 8 weeks of hot water 
immersion. Also please note that all time frames and compensation amounts in this 
section of the consent form only include the initial 8 weeks of hot water immersion.  
If you are interested in being asked later on about participating in follow-up  
testing, please initial here: _______. You can still change your mind at any time.   
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How long will I be in the study? 
You will be in the study for 8-11 weeks. You will participate in one screening session 
(about 60 min), seven experimental days (a total of up to 25 hours), and 36 heating 
sessions (up to 2 hours per session).  
What are the risks of the study? 
1. Heat exposure: There are some risks associated with heat exposure, including: 
fatigue, light-headedness, muscle cramps, dehydration, and neurological detriments 
(i.e. heat stroke). However, these symptoms do not typically occur until core 
temperature rises above 40°C. Your core temperature will be constantly recorded 
(rectal probe), and you will be removed from the hot bath immediately if either core 
temperature reaches 39.5°C or you experience any symptoms of heat-related illness. 
You will be instructed to notify the investigators immediately if you experience any 
of these symptoms. All symptoms subside upon lowering core temperature. Ice packs 
will be on hand for rapid cooling if necessary. Additionally, heat exposure may have 
detrimental effects on a developing fetus in females and` on sperm counts in males. 
Thus, subjects who are pregnant, trying to conceive, and/or undergoing treatment to 
increase sperm counts will be excluded from the study.   
2. Rectal temperature probes: The use of rectal probes to measure core body 
temperature, even during exercise, carries minimal risk. The primary risk is of 
damage to the lining of the rectum; however, this risk is very slight as we use a 
flexible probe that is designed for this purpose.  There is also the risk of infection, 
either by you not washing your hands properly or exposure to a poorly cleaned probe. 
The probe has been sterilized before use, and we will instruct you on how to properly 
clean the probe after each time you use it. The risk of infection is similar to that of 
having a bowel movement, and is considered minimal (similar to daily 
experience).  There is also the risk of embarrassment. The approach is typically well 
tolerated by subjects, and the investigative team is professional in regard to how they 
treat you. 
3. Venous blood draws and catheters: There may be some discomfort during the blood 
draw. Once the catheter is in place, or once the needle is removed, the pain should 
subside. After the blood draw, the needle will be withdrawn and a sterile dressing will 
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be applied. Any swelling or redness after the study should subside by a few hours 
after completion of the study. Although the needles are sterile, there is a slight risk of 
infection at the site where the needle was placed in your skin. You will be instructed 
how to keep the area clean for a day or two following the experimental day. The most 
common complications of inserting a small needle into a vein is a small bruise and 
pain at the site of the needle location which may last several days after removal of the 
needle. A small amount of bleeding may occur directly after removal of the catheter. 
Application of pressure and a gauze dressing will alleviate the bleeding. The 
maximum amount of blood we will draw across the entire study is 270ml, or about 18 
tablespoons, which is well below the volume drawn in a standard blood donation 
(~450ml). Even so, we will exclude you from the study if you have donated blood 
within the last two months. 
4. Skin microdialysis: There may be some discomfort during the insertion of the small 
fibers in your skin.  Once the needle is in place, the pain should subside.  There is 
also a risk of syncope (fainting) during needle placement. You will be sitting in a 
reclining chair during the study, which reduces this risk, and you will be asked to 
inform the investigator if you feel light-headed, nauseous, dizzy, etc. during needle 
placement. If you do experience any of these symptoms, we will discontinue placing 
the needles and ensure the symptoms subside. Infusions through the fibers should not 
be painful, and there should only be minor swelling at the site.  At the end of the 
study, the fibers will be withdrawn and a sterile dressing will be applied.  Any 
swelling or redness after the study should be gone a few hours after completion of the 
study.  Although the small tubes are sterile, there is a slight risk of infection and/or 
allergic reaction at the sites where the small tubes were placed in your skin.  You will 
be instructed how to keep the area clean for a day or two following the study. If you 
see any signs of infection (redness, swelling, and/or pain around the sites) or 
experience some other abnormal reaction at the insertion site following the study, 
please contact us immediately. We will show you photos of what normal and 
abnormal healing looks like at the sites. There is a possibility the fibers may break 
while in your skin or while they are being removed. We remove the fibers in a way 
such that we can still remove the entire fiber, even if it does break. However, there is 
  164 
still a slight risk a small part of the fiber could remain in your skin. If this occurs, the 
piece should be able to work its way out of the skin within a few days (similar to a 
splinter), and we will follow-up with you to ensure this has happened. If the piece 
does not work its way out, or if a site seems infected, we will evaluate the site(s) and, 
if necessary, recommend you seek medical treatment with a healthcare provider. 
5. Microdialysis drugs: We will be infusing very small doses of each drug and only into 
a very small area of your skin.  You will not have any systemic (whole body) effects 
of these drugs, and they will not alter your blood pressure in the small doses given in 
this study.  However, as with any infusions or medications, there is the possibility that 
you are allergic to the drug and may have an allergic reaction to the drug including 
changes in blood pressure and difficulty breathing. In the case of an adverse event, 
the study will be discontinued. Investigators are trained in Advanced Cardiac Life 
Support and anaphylaxis. 
6. Local Skin Heating:  The local skin heaters may cause some minor skin discomfort.  
The goal is to warm the area of skin to a temperature that has been determined to be 
below the threshold for pain.  If the local heating becomes painful, you should tell the 
investigator and the temperature of the local heater will be lowered.  There is a slight 
risk of burning the skin at this site, so it is important that you tell the investigators of 
any pain you are feeling.  The heating device may be removed at any time if you 
experience any discomfort. 
7. Laser-Doppler Probes:  These probes send a small light into your skin.  You will not 
feel anything except the probe touching your skin. There are no major risks associated 
with this procedure. 
8. Blood Flow Occlusion:  The inflation of the blood pressure cuff to stop blood flow 
may cause a slight tingling sensation and may cause slight bruising.  The sensations 
with prolonged blood flow occlusion greater than 10 minutes are similar to those 
when a limb has “fallen asleep.”  During certain surgical procedures, blood flow is 
often stopped for 2 hours without any significant risk to the patient.  If, at any time, 
you experience any discomfort you may request that the blood pressure cuff be either 
loosened or removed. 
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9. Finger Blood Pressure:  In some people, this blood pressure cuff becomes 
uncomfortable after a long period (over 40 minutes).  We will only inflate the cuff for 
10 minutes at a time and then give your finger a rest.  If your finger becomes 
uncomfortable during the 10 minutes the cuff is inflated, let the investigator know and 
they will turn it off for a few minutes.  There are no major risks associated with this 
device. 
10. Nitroglycerin administration: We will administer the standard dose of nitroglycerin 
under your tongue. This drug has minimal risk when used in low doses. Nitroglycerin 
is commonly prescribed to prevent and treat angina pectoris (chest pain), a condition 
occurring from constriction in the arteries of the heart. Nitroglycerin is a potent blood 
vessel dilator, causing the artery to open up and increase blood flow. You may feel 
slight light-headedness or dizziness, but this symptom should not last more than a few 
minutes. Please inform your investigator if these feelings persist during the study and 
do not simply come and go. You may feel your heart rate slowing as this drug causes 
a drop in blood pressure (transient hypotension), but this will also last only a few 
minutes. After nitroglycerin administration, we will take ultrasound images for 
several minutes to monitor changes in your blood flow and vessel size. You will 
remain laying down on your back for an additional 15 minutes to ensure that your 
blood pressure and heart rate are back to their normal values before we allow you to 
leave the study area. There is a risk that you may experience a headache after this 
treatment, and if you are predisposed, you may experience the onset of a migraine 
headache.  
11. Blood Volume Measurement: This measurement involves exposure to a small amount 
of carbon monoxide. Carbon monoxide is a colorless, odorless gas. We typically 
express CO in the blood as bound to a molecule called hemoglobin (Hb; HbCO).  
Healthy nonsmoking city dwellers typically have 1.5-2.0% of their Hb as HbCO.  
This test will increase this level by roughly 6%. Although you do not want to increase 
your level of HbCO, the levels used for this test are low and present minimal risks. 
The side effects associated with excessive HbCO typically occur at levels above 8% 
and may include headache, fatigue, shortness of breath, nausea, cherry-red colored 
lips, dizziness, and death, the last of which rarely occurs below 15% HbCO in normal 
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individuals. This method has been in use in research for measuring blood volume for 
over 100 years without notable complications. Over time the CO bound to Hb in your 
blood will be removed. This process will occur naturally over the several hours 
following the test. For every 5 to 6 hours that passes after the test, half of the CO will 
leave your blood. Thus, after 15-18 hours you would have less than 1% CO in your 
blood. 
 In order to assure that subjects remain below the level of %HbCO that is 
associated with side effects, we will test %HbCO in each individual prior to 
administration of CO. If an individual’s baseline %HbCO is greater than 2.0% we 
will not administer CO to that individual. Furthermore, if for any reason an 
individual’s post-administration %HbCO rises above 10% or an individual develops 
side-effects associated with excess %HbCO, we will initiate O2 therapy to accelerate 
CO clearance from their system. O2 will be given using a nasal administration similar 
to what someone may wear while in the hospital. Administering O2 reduces the half-
life of CO (speeds up the process of getting rid of it) from ~5 hours to ~80 minutes.  
We will measure %HbCO throughout the O2 administration and periodically 
afterwards.  We will stop treatment if %HbCO is < 8% or the symptoms go away. If 
symptoms progress or do not improve, the Department of Public Safety (6-6666) or 
911 directly will be called depending on the perceived or real severity of the 
symptoms. In the unlikely case of an adverse cardiovascular event, the laboratory is 
equipped with an Automatic Electronic Defibrillator (located in a clearly marked 
first-aid cabinet), and Vienna Brunt, Brett Ely, and Dr. Minson are trained in 
Advanced Cardiac Life Support (ACLS). 
12. Emergencies:  In the event of an emergency, you will be transported by ambulance to 
a local emergency facility. 
May I participate if I am pregnant or breast-feeding? 
No. There is not enough medical information to know what the risks might be to a breast-
fed infant or to an unborn child in a woman who takes part in this study.  Breast-feeding 
mothers are not able to take part in this study. Women who can still become pregnant 
must have a negative pregnancy test no more than 24 hours before taking part in each 
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experimental day. If the pregnancy test is positive (meaning that you are pregnant), you 
will no longer be able to take part in the study. 
Are there benefits to taking part in this study? 
This study will likely not make your health better. This study is being conducted to learn 
about the effects of chronic heat exposure on cardiovascular health. It is possible the 
information gathered in this study could be used to better treat patients with elevated 
cardiovascular risk in the future.  
What other choices do I have if I don’t take part in this study? 
This study is only being done to gather information.  You may choose not to take part in 
this study. 
What are the costs of tests and procedures? 
You will not need to pay for any tests or procedures that are done just for this research 
study. You will receive compensation for completed each session in the study as follows: 
initial screening session, $10; Experimental Days 1-5, $30 each; Experimental Day 6, 
$50; Experimental Days 7, $40 each; and $10 per heating session completed. If you 
complete all parts of the study, you will receive $630. This money is for the 
inconvenience and time you spent in this study, and works out to be approximately $10 
per hour of participation in experimental days and $10 per heating session.  If you start 
the study but stop before the study has ended, you will get part of this money. The partial 
amount will be calculated based on which study sessions you completed. You will 
receive compensation in the form of a check at the end of the study, or if you prefer, 
approximately every 2 weeks into the study. If you choose to receive compensation every 
2 weeks, you will receive an amount corresponding to which study sessions you 
completed in each two-week time interval. There will be no difference in the total 
compensation you will receive if you chose to receive compensation at the end of the 
study versus every 2 weeks.  
Please note, compensation from participation in Human Subjects Research studies 
may be considered taxable income.  Compensation amounts are tracked across all studies 
in which you participate. If compensation totals $600 or more in a calendar year, the 
University is required to report the income to the IRS.  University departments are 
required to track participant compensation and may contact you to complete a W9 form 
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for tax reporting purposes.   Because of this, your name will be associated with 
participation in a research study. Department and university administrators will have 
access to this information, but will not have access to research data. 
Who can answer my questions? 
You may talk to Dr. Christopher Minson or his student, Vienna Brunt, M.S. at any time 
about any question you have on this study.  You may contact Dr. Minson by calling (541) 
346-4105, (541) 346-4311 or on his cell phone (541) 953-2231, and Vienna Brunt at 
(541) 346-4507 or on her cell phone at (541) 968-2635. 
What are my rights if I take part in this study? 
Taking part in this research study is your decision.  You do not have to take part in this 
study, but if you do, you can stop at any time. Your decision whether or not to participate 
will not affect your relationship with The University of Oregon. 
You do not waive any liability rights for personal injury by signing this form.  All 
forms of medical diagnosis and treatment whether routine or experimental, involve some 
risk of injury.  In spite of all precautions, you might develop medical complications from 
participating in this study. 
The investigators may stop you from taking part in this study at any time if it is in 
your best interest, if you do not follow the study rules, or if the study is stopped.  You 
will be told of important new findings or any changes in the study or procedures that may 
happen. 
If you experience harm because of the project, you can ask the State of Oregon to 
pay you. A law called the Oregon Tort Claims Act limits the amount of money you can 
receive from the State of Oregon if you are harmed. If you have been harmed, there are 
two University representatives you need to contact.  Here are their addresses and phone 
numbers: 
 General Counsel  Research Compliance Services 
 Office of the President University of Oregon 
 University of Oregon  Eugene, OR  97403 
 Eugene, OR 97403  (541) 346-2510 
 (541) 346-3082 
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What about confidentiality? 
Any information that is obtained in connection with this study and that can be identified 
with you will remain confidential and will be disclosed only with your permission. 
Subject identities will be kept confidential by assigning you a “subject identification 
number”.  The names associated with each subject identification number will be stored on 
a secure computer with double password protection in Dr. Minson’s office and only one 
list with names and identification numbers will exist.  This list will be destroyed after all 
data has been collected and analyzed and for a period of one year after the results from 
the study have been published. Only coded specimens and data will exist thereafter. 
Your blood will be analyzed for such things as heat shock proteins, hormone 
concentrations, and cytokines (factors released by cells that affect other cells). Your 
muscle tissue will be analyzed for changes in DNA (not genetic testing), RNA, cell 
signaling, and changes in cell structure. The researchers may store the information 
gathered during this study indefinitely.  
I have had an opportunity to have my questions answered.  I have been given a copy 
of this form.  I agree to take part in this study.   
If you have questions regarding your rights as a research subject, contact Research 
Compliance Services, 5219 University of Oregon, Eugene, OR 97403, 541/346-2510. 
Your signature indicates that you have read and understand the information 
provided above, that you willingly agree to participate, that you may withdraw your 
consent at any time and discontinue participation without penalty, that you will receive a 
copy of this form, and that you are not waiving any legal claims, rights or remedies. 
                                                                                                                       
(Date)                      (Signature of Participant)                                 
                                                                                                                      
                                (Printed Name of Participant)                                  
                                                                                                             
(Date)                      (Signature of Individual Obtaining Consent) 
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Group 2: Able-bodied thermoneutral water immersion 
TITLE: “Chronic heat exposure and cardiovascular health”   
INVESTIGATORS: Vienna E Brunt, M.S., Dr. Christopher T Minson, and colleagues 
APPROVED BY INSTITUTIONAL REVIEW BOARD:  February 5, 2014 
This is an important form.  Please read it carefully.  It tells you what you need to know 
about this study.  If you agree to take part in this research study, you need to sign this 
form.  Your signature means that you have been told about the study and what the risks 
are.  Your signature on this form also means that you want to take part in this study. 
Why is this study being done? 
Cardiovascular disease is the number one cause of death in the United States. Exercise is 
a potent means of improving cardiovascular health, but not all patient populations are 
able to exercise effectively. There is high demand for novel therapies to better manage 
cardiovascular risk in these patients. Heat exposure can have many beneficial effects on 
the cardiovascular system. As such, long-term heat exposure (i.e. sitting in a hot tub 4-5x 
per week) may provide an alternative means to exercise for improving cardiovascular 
health. This project will assess the benefits of long-term heat exposure on the health of 
the vasculature and on the cellular pathways that improve vascular health, which is 
important as the majority of cardiovascular diseases affect the arteries. We will measure 
various biomarkers of vascular health before and after 8 weeks of heat exposure in able-
bodied individuals and patients with spinal cord injury. SCI patients are a population with 
elevated cardiovascular risk who have limited exercise capabilities, and who may benefit 
greatly from chronic heat exposure. 
We will address the following questions in this study:   
• How does 8 weeks of passive heat exposure affect cardiovascular health, as measured 
by various biomarkers of cardiovascular function? 
• How does 8 weeks of passive heat exposure affect levels of factors circulating in the 
blood and located within muscle tissue that are important for cardiovascular health? 
• Do effects differ between healthy able-bodied individuals and spinal cord injury 
patients?  
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What will happen in the study? 
1. If you meet all the initial subject criteria (based on initial phone and/or email 
conversations) and are interested in participating in the study, we will schedule an 
appointment with you to meet with one of the investigators of the study to discuss the 
project, to see the laboratory, and to read this form. Additionally, you will fill out a 
health history form so that we can ensure you are healthy enough to participate in the 
study. This visit should last about 60 minutes.  
2. We will assign you to a subject group. To do this, we will match you to a spinal cord 
injury patient who is currently enrolled in the study based on your age, sex, and 
approximate fitness level. You will be assigned to the same group (heating or 
thermoneutral/control) as that subject. You will be informed of what group you are in 
prior to reading this form. If you are reading this form, you are in the able-bodied 
thermoneutral group.  
3. Throughout the study, you will report to the laboratory 4-5 times per week for 
thermoneutral water immersion sessions. You will participate in 7 experimental days 
over the course of 8-11 weeks. Experimental Days 1-2 will occur prior to the 8 weeks 
thermoneutral water immersion, and Days 6-7 will occur immediately following the 8 
weeks of thermoneutral water immersion. Days 3, 4, and 5 will occur at Weeks 2, 4, 
and 6 into thermoneutral water immersion. We will perform the same procedures in 
Experimental Days 1 and 7, and in Days 2-6. All procedures are explained in detail 
below.  
4. During the screening session, we will schedule your initial experimental days (3 
sessions), the start of your thermoneutral water immersion sessions, and tentatively 
schedule all other sessions. We will give you a hard copy of your schedule to take 
home with you.  
 
Thermoneutral Water Immersion Sessions: 
1. You will report to the laboratory 4-5 times per week for 8 weeks, for a total of 36 
sessions. Each session will take approximately 2-2.5 hours. You will be asked to 
bring a swimsuit to wear during the session. If you do not have one, we will provide 
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one for you to use for the duration of the 8 weeks. No other subjects will use the same 
swimsuit.  
2. You may be asked to provide a urine sample so that we can ensure you are properly 
hydrated. If you are dehydrated, we will give you 5mL/kg body weight (about half a 
normal sized 20oz bottle of Gatorade®) of fluids to drink prior to getting in the tub. 
You will be able to drink fluids throughout the water immersion period.  
3. You will be instrumented with a Polar® heart rate monitor chest strap so that we can 
continuously monitor your heart rate throughout the procedure.  
4. We will give you a rectal probe labeled with your subject number. It is made of a thin 
rubber (flexible) material that is inserted 10 cm (approximately 4 inches) past the anal 
sphincter. The probe will remain in place throughout the entire study session (up to 
2.5 hours). The probe has a “tail” that will be connected to an external apparatus. The 
procedure may be a little uncomfortable at first (during insertion) but it should not be 
painful at anytime. You will be instructed how to self-insert the rectal probe, as well 
as how to remove it and clean it. If you needed assistance, a lab researcher of the 
same sex will help you. Once in place, you may not even feel the probe at all. This 
technique is widely used and it’s considered the “gold standard” procedure for 
measuring body (“core”) temperature. 
5. On the very first and very last heating session (and possibly during one sesson at 
about 4wks), we will place 1 small flexible needle (these are called “intravenous 
catheters”, and are smaller than the lead of a pencil) into a vein near your elbow. The 
skin will be cleaned before this procedure. This catheter will remain in your vein 
throughout the water immersion session. We will take about 40ml of blood, about 2.7 
tablespoons, prior to getting into the bathtub, and another 25ml of blood at the end of 
the heating period so that we can measure various factors in your blood that may be 
affected by heat exposure. We will remove the catheter after the second blood draw 
and place a sterile bandage over the site. The vials in which we collect the blood will 
be coded such that the investigators can determine all samples came from the same 
subject and the time the sample was taken. No one will be able to determine your 
identity from the sample.    
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6. You will then be transferred to a hot tub. The tub will be filled with water at 36°C 
(96.8°F). The tub is hooked up to a water pump and heater such that water can be 
circulated and maintained at a desired temperature. You will lay down in the bath tub 
such that the water level comes up to the level of your collar bone (to the top of your 
shoulders). You will lay down in this position for 30 minutes. At this point, you will 
sit up such that the water level reaches the middle of your chest (with your shoulders 
and arms out of the water). You will remain sitting up for another 60 minutes.  
7. At the end of the water immersion period, you will get out of the tub and sit in a 
recovery chair. We will give you cool fluids to drink and a towel to dry off, and will 
offer you a light snack.  
8. We will instruct you on how to remove the rectal probe, clean it, and place it in a 
location allocated to you. You will then be free to leave the lab.  
 
Experimental Days 1 and 7 (Skin Studies):  
1. You will arrive at Dr. Minson’s laboratory in Esslinger Hall at the University of 
Oregon to participate in the experimental protocol. The testing will take 
approximately 4-5 hours. The day before the study, we will contact you (either by 
phone or email depending on your preference) to remind you to refrain from all over-
the-counter medications, including vitamins and supplements, for 24 hours, alcohol 
and caffeine for 12 hours, food for 4 hours, and heavy exercise for 24 hours. 
Additionally, you will be asked to wear a short-sleeved shirt. 
2. Upon arrival at the laboratory, your height and weight and resting blood pressure will 
be measured. Female subjects will be asked to take a urine pregnancy test. You 
cannot participate in the study if the pregnancy test is positive, as the study 
procedures could be harmful to an unborn child. 
3. We will place 3 small tubes (these are called “microdialysis fibers”, and are about the 
size of sewing thread) in the skin of your forearm. A small needle will be placed just 
under the surface of your skin and will exit back out about 1½ inches from where it 
entered your skin.  The small tubes will be placed inside the needle, and the needle 
will be withdrawn, leaving the small tubes under your skin.  These will remain in 
your skin throughout the rest of the study.  
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4. We need to wait about 1-2 hours after the small tubes are placed in your skin to let the 
insertion trauma (redness of your skin around the small tubes) to go away.  During 
this time, a small probe (laser-Doppler probe) will be placed over each area of skin 
where the small tubes are so that we can measure skin blood flow over the small tube.   
5. During the study, we may periodically inflate a small cuff that is placed on your 
middle finger of one of your hands to measure your blood pressure (Portapres 
device).  We will only inflate this cuff for about 10 minutes at a time.  If the cuff 
becomes uncomfortable, let the investigator know and they will turn it off for a few 
minutes. 
6. Blood pressure will also be measured periodically throughout the study using an 
inflation cuff on your upper arm.  
7. During the protocol we will put some very small doses of drugs through the small 
tubes in your skin.  These drugs will cause the vessels of your skin to either widen or 
become narrow.  You should not feel anything when the drugs are going into your 
skin.  However, it is possible you may feel a slight tingling in the skin where the 
probe is. You will receive the following drugs:  
a. L-NNA:  this stops nitric oxide from being produced and causes the skin vessels 
to narrow 
b. Tempol: This is a substance that may cause your blood vessels to open.  
c. Sodium nitroprusside:  this is a substance that is used to lower blood pressure in 
patients and causes the skin vessels to open 
8. We will heat a small area of your skin with a small heater up to 43.5° Celsius (110 
degrees Fahrenheit) to open the vessels in your skin.  This is below the temperature 
where heating becomes painful (about 113 degrees Fahrenheit) and well below the 
temperature that may burn your skin (about 117 degrees Fahrenheit).  If you think the 
heater is becoming painful, you need to tell the investigator and the temperature will 
be lowered. 
9. After the study, we will remove the small tubes in your skin and a bandage will be 
placed over the area of skin where the tubes were placed. 
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Although you will not be allowed food or beverages during the study, you will be given a 
light snack and fluids to drink before you leave. 
 
Experimental Days 2-6 (Vascular Function): 
1. You will arrive at Dr. Minson’s laboratory in Esslinger Hall at the University of 
Oregon to participate in the experimental protocol. This testing will take 
approximately 3-4 hours. The day before the study, we will contact you (either by 
phone or email depending on your preference) to remind you to refrain from all over-
the-counter medications, including vitamins and supplements, for 24 hours, alcohol 
and caffeine for 12 hours, food for 4 hours, and heavy exercise for 24 hours. 
Additionally, you will be asked to wear a short-sleeved shirt and shorts that can be 
easily pushed up.  
2. Upon arrival at the laboratory, your height and weight and resting blood pressure will 
be measured. Female subjects will be asked to take a urine pregnancy test. You 
cannot participate in the study if the pregnancy test is positive, as the study 
procedures could be harmful to an unborn child.  
3. We will prep you for the study by placing 5 sticky electrodes on your skin and 
attaching a small wire or lead to each electrode.  These leads will be attached to a 
monitor that will allow us to measure your heart rate and heart rhythm. These 
electrodes will be placed on your skin by a member of the same sex. The electrodes 
will be placed on your body in the following locations: 2 electrodes are placed on 
your upper chest close to your shoulder (one on the left and one on the right); 2 
electrodes will be placed on your stomach just above your hip bones (just above 
where your pants line is) on the left and right side; and one will be placed on your 
lower ribcage on the left side.  
4. After these electrodes are in place, you will lay down on a padded exam table for the 
remainder of the study.  
5. During the study, blood pressure will be measured periodically throughout the study 
using an inflation cuff on your upper arm.  
6. We may also periodically inflate a small cuff that is placed on your middle finger of 
one of your hands to measure your blood pressure.  We will only inflate this cuff for 
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about 10 minutes at a time.  If the cuff becomes uncomfortable, let the investigator 
know and they will turn it off for a few minutes. 
7. We will use an ultrasound probe to image the large arteries in your neck (carotid) and 
thigh (femoral). We will be measuring the diameter of the arteries, the thickness of 
the artery walls, and the resting blood flow.  
8. You will undergo carotid arterial tonometry with ultrasound. An ultrasound probe 
will be placed on one carotid artery while a non-invasive tonometer device (looks like 
a blunt pencil) is placed on the opposite carotid artery which non-invasively measures 
blood pressure using pressure sensors pressed against the skin over the artery. The 
ultrasound probe measures carotid artery diameter and blood velocity, while the 
tonometer measures the blood pressure wave traveling down the vessel. The two 
values are compared to give an index of the stiffness of the arteries. This is a non-
invasive procedure and should not be uncomfortable, other than some minor pressure 
of the measurement sites.  
9. Your pulse wave will be measured using tonometry. Two tonometers that measure 
blood pressure waves will be placed on the skin over arteries on your neck and thigh 
(carotid and femoral) and your arm and foot (brachial and posterior tibial or dorsal 
pedal). The time between the onset of the pulse waves from the two locations will be 
measured and compared. This is a non-invasive procedure and should not be 
uncomfortable, other than some minor pressure at the measurement sites.  
10. You will have a blood pressure cuff placed around your forearm, just below your 
elbow. We will position an ultrasound transducer probe on your upper arm (above 
your elbow) at the brachial artery.  We will occlude blood flow to your arm by 
inflating the blood pressure cuff on your lower arm to 250 mmHg for 5 min.  There is 
possible risk of discomfort due to the occlusion of the forearm. This discomfort 
should be mild, and only comparable to the lower portion of the arm falling asleep. 
This discomfort should subside immediately following deflation of the cuff. 
However, if this discomfort exceeds a tolerable level, please alert the investigator so 
that the cuff can be deflated early. We will use the ultrasound transducer probe to 
image your brachial artery before and after the blood pressure cuff is inflated and 
  177 
released.  This test may be repeated 1-2 times. If it is repeated, we will allow a rest 
period of at least 20 min in between each blood flow occlusion.  
11. Next, we will administer one spray of nitroglycerin below your tongue and continue 
to image your brachial artery for 10 more minutes. This will cause your blood vessels 
to relax, and will slightly lower your blood pressure. This test causes the smooth 
muscle of your brachial artery blood vessel to relax and dilate allowing an increase in 
blood flow, and we call this test ‘endothelium-independent vasodilation’. You will 
continue to lie supine for at least 15 minutes after nitroglycerin administration to 
ensure your blood pressure has returned to normal.  
12. At the end of the study, we will estimate your total blood volume using a carbon 
monoxide (CO) uptake test. For this test, you will breathe 100% oxygen for 4 minutes 
to remove nitrogen from your lungs (this naturally exists). Then, you will start to 
breathe on a rebreathing system. This essentially means you will inhale and exhale 
into a bag. The air in this rebreathing system is pre-filled with 100% oxygen. After 
several minutes you will expire all of the air out that you possibly can through your 
nose. When you cannot get any more air out, your nose will be closed with noseclips. 
A dose of CO (1.0 mL CO/kg of body mass) will then be injected into the breathing 
system and you will inhale deeply to make sure you inhale as much CO as possible. 
CO is a gas that quickly moves from the air in your lungs to your blood. To further 
help this you will hold your breath for ~10 seconds after you deeply inhale. You will 
then breathe 100% oxygen normally for another several minutes. Small blood 
samples (~5ml) will be taken before you start breathing on the rebreathing system and 
immediately after you stop breathing on the rebreathing system.  These blood samples 
will be taken from the catheter in your arm.  
13. Although you will not be allowed food or beverages during the study, you will be 
given a light snack and fluids to drink before you leave. 
How long will I be in the study? 
You will be in the study for 8-11 weeks. You will participate in one screening session 
(about 60 min), seven experimental days (a total of up to 25 hours), and 36 water 
immersion sessions (up to 2 hours each).  
 
  178 
What are the risks of the study? 
1. Rectal temperature probes: The use of rectal probes to measure core body 
temperature, even during exercise, carries minimal risk. The primary risk is of 
damage to the lining of the rectum; however, this risk is very slight as we use a 
flexible probe that is designed for this purpose.  There is also the risk of infection, 
either by you not washing your hands properly or exposure to a poorly cleaned probe. 
The probe has been sterilized before use, and we will instruct you on how to properly 
clean the probe after each time you use it. The risk of infection is similar to that of 
having a bowel movement, and is considered minimal (similar to daily 
experience).  There is also the risk of embarrassment. The approach is typically well 
tolerated by subjects, and the investigative team is professional in regard to how they 
will treat you. 
2. Venous blood draws and catheters: There may be some discomfort during the blood 
draw. Once the catheter is in place, or once the needle is removed, the pain should 
subside. After the blood draw, the needle will be withdrawn and a sterile dressing will 
be applied. Any swelling or redness after the study should subside by a few hours 
after completion of the study. Although the needles are sterile, there is a slight risk of 
infection at the site where the needle was placed in your skin. You will be instructed 
how to keep the area clean for a day or two following the experimental day. The most 
common complications of inserting a small needle into a vein is a small bruise and 
pain at the site of the needle location which may last several days after removal of the 
needle. A small amount of bleeding may occur directly after removal of the catheter. 
Application of pressure and a gauze dressing will alleviate the bleeding. The 
maximum amount of blood we will draw across the entire study is 270ml, or about 18 
tablespoons, which is well below the volume drawn in a standard blood donation 
(~450ml). Even so, we will exclude you from the study if you have donated blood 
within the last two months. 
3. Skin microdialysis: There may be some discomfort during the insertion of the small 
fibers in your skin.  Once the needle is in place, the pain should subside.  There is 
also a risk of syncope (fainting) during needle placement. You will be sitting in a 
reclining chair during the study, which reduces this risk, and you will be asked to 
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inform the investigator if you feel light-headed, nauseous, dizzy, etc. during needle 
placement. If you do experience any of these symptoms, we will discontinue placing 
the needles and ensure the symptoms subside. Infusions through the fibers should not 
be painful, and there should only be minor swelling at the site.  At the end of the 
study, the fibers will be withdrawn and a sterile dressing will be applied.  Any 
swelling or redness after the study should be gone a few hours after completion of the 
study.  Although the small tubes are sterile, there is a slight risk of infection and/or 
allergic reaction at the sites where the small tubes were placed in your skin.  You will 
be instructed how to keep the area clean for a day or two following the study. If you 
see any signs of infection (redness, swelling, and/or pain around the sites) or 
experience some other abnormal reaction at the insertion site following the study, 
please contact us immediately. We will show you photos of what normal and 
abnormal healing looks like at the sites. There is a possibility the fibers may break 
while in your skin or while they are being removed. We remove the fibers in a way 
such that we can still remove the entire fiber, even if it does break. However, there is 
still a slight risk a small part of the fiber could remain in your skin. If this occurs, the 
piece should be able to work its way out of the skin within a few days (similar to a 
splinter), and we will follow-up with you to ensure this has happened. If the piece 
does not work its way out, or if a site seems infected, we will evaluate the site(s) and, 
if necessary, recommend you seek medical treatment with a healthcare provider. 
4. Microdialysis drugs: We will be infusing very small doses of each drug and only into 
a very small area of your skin.  You will not have any systemic (whole body) effects 
of these drugs, and they will not alter your blood pressure in the small doses given in 
this study.  However, as with any infusions or medications, there is the possibility that 
you are allergic to the drug and may have an allergic reaction to the drug including 
changes in blood pressure and difficulty breathing. In the case of an adverse event, 
the study will be discontinued. Investigators are trained in Advanced Cardiac Life 
Support and anaphylaxis. 
5. Local Skin Heating:  The local skin heaters may cause some minor skin discomfort.  
The goal is to warm the area of skin to a temperature that has been determined to be 
below the threshold for pain.  If the local heating becomes painful, you should tell the 
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investigator and the temperature of the local heater will be lowered.  There is a slight 
risk of burning the skin at this site, so it is important that you tell the investigators of 
any pain you are feeling.  The heating device may be removed at any time if you 
experience any discomfort. 
6. Laser-Doppler Probes:  These probes send a small light into your skin.  You will not 
feel anything except the probe touching your skin. There are no major risks associated 
with this procedure. 
7. Blood Flow Occlusion:  The inflation of the blood pressure cuff to stop blood flow 
may cause a slight tingling sensation and may cause slight bruising.  The sensations 
with prolonged blood flow occlusion greater than 10 minutes are similar to those 
when a limb has “fallen asleep.”  During certain surgical procedures, blood flow is 
often stopped for 2 hours without any significant risk to the patient.  If, at any time, 
you experience any discomfort you may request that the blood pressure cuff be either 
loosened or removed. 
8. Finger Blood Pressure:  In some people, this blood pressure cuff becomes 
uncomfortable after a long period (over 40 minutes).  We will only inflate the cuff for 
10 minutes at a time and then give your finger a rest.  If your finger becomes 
uncomfortable during the 10 minutes the cuff is inflated, let the investigator know and 
they will turn it off for a few minutes.  There are no major risks associated with this 
device. 
9. Nitroglycerin administration: We will administer the standard dose of nitroglycerin 
under your tongue. This drug has minimal risk when used in low doses. Nitroglycerin 
is commonly prescribed to prevent and treat angina pectoris (chest pain), a condition 
occurring from constriction in the arteries of the heart. Nitroglycerin is a potent blood 
vessel dilator, causing the artery to open up and increase blood flow. You may feel 
slight light-headedness or dizziness, but this symptom should not last more than a few 
minutes. Please inform your investigator if these feelings persist during the study and 
do not simply come and go. You may feel your heart rate slowing as this drug causes 
a drop in blood pressure (transient hypotension), but this will also last only a few 
minutes. After nitroglycerin administration, we will take ultrasound images for 
several minutes to monitor changes in your blood flow and vessel size. You will 
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remain laying down on your back for an additional 15 minutes to ensure that your 
blood pressure and heart rate are back to their normal values before we allow you to 
leave the study area. There is a risk that you may experience a headache after this 
treatment, and if you are predisposed, you may experience the onset of a migraine 
headache.  
10. Blood Volume Measurement: This measurement involves exposure to a small amount 
of carbon monoxide. Carbon monoxide is a colorless, odorless gas. We typically 
express CO in the blood as bound to a molecule called hemoglobin (Hb; HbCO).  
Healthy nonsmoking city dwellers typically have 1.5-2.0% of their Hb as HbCO.  
This test will increase this level by roughly 6%. Although you do not want to increase 
your level of HbCO, the levels used for this test are low and present minimal risks. 
The side effects associated with excessive HbCO typically occur at levels above 8% 
and may include headache, fatigue, shortness of breath, nausea, cherry-red colored 
lips, dizziness, and death, the last of which rarely occurs below 15% HbCO in normal 
individuals. This method has been in use in research for measuring blood volume for 
over 100 years without notable complications. Over time the CO bound to Hb in your 
blood will be removed. This process will occur naturally over the several hours 
following the test. For every 5 to 6 hours that passes after the test, half of the CO will 
leave your blood. Thus, after 15-18 hours you would have less than 1% CO in your 
blood. 
 In order to assure that subjects remain below the level of %HbCO that is 
associated with side effects, we will test %HbCO in each individual prior to 
administration of CO. If an individual’s baseline %HbCO is greater than 2.0% we 
will not administer CO to that individual. Furthermore, if for any reason an 
individual’s post-administration %HbCO rises above 10% or an individual develops 
side-effects associated with excess %HbCO, we will initiate O2 therapy to accelerate 
CO clearance from their system. O2 will be given using a nasal administration similar 
to what someone may wear while in the hospital. Administering O2 reduces the half-
life of CO (speeds up the process of getting rid of it) from ~5 hours to ~80 minutes.  
We will measure %HbCO throughout the O2 administration and periodically 
afterwards.  We will stop treatment if %HbCO is < 8% or the symptoms go away. If 
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symptoms progress or do not improve, the Department of Public Safety (6-6666) or 
911 directly will be called depending on the perceived or real severity of the 
symptoms. In the unlikely case of an adverse cardiovascular event, the laboratory is 
equipped with an Automatic Electronic Defibrillator (located in a clearly marked 
first-aid cabinet), and Vienna Brunt, Brett Ely, and Dr. Minson are trained in 
Advanced Cardiac Life Support (ACLS). 
11. Emergencies:  In the event of an emergency, you will be transported by ambulance to 
a local emergency facility. 
May I participate if I am pregnant or breast-feeding? 
No. There is not enough medical information to know what the risks might be to a breast-
fed infant or to an unborn child in a woman who takes part in this study.  Breast-feeding 
mothers are not able to take part in this study. Women who can still become pregnant 
must have a negative pregnancy test no more than 24 hours before taking part in each 
experimental day. If the pregnancy test is positive (meaning that you are pregnant), you 
will no longer be able to take part in the study. 
Are there benefits to taking part in this study? 
This study will likely not make your health better. This study is being conducted to learn 
about the effects of chronic heat exposure on cardiovascular health. It is possible the 
information gathered in this study could be used to better treat patients with elevated 
cardiovascular risk in the future.  
What other choices do I have if I don’t take part in this study? 
This study is only being done to gather information.  You may choose not to take part in 
this study. 
What are the costs of tests and procedures? 
You will not need to pay for any tests or procedures that are done just for this research 
study. You will receive compensation for completed each session in the study as follows: 
initial screening session, $10; Experimental Days 1-5, $30 each; Experimental Day 6, 
$50; Experimental Days 7, $40 each; and $10 per heating session completed. If you 
complete all parts of the study, you will receive $630. This money is for the 
inconvenience and time you spent in this study, and works out to be approximately $10 
per hour of participation in experimental days and $10 per heating session.  If you start 
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the study but stop before the study has ended, you will get part of this money. The partial 
amount will be calculated based on which study sessions you completed. You will 
receive compensation in the form of a check at the end of the study, or if you prefer, 
approximately every 2 weeks into the study. If you choose to receive compensation every 
2 weeks, you will receive an amount corresponding to which study sessions you 
completed in each two-week time interval. There will be no difference in the total 
compensation you will receive if you chose to receive compensation at the end of the 
study versus every 2 weeks. 
Please note, compensation from participation in Human Subjects Research studies 
may be considered taxable income.  Compensation amounts are tracked across all studies 
in which you participate. If compensation totals $600 or more in a calendar year, the 
University is required to report the income to the IRS.  University departments are 
required to track participant compensation and may contact you to complete a W9 form 
for tax reporting purposes.   Because of this, your name will be associated with 
participation in a research study. Department and university administrators will have 
access to this information, but will not have access to research data. 
Who can answer my questions? 
You may talk to Dr. Christopher Minson or his student, Vienna Brunt, M.S. at any time 
about any question you have on this study.  You may contact Dr. Minson by calling (541) 
346-4105, (541) 346-4311 or on his cell phone (541) 953-2231, and Vienna Brunt at 
(541) 346-4507 or on her cell phone at (541) 968-2635. 
What are my rights if I take part in this study? 
Taking part in this research study is your decision.  You do not have to take part in this 
study, but if you do, you can stop at any time. Your decision whether or not to participate 
will not affect your relationship with The University of Oregon. 
You do not waive any liability rights for personal injury by signing this form.  All 
forms of medical diagnosis and treatment whether routine or experimental, involve some 
risk of injury.  In spite of all precautions, you might develop medical complications from 
participating in this study. 
The investigators may stop you from taking part in this study at any time if it is in 
your best interest, if you do not follow the study rules, or if the study is stopped.  You 
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will be told of important new findings or any changes in the study or procedures that may 
happen. 
 If you experience harm because of the project, you can ask the State of Oregon to 
pay you. A law called the Oregon Tort Claims Act limits the amount of money you can 
receive from the State of Oregon if you are harmed. If you have been harmed, there are 
two University representatives you need to contact.  Here are their addresses and phone 
numbers: 
 General Counsel  Research Compliance Services 
 Office of the President University of Oregon 
 University of Oregon  Eugene, OR  97403 
 Eugene, OR 97403  (541) 346-2510 
 (541) 346-3082 
What about confidentiality? 
Any information that is obtained in connection with this study and that can be identified 
with you will remain confidential and will be disclosed only with your permission. 
Subject identities will be kept confidential by assigning you a “subject identification 
number”.  The names associated with each subject identification number will be stored on 
a secure computer with double password protection in Dr. Minson’s office and only one 
list with names and identification numbers will exist.  This list will be destroyed after all 
data has been collected and analyzed and for a period of one year after the results from 
the study have been published. Only coded specimens and data will exist thereafter. 
Your blood will be analyzed for such things as heat shock proteins, hormone 
concentrations, and cytokines (factors released by cells that affect other cells). Your 
muscle tissue will be analyzed for changes in DNA (not genetic testing), RNA, cell 
signaling, and changes in cell structure. The researchers may store the information 
gathered during this study indefinitely.  
I have had an opportunity to have my questions answered.  I have been given a copy 
of this form.  I agree to take part in this study.   
If you have questions regarding your rights as a research subject, contact Research 
Compliance Services, 5219 University of Oregon, Eugene, OR 97403, 541/346-2510. 
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Your signature indicates that you have read and understand the information provided 
above, that you willingly agree to participate, that you may withdraw your consent at any 
time and discontinue participation without penalty, that you will receive a copy of this 
form, and that you are not waiving any legal claims, rights or remedies. 
                                                                                                                       
(Date)                      (Signature of Participant)                                 
                                                                                                                      
                                (Printed Name of Participant)                                  
                                                                                                             
(Date)                      (Signature of Individual Obtaining Consent) 
 
 
 
 
Group 3: Spinal cord injury Heat Therapy 
TITLE: “Chronic heat exposure and cardiovascular health”   
INVESTIGATORS: Vienna E Brunt, M.S., Dr. Christopher T Minson, and colleagues 
APPROVED BY INSTITUTIONAL REVIEW BOARD:  February 5, 2014 
This is an important form.  Please read it carefully.  It tells you what you need to know 
about this study.  If you agree to take part in this research study, you need to sign this 
form.  Your signature means that you have been told about the study and what the risks 
are.  Your signature on this form also means that you want to take part in this study. 
Why is this study being done? 
Cardiovascular disease is the number one cause of death in the United States. Exercise is 
a potent means of improving cardiovascular health, but not all patient populations are 
able to exercise effectively. There is high demand for novel therapies to better manage 
cardiovascular risk in these patients. Heat exposure can have many beneficial effects on 
the cardiovascular system. As such, long-term heat exposure (i.e. sitting in a hot tub 4-5x 
per week) may provide an alternative means to exercise for improving cardiovascular 
health. This project will assess the benefits of long-term heat exposure on the health of 
the vasculature and on the cellular pathways that improve vascular health, which is 
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important as the majority of cardiovascular diseases affect the arteries. We will measure 
various biomarkers of vascular health before and after 8 weeks of heat exposure in able-
bodied individuals and patients with spinal cord injury. SCI patients are a population with 
elevated cardiovascular risk who have limited exercise capabilities, and who may benefit 
greatly from chronic heat exposure. 
We will address the following questions in this study:   
• How does 8 weeks of passive heat exposure affect cardiovascular health, as measured 
by various biomarkers of cardiovascular function? 
• How does 8 weeks of passive heat exposure affect levels of factors circulating in the 
blood and located within muscle tissue that are important for cardiovascular health? 
• Do effects differ between healthy able-bodied individuals and spinal cord injury 
patients?  
What will happen in the study? 
1. If you meet all the initial subject criteria (based on initial phone and/or email 
conversations) and are interested in participating in the study, we will schedule an 
appointment with you to meet with one of the investigators of the study to discuss the 
project, to see the laboratory, and to read this form. Additionally, you will fill out a 
health history form and meet with a physician, so that we can ensure you are healthy 
enough to participate in the study. In addition, the physician will be available to you 
to answer any medical questions or concerns you may have throughout the duration 
of your participation in the study. This visit should last about 60 minutes.  
2. If you qualify for the study, we will also give you a letter of participation to take back 
to your primary medical provider. The letter will include details about all procedures 
that will be performed over the course of the study. We will ask you to have your 
primary medical provider read the letter and sign it, and to then return it to us. Their 
signature will mean they believe you are medically healthy enough to participate in 
the study. The letter can be emailed, mailed, or brought to us in person. Our email 
address is minsonlab@gmail.com. If you would like to mail the letter, we will 
provide you with a stamped addressed envelope. If it is not possible to return a 
signed letter, you will still be able to participate in the study, although we 
recommend that you do consult with your primary medical provider. 
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3. We will assign you to a subject group. Theses assignments are random in order to 
ensure the highest quality of research. You will be informed of what group you are in 
prior to reading this form. If you are reading this form, you are in the SCI heating 
group.  
4. You will report to the laboratory 4-5 times per week over the course of 8 weeks for 
heat exposure sessions. Additionally, you will participate in 7 experimental days. 
Experimental Days 1-2 will occur prior to the 8 weeks heat exposure sessions, and 
Days 6-7 will occur immediately following the 8 weeks of heat exposure sessions. 
Days 3, 4, and 5 will occur at Weeks 2, 4, and 6 into heat exposure sessions. We will 
perform the same procedures in Experimental Days 1 and 7, and in Days 2-6. All 
procedures are explained in detail below.  
5. During the screening session, we will schedule your initial experimental days (2 
sessions), the start of your heat exposure sessions, and tentatively schedule all other 
sessions. We will give you a hard copy of your schedule to take home with you.  
 
Heating Sessions: 
1. You will report to the laboratory 4-5 times per week for 8 weeks, for a total of 36 
sessions. Each session will take approximately 2-2.5 hours. You will be asked to 
bring a swimsuit to wear during the session. If you do not have one, we will provide 
one for you to use for the duration of the 8 weeks. No other subjects will use the same 
swimsuit.  
2. You will be asked to provide a urine sample so that we can ensure you are properly 
hydrated before undergoing heat stress. If you are dehydrated, we will give you 
5mL/kg body weight (about half a normal sized 20oz bottle of Gatorade®) of fluids 
to drink prior to getting in the hot tub.  
3. We will ask you if you have had any bouts of autonomic dysreflexia previously that 
day, or any falls, bumps, or other stressful events. If the answer is yes to any of those 
questions, we cannot let you participate in the heating session for that day. We will 
also ask you to void your bladder prior to getting in the hot tub to avoid autonomic 
dysreflexia.  
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4. You will be instrumented with a Polar® heart rate monitor chest strap so that we can 
continuously monitor your heart rate throughout the procedure and a cuff on your 
upper arm so that we can monitor your blood pressure.  
5. We will give you a rectal probe labeled with your subject number. It is made of a thin 
rubber (flexible) material that is inserted 10 cm (approximately 4 inches) past the anal 
sphincter. The probe will remain in place throughout the entire study session (up to 
2.5 hours). The probe has a “tail” that will be connected to an external apparatus. The 
procedure may be a little uncomfortable at first (during insertion) but it should not be 
painful at anytime. You will be instructed how to self-insert the rectal probe, as well 
as how to remove it and clean it. If you needed assistance, a lab researcher of the 
same sex will help you. Once in place, you may not even feel the probe at all. This 
technique is widely used and it’s considered the “gold standard” procedure for 
measuring body (“core”) temperature. 
6. On the very first and very last heating session (and possibly during one session at 
about 4wks), we will place 1 small flexible needle (these are called “intravenous 
catheters”, and are smaller than the lead of a pencil) into a vein near your elbow. The 
skin will be cleaned before this procedure. This catheter will remain in your vein 
throughout the heating session. We will take about 40ml of blood, about 2.7 
tablespoons, prior to getting into the bathtub, and another 25ml of blood at the end of 
the heating period so that we can measure various factors in your blood that are 
affected by the heat exposure. We will remove the catheter after the second blood 
draw and place a sterile bandage over the site. The vials in which we collect the blood 
will be coded such that the investigators can determine all samples came from the 
same subject and the time the sample was taken. No one will be able to determine 
your identity from the sample.    
7. You will then be transferred to a bathtub that will be filled with water at 40°C 
(104.0°F). The tub is hooked up to a water pump and heater such that water can be 
circulated and maintained at a desired temperature. You will lay down in the bath tub 
such that the water level comes up to the level of your collar bone (to the top of your 
shoulders). You will lay down in this position until your core temperature has reached 
38.5°C (101.3°F). This takes approximately 25-35 minutes. At this point, you will sit 
  189 
up such that the water level reaches the middle of your chest (with your shoulders and 
arms out of the water). You will remain sitting up for another 60 minutes, or until the 
total time in the hot tub reaches 90 minutes, whichever comes first.  
8. We will continuously check in with you throughout the heating period. You will be 
instructed to inform an investigator if you feel any of the following symptoms: light-
headedness, dizziness, nausea, headache, or if you feel unbearably warm. If you feel 
these symptoms, we will have you sit up if you were previously laying down in the 
bath, or we will have you get out of the bath if you were previously sitting up. If your 
body temperature gets too high (above 39.5°C, 103°F), we will have you get out of 
the bath, even if you feel fine.  
9. If your blood pressure or heart either get too high or too low, or if you experience 
autonomic dysreflexia, we will remove you from the bath tub. A lift will be available 
for use if you are unable to transfer yourself out of the bath.  
10. You will be asked to drink fluids while in the hot tub in an amount equivalent to ~1% 
of your body weight (approximately 1-1.5 normal sized bottles of Gatorade®). This is 
to replace some of the fluid you will lose due to sweating. You will be allowed to 
drink more than this amount if you want to.  
11. At the end of the heating period, you will get out of the hot tub and sit in a recovery 
chair. We will continue to monitor your body temperature until your core temperature 
begins to return back to normal. If your body temperature remains high for too long, 
or if you feel too hot, dizzy, or nauseous, we will cool you down more quickly with 
cold packs. We will provide you with a towel to dry off during this time.  
12. Once you feel fine, you will remove the rectal probe, clean it, and place it in a 
location allocated to you. Before you leave the lab, we will offer you cool fluids and a 
light snack.  
 
Experimental Days 1 and 7 (Skin Studies):  
1. You will arrive at Dr. Minson’s laboratory in Esslinger Hall at the University of 
Oregon to participate in the experimental protocol. The testing will take 
approximately 4-5 hours. The day before the study, we will contact you (either by 
phone or email depending on your preference) to remind you to refrain from all over-
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the-counter medications, including vitamins and supplements, for 24 hours, alcohol 
and caffeine for 12 hours, food for 4 hours, and heavy exercise for 24 hours. 
Additionally, you will be asked to wear a short-sleeved shirt. 
2. Upon arrival at the laboratory, your height and weight and resting blood pressure will 
be measured. Female subjects will be asked to take a urine pregnancy test. You 
cannot participate in the study if the pregnancy test is positive, as the study 
procedures could be harmful to an unborn child. 
3. We will place 3 small tubes (these are called “microdialysis fibers”, and are about the 
size of sewing thread) in the skin of your forearm. A small needle will be placed just 
under the surface of your skin and will exit back out about 1½ inches from where it 
entered your skin.  The small tubes will be placed inside the needle, and the needle 
will be withdrawn, leaving the small tubes under your skin.  These will remain in 
your skin throughout the rest of the study.  
4. We need to wait about 1-2 hours after the small tubes are placed in your skin to let the 
insertion trauma (redness of your skin around the small tubes) to go away.  During 
this time, a small probe (laser-Doppler probe) will be placed over each area of skin 
where the small tubes are so that we can measure skin blood flow over the small tube.   
5. During the study, we may periodically inflate a small cuff that is placed on your 
middle finger of one of your hands to measure your blood pressure (Portapres 
device).  We will only inflate this cuff for about 10 minutes at a time.  If the cuff 
becomes uncomfortable, let the investigator know and they will turn it off for a few 
minutes. 
6. Blood pressure will also be measured periodically throughout the study using an 
inflation cuff on your upper arm.  
7. During the protocol we will put some very small doses of drugs through the small 
tubes in your skin.  These drugs will cause the vessels of your skin to either widen or 
become narrow.  You should not feel anything when the drugs are going into your 
skin.  However, it is possible you may feel a slight tingling in the skin where the 
probe is. You will receive the following drugs:  
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a. L-NNA:  this stops nitric oxide from being produced and causes the skin vessels 
to narrow 
b. Tempol: This is a substance that may cause your blood vessels to open.  
c. Sodium nitroprusside:  this is a substance that is used to lower blood pressure in 
patients and causes the skin vessels to open 
8. We will heat a small area of your skin with a small heater up to 43.5° Celsius (110 
degrees Fahrenheit) to open the vessels in your skin.  This is below the temperature 
where heating becomes painful (about 113 degrees Fahrenheit) and well below the 
temperature that may burn your skin (about 117 degrees Fahrenheit).  If you think the 
heater is becoming painful, you need to tell the investigator and the temperature will 
be lowered. 
9. After the study, we will remove the small tubes in your skin and a bandage will be 
placed over the area of skin where the tubes were placed. 
10. Although you will not be allowed food or beverages during the study, you will be 
given a light snack and fluids to drink before you leave. 
 
Experimental Days 2-6 (Vascular Function): 
1. You will arrive at Dr. Minson’s laboratory in Esslinger Hall at the University of 
Oregon to participate in the experimental protocol. This testing will take 
approximately 3-4 hours. The day before the study, we will contact you (either by 
phone or email depending on your preference) to remind you to refrain from all over-
the-counter medications, including vitamins and supplements, for 24 hours, alcohol 
and caffeine for 12 hours, food for 4 hours, and heavy exercise for 24 hours. 
Additionally, you will be asked to wear a short-sleeved shirt and shorts that can be 
easily pushed up.  
2. Upon arrival at the laboratory, your height and weight and resting blood pressure will 
be measured. Female subjects will be asked to take a urine pregnancy test. You 
cannot participate in the study if the pregnancy test is positive, as the study 
procedures could be harmful to an unborn child.  
3. We will prep you for the study by placing 5 sticky electrodes on your skin and 
attaching a small wire or lead to each electrode.  These leads will be attached to a 
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monitor that will allow us to measure your heart rate and heart rhythm. These 
electrodes will be placed on your skin by a member of the same sex. The electrodes 
will be placed on your body in the following locations: 2 electrodes are placed on 
your upper chest close to your shoulder (one on the left and one on the right); 2 
electrodes will be placed on your stomach just above your hip bones (just above 
where your pants line is) on the left and right side; and one will be placed on your 
lower ribcage on the left side.  
4. After these electrodes are in place, you will lay down on a padded exam table for the 
remainder of the study.  
5. During the study, blood pressure will be measured periodically throughout the study 
using an inflation cuff on your upper arm.  
6. We may also periodically inflate a small cuff that is placed on your middle finger of 
one of your hands to measure your blood pressure.  We will only inflate this cuff for 
about 10 minutes at a time.  If the cuff becomes uncomfortable, let the investigator 
know and they will turn it off for a few minutes. 
7. We will use an ultrasound probe to image the large arteries in your neck (carotid) and 
thigh (femoral). We will be measuring the diameter of the arteries, the thickness of 
the artery walls, and the resting blood flow.  
8. You will undergo carotid arterial tonometry with ultrasound. An ultrasound probe 
will be placed on one carotid artery while a non-invasive tonometer device (looks like 
a blunt pencil) is placed on the opposite carotid artery which non-invasively measures 
blood pressure using pressure sensors pressed against the skin over the artery. The 
ultrasound probe measures carotid artery diameter and blood velocity, while the 
tonometer measures the blood pressure wave traveling down the vessel. The two 
values are compared to give an index of the stiffness of the arteries. This is a non-
invasive procedure and should not be uncomfortable, other than some minor pressure 
of the measurement sites.  
9. Your pulse wave will be measured using tonometry. Two tonometers that measure 
blood pressure waves will be placed on the skin over arteries on your neck and thigh 
(carotid and femoral) and your arm and foot (brachial and posterior tibial or dorsal 
pedal). The time between the onset of the pulse waves from the two locations will be 
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measured and compared. This is a non-invasive procedure and should not be 
uncomfortable, other than some minor pressure at the measurement sites.  
10. You will have a blood pressure cuff placed around your forearm, just below your 
elbow. We will position an ultrasound transducer probe on your upper arm (above 
your elbow) at the brachial artery.  We will occlude blood flow to your arm by 
inflating the blood pressure cuff on your lower arm to 250 mmHg for 5 min.  There is 
possible risk of discomfort due to the occlusion of the forearm. This discomfort 
should be mild, and only comparable to the lower portion of the arm falling asleep. 
This discomfort should subside immediately following deflation of the cuff. 
However, if this discomfort exceeds a tolerable level, please alert the investigator so 
that the cuff can be deflated early. We will use the ultrasound transducer probe to 
image your brachial artery before and after the blood pressure cuff is inflated and 
released.  This test may be repeated 1-2 times. If it is repeated, we will allow a rest 
period of at least 20 min in between each blood flow occlusion.  
11. Next, we will administer one spray of nitroglycerin below your tongue and continue 
to image your brachial artery for 10 more minutes. This will cause your blood vessels 
to relax, and will slightly lower your blood pressure. This test causes the smooth 
muscle of your brachial artery blood vessel to relax and dilate allowing an increase in 
blood flow, and we call this test ‘endothelium-independent vasodilation’. You will 
continue to lie supine for at least 15 minutes after nitroglycerin administration to 
ensure your blood pressure has returned to normal.  
12. At the end of the study, we will estimate your total blood volume using a carbon 
monoxide (CO) uptake test.  For this test, you will breathe 100% oxygen for 4 
minutes to remove nitrogen from your lungs (this naturally exists).  Then, you will 
start to breathe on a rebreathing system.  This essentially means you will inhale and 
exhale into a bag.  The air in this rebreathing system is pre-filled with 100% oxygen.  
After several minutes you will expire all of the air out that you possibly can through 
your nose.  When you cannot get any more air out, your nose will be closed with 
noseclips.  A dose of CO (1.0 mL CO/kg of body mass) will then be injected into the 
breathing system and you will inhale deeply to make sure you inhale as much CO as 
possible.  CO is a gas that quickly moves from the air in your lungs to your blood.  To 
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further help this you will hold your breath for ~10 seconds after you deeply inhale.  
You will then breathe 100% oxygen normally for another several minutes.  Small 
blood samples (~5ml) will be taken before you start breathing on the rebreathing 
system and immediately after you stop breathing on the rebreathing system.  These 
blood samples will be taken from the catheter in your arm.  
13. Although you will not be allowed food or beverages during the study, you will be 
given a light snack and fluids to drink before you leave. 
 
Optional Follow-Up Testing:  
If you are interested and if you continue to qualify, you may be asked by the investigators 
to return to the laboratory after you have completed the 8 weeks of hot water immersion. 
This is so that we can assess how long any changes in your cardiovascular health last. 
Follow-up testing would take place 2, 4, 6, and/ 8 weeks after your last hot tub session. If 
you are interested in participating in follow-up testing, you will be asked to give consent 
and will sign an additional consent form closer to the end of your 8 weeks of hot water 
immersion. Importantly, if you are not interested in participating in follow-up testing, it 
does not affect your participation in the primary study, the 8 weeks of hot water 
immersion. Also please note that all time frames and compensation amounts in this 
section of the consent form only include the initial 8 weeks of hot water immersion.  
If you are interested in being asked later on about participating in follow-up  
testing, please initial here: _______. You can still change your mind at any time.   
How long will I be in the study? 
You will be in the study for 8-11 weeks. You will participate in one screening session 
(about 60 min), seven experimental days (a total of up to 25 hours), and 36 heating 
sessions.  
What are the risks of the study? 
1. Heat exposure: There are some risks associated with heat exposure, including: 
fatigue, light-headedness, muscle cramps, dehydration, and neurological detriments 
(i.e. heat stroke). However, these symptoms do not typically occur until core 
temperature rises above 40°C. Your core temperature will be constantly recorded 
(rectal probe), and you will be removed from the hot bath immediately if either core 
  195 
temperature reaches 39.5°C or you experience any symptoms of heat-related illness. 
You will be instructed to notify the investigators immediately if you experience any 
of these symptoms. All symptoms subside upon lowering core temperature. Ice packs 
will be on hand for rapid cooling if necessary. Additionally, heat exposure may have 
detrimental effects on a developing fetus in females and on sperm counts in males. 
Thus, subjects who are pregnant, trying to conceive, and/or undergoing treatment to 
increase sperm counts will be excluded from the study.   
2. Rectal temperature probes (heating group only): The use of rectal probes to measure 
core body temperature, even during exercise, carries minimal risk. The primary risk is 
of damage to the lining of the rectum; however, this risk is very slight as we use a 
flexible probe that is designed for this purpose.  There is also the risk of infection, 
either by you not washing your hands properly or exposure to a poorly cleaned probe. 
The probe has been sterilized before use, and we will instruct you on how to properly 
clean the probe after each time you use it. The risk of infection is similar to that of 
having a bowel movement, and is considered minimal (similar to daily 
experience).  There is also the risk of embarrassment. The approach is typically well 
tolerated by subjects, and the investigative team is professional in regard to how they 
will treat you. 
3. Venous blood draws and catheters: There may be some discomfort during the blood 
draw. Once the catheter is in place, or once the needle is removed, the pain should 
subside. After the blood draw, the needle will be withdrawn and a sterile dressing will 
be applied. Any swelling or redness after the study should subside by a few hours 
after completion of the study. Although the needles are sterile, there is a slight risk of 
infection at the site where the needle was placed in your skin. You will be instructed 
how to keep the area clean for a day or two following the experimental day. The most 
common complications of inserting a small needle into a vein is a small bruise and 
pain at the site of the needle location which may last several days after removal of the 
needle. A small amount of bleeding may occur directly after removal of the catheter. 
Application of pressure and a gauze dressing will alleviate the bleeding. The 
maximum amount of blood we will draw across the entire study is 270ml, or about 18 
tablespoons, which is well below the volume drawn in a standard blood donation 
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(~450ml). Even so, we will exclude you from the study if you have donated blood 
within the last two months.   
4. Skin microdialysis: There may be some discomfort during the insertion of the small 
fibers in your skin.  Once the needle is in place, the pain should subside.  There is 
also a risk of syncope (fainting) during needle placement. You will be sitting in a 
reclining chair during the study, which reduces this risk, and you will be asked to 
inform the investigator if you feel light-headed, nauseous, dizzy, etc. during needle 
placement. If you do experience any of these symptoms, we will discontinue placing 
the needles and ensure the symptoms subside. Infusions through the fibers should not 
be painful, and there should only be minor swelling at the site.  At the end of the 
study, the fibers will be withdrawn and a sterile dressing will be applied.  Any 
swelling or redness after the study should be gone a few hours after completion of the 
study.  Although the small tubes are sterile, there is a slight risk of infection and/or 
allergic reaction at the sites where the small tubes were placed in your skin.  You will 
be instructed how to keep the area clean for a day or two following the study. If you 
see any signs of infection (redness, swelling, and/or pain around the sites) or 
experience some other abnormal reaction at the insertion site following the study, 
please contact us immediately. We will show you photos of what normal and 
abnormal healing looks like at the sites. There is a possibility the fibers may break 
while in your skin or while they are being removed. We remove the fibers in a way 
such that we can still remove the entire fiber, even if it does break. However, there is 
still a slight risk a small part of the fiber could remain in your skin. If this occurs, the 
piece should be able to work its way out of the skin within a few days (similar to a 
splinter), and we will follow-up with you to ensure this has happened. If the piece 
does not work its way out, or if a site seems infected, we will evaluate the site(s) and, 
if necessary, recommend you seek medical treatment with a healthcare provider. 
5. Microdialysis drugs: We will be infusing very small doses of each drug and only into 
a very small area of your skin.  You will not have any systemic (whole body) effects 
of these drugs, and they will not alter your blood pressure in the small doses given in 
this study.  However, as with any infusions or medications, there is the possibility that 
you are allergic to the drug and may have an allergic reaction to the drug including 
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changes in blood pressure and difficulty breathing. In the case of an adverse event, 
the study will be discontinued. Investigators are trained in Advanced Cardiac Life 
Support and anaphylaxis. 
6. Local Skin Heating:  The local skin heaters may cause some minor skin discomfort.  
The goal is to warm the area of skin to a temperature that has been determined to be 
below the threshold for pain.  If the local heating becomes painful, you should tell the 
investigator and the temperature of the local heater will be lowered.  There is a slight 
risk of burning the skin at this site, so it is important that you tell the investigators of 
any pain you are feeling.  The heating device may be removed at any time if you 
experience any discomfort. 
7. Laser-Doppler Probes:  These probes send a small light into your skin.  You will not 
feel anything except the probe touching your skin. There are no major risks associated 
with this procedure. 
8. Blood Flow Occlusion:  The inflation of the blood pressure cuff to stop blood flow 
may cause a slight tingling sensation and may cause slight bruising.  The sensations 
with prolonged blood flow occlusion greater than 10 minutes are similar to those 
when a limb has “fallen asleep.”  During certain surgical procedures, blood flow is 
often stopped for 2 hours without any significant risk to the patient.  If, at any time, 
you experience any discomfort you may request that the blood pressure cuff be either 
loosened or removed. 
9. Finger Blood Pressure:  In some people, this blood pressure cuff becomes 
uncomfortable after a long period (over 40 minutes).  We will only inflate the cuff for 
10 minutes at a time and then give your finger a rest.  If your finger becomes 
uncomfortable during the 10 minutes the cuff is inflated, let the investigator know and 
they will turn it off for a few minutes.  There are no major risks associated with this 
device. 
10. Nitroglycerin administration: We will administer the standard dose of nitroglycerin 
under your tongue. This drug has minimal risk when used in low doses. Nitroglycerin 
is commonly prescribed to prevent and treat angina pectoris (chest pain), a condition 
occurring from constriction in the arteries of the heart. Nitroglycerin is a potent blood 
vessel dilator, causing the artery to open up and increase blood flow. You may feel 
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slight light-headedness or dizziness, but this symptom should not last more than a few 
minutes. Please inform your investigator if these feelings persist during the study and 
do not simply come and go. You may feel your heart rate slowing as this drug causes 
a drop in blood pressure (transient hypotension), but this will also last only a few 
minutes. After nitroglycerin administration, we will take ultrasound images for 
several minutes to monitor changes in your blood flow and vessel size. You will 
remain laying down on your back for an additional 15 minutes to ensure that your 
blood pressure and heart rate are back to their normal values before we allow you to 
leave the study area. There is a risk that you may experience a headache after this 
treatment, and if you are predisposed, you may experience the onset of a migraine 
headache.  
11. Blood Volume Measurement: This measurement involves exposure to a small amount 
of carbon monoxide. Carbon monoxide is a colorless, odorless gas. We typically 
express CO in the blood as bound to a molecule called hemoglobin (Hb; HbCO).  
Healthy nonsmoking city dwellers typically have 1.5-2.0% of their Hb as HbCO.  
This test will increase this level by roughly 6%.  Although you do not want to 
increase your level of HbCO, the levels used for this test are low and present minimal 
risks.  The side effects associated with excessive HbCO typically occur at levels 
above 8% and may include headache, fatigue, shortness of breath, nausea, cherry-red 
colored lips, dizziness, and death, the last of which rarely occurs below 15% HbCO in 
normal individuals.  This method has been in use in research for measuring blood 
volume for over 100 years without notable complications.  Over time the CO bound 
to Hb in your blood will be removed.  This process will occur naturally over the 
several hours following the test. For every 5 to 6 hours that passes after the test, half 
of the CO will leave your blood.  Thus, after 15-18 hours you would have less than 
1% CO in your blood. 
 In order to assure that subjects remain below the level of %HbCO that is 
associated with side effects, we will test %HbCO in each individual prior to 
administration of CO.  If an individual’s baseline %HbCO is greater than 2.0% we 
will not administer CO to that individual.  Furthermore, if for any reason an 
individual’s post-administration %HbCO rises above 10% or an individual develops 
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side-effects associated with excess %HbCO, we will initiate O2 therapy to accelerate 
CO clearance from their system.  O2 will be given using a nasal administration similar 
to what someone may wear while in the hospital.  Administering O2 reduces the half-
life of CO (speeds up the process of getting rid of it) from ~5 hours to ~80 minutes.  
We will measure %HbCO throughout the O2 administration and periodically 
afterwards.  We will stop treatment if %HbCO is < 8% or the symptoms go away.  If 
symptoms progress or do not improve, the Department of Public Safety (6-6666) or 
911 directly will be called depending on the perceived or real severity of the 
symptoms.  In the unlikely case of an adverse cardiovascular event, the laboratory is 
equipped with an Automatic Electronic Defibrillator (located in a clearly marked 
first-aid cabinet), and Vienna Brunt, Brett Ely, and Dr. Minson are trained in 
Advanced Cardiac Life Support (ACLS). 
12. Emergencies:  In the event of an emergency, you will be transported by ambulance to 
a local emergency facility. 
May I participate if I am pregnant or breast-feeding? 
No. There is not enough medical information to know what the risks might be to a breast-
fed infant or to an unborn child in a woman who takes part in this study.  Breast-feeding 
mothers are not able to take part in this study.  Women who can still become pregnant 
must have a negative pregnancy test no more than 24 hours before taking part in each 
experimental day.  If the pregnancy test is positive (meaning that you are pregnant), you 
will no longer be able to take part in the study. 
Are there benefits to taking part in this study? 
This study will likely not make your health better. This study is being conducted to learn 
about the effects of chronic heat exposure on cardiovascular health. It is possible the 
information gathered in this study could be used to better treat patients with elevated 
cardiovascular risk in the future.  
What other choices do I have if I don’t take part in this study? 
This study is only being done to gather information.  You may choose not to take part in 
this study. 
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What are the costs of tests and procedures? 
You will not need to pay for any tests or procedures that are done just for this research 
study. You will receive compensation for completed each session in the study as follows: 
initial screening session, $10; Experimental Days 1-5, $30 each; Experimental Day 6, 
$50; Experimental Day 7, $40 each; and $10 per heating session completed. If you 
complete all parts of the study, you will receive $630. This money is for the 
inconvenience and time you spent in this study, and works out to be approximately $10 
per hour of participation in experimental days and $10 per heating session.  If you start 
the study but stop before the study has ended, you will get part of this money. The partial 
amount will be calculated based on which study sessions you completed. You will 
receive compensation in the form of a check at the end of the study, or if you prefer, 
approximately every 2 weeks into the study. If you choose to receive compensation every 
2 weeks, you will receive an amount corresponding to which study sessions you 
completed in each two-week time interval. There will be no difference in the total 
compensation you will receive if you chose to receive compensation at the end of the 
study versus every 2 weeks.  
Please note, compensation from participation in Human Subjects Research studies 
may be considered taxable income.  Compensation amounts are tracked across all studies 
in which you participate. If compensation totals $600 or more in a calendar year, the 
University is required to report the income to the IRS.  University departments are 
required to track participant compensation and may contact you to complete a W9 form 
for tax reporting purposes.   Because of this, your name will be associated with 
participation in a research study. Department and university administrators will have 
access to this information, but will not have access to research data. 
Who can answer my questions? 
You may talk to Dr. Christopher Minson or his student, Vienna Brunt, M.S. at any time 
about any question you have on this study.  You may contact Dr. Minson by calling (541) 
346-4105, (541) 346-4311 or on his cell phone (541) 953-2231, and Vienna Brunt at 
(541) 346-4507 or on her cell phone at (541) 968-2635. 
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What are my rights if I take part in this study? 
Taking part in this research study is your decision.  You do not have to take part in this 
study, but if you do, you can stop at any time. Your decision whether or not to participate 
will not affect your relationship with The University of Oregon. 
You do not waive any liability rights for personal injury by signing this form.  All 
forms of medical diagnosis and treatment whether routine or experimental, involve some 
risk of injury.  In spite of all precautions, you might develop medical complications from 
participating in this study. 
The investigators may stop you from taking part in this study at any time if it is in 
your best interest, if you do not follow the study rules, or if the study is stopped.  You 
will be told of important new findings or any changes in the study or procedures that may 
happen. 
 If you experience harm because of the project, you can ask the State of Oregon to 
pay you. A law called the Oregon Tort Claims Act limits the amount of money you can 
receive from the State of Oregon if you are harmed. If you have been harmed, there are 
two University representatives you need to contact.  Here are their addresses and phone 
numbers: 
 General Counsel  Research Compliance Services 
 Office of the President University of Oregon 
 University of Oregon  Eugene, OR  97403 
 Eugene, OR 97403  (541) 346-2510 
 (541) 346-3082 
What about confidentiality? 
Any information that is obtained in connection with this study and that can be identified 
with you will remain confidential and will be disclosed only with your permission. 
Subject identities will be kept confidential by assigning you a “subject identification 
number”.  The names associated with each subject identification number will be stored on 
a secure computer with double password protection in Dr. Minson’s office and only one 
list with names and identification numbers will exist.  This list will be destroyed after all 
data has been collected and analyzed and for a period of one year after the results from 
the study have been published. Only coded specimens and data will exist thereafter. 
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Your blood will be analyzed for such things as heat shock proteins, hormone 
concentrations, and cytokines (factors released by cells that affect other cells). Your 
muscle tissue will be analyzed for changes in DNA (not genetic testing), RNA, cell 
signaling, and changes in cell structure. The researchers may store the information 
gathered during this study indefinitely.  
I have had an opportunity to have my questions answered.  I have been given a copy 
of this form.  I agree to take part in this study.   
If you have questions regarding your rights as a research subject, contact Research 
Compliance Services, 5219 University of Oregon, Eugene, OR 97403, 541/346-2510. 
Your signature indicates that you have read and understand the information 
provided above, that you willingly agree to participate, that you may withdraw your 
consent at any time and discontinue participation without penalty, that you will receive a 
copy of this form, and that you are not waiving any legal claims, rights or remedies. 
                                                                                                                       
(Date)                      (Signature of Participant)                                 
                                                                                                                      
                                (Printed Name of Participant)                                  
                                                                                                             
(Date)                      (Signature of Individual Obtaining Consent) 
 
 
 
 
Group 4: Spinal cord injury Time Control 
TITLE: “Chronic heat exposure and cardiovascular health”   
INVESTIGATORS: Vienna E Brunt, M.S., Dr. Christopher T Minson, and colleagues 
APPROVED BY INSTITUTIONAL REVIEW BOARD:  February 5, 2014 
This is an important form.  Please read it carefully.  It tells you what you need to know 
about this study.  If you agree to take part in this research study, you need to sign this 
form.  Your signature means that you have been told about the study and what the risks 
are.  Your signature on this form also means that you want to take part in this study. 
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Why is this study being done? 
Cardiovascular disease is the number one cause of death in the United States. Exercise is 
a potent means of improving cardiovascular health, but not all patient populations are 
able to exercise effectively. There is high demand for novel therapies to better manage 
cardiovascular risk in these patients. Heat exposure can have many beneficial effects on 
the cardiovascular system. As such, long-term heat exposure (i.e. sitting in a hot tub 4-5x 
per week) may provide an alternative means to exercise for improving cardiovascular 
health. This project will assess the benefits of long-term heat exposure on the health of 
the vasculature and on the cellular pathways that improve vascular health, which is 
important as the majority of cardiovascular diseases affect the arteries. We will measure 
various biomarkers of vascular health before and after 8 weeks of heat exposure in able-
bodied individuals and patients with spinal cord injury. SCI patients are a population with 
elevated cardiovascular risk who have limited exercise capabilities, and who may benefit 
greatly from chronic heat exposure. 
We will address the following questions in this study:   
• How does 8 weeks of passive heat exposure affect cardiovascular health, as measured 
by various biomarkers of cardiovascular function? 
• How does 8 weeks of passive heat exposure affect levels of factors circulating in the 
blood and located within muscle tissue that are important for cardiovascular health? 
• Do effects differ between healthy able-bodied individuals and spinal cord injury 
patients?  
What will happen in the study? 
1. If you meet all the initial subject criteria (based on initial phone and/or email 
conversations) and are interested in participating in the study, we will schedule an 
appointment with you to meet with one of the investigators of the study to discuss the 
project, to see the laboratory, and to read this form. Additionally, you will fill out a 
health history form and meet with a physician, so that we can ensure you are healthy 
enough to participate in the study. In addition, the physician will be available to you 
to answer any medical questions or concerns you may have throughout the duration 
of your participation in the study. This visit should last about 60 minutes. 
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2. If you qualify for the study, we will also give you a letter of participation to take back 
to your primary medical provider. The letter will include details about all procedures 
that will be performed over the course of the study. We will ask you to have your 
primary medical provider read the letter and sign it, and to then return it to us. Their 
signature will mean they believe you are medically healthy enough to participate in 
the study. The letter can be emailed, mailed, or brought to us in person. Our email 
address is minsonlab@gmail.com. If you would like to mail the letter, we will 
provide you with a stamped addressed envelope. If it is not possible to return a 
signed letter, you will still be able to participate in the study, although we 
recommend that you do consult with your primary medical provider. 
3. We will assign you to a subject group. Theses assignments are random in order to 
ensure the highest quality of research. You will be informed of what group you are in 
prior to reading this form. If you are reading this form, you are assigned to the 
control group.  
4. You will participate in 7 experimental days over the course of 8-11 weeks. 
Experimental Days 1-2 will occur within a 2 week time period. Days 3, 4, and 5 will 
occur 2, 4, and 6 weeks after the initial testing. Days 6-7 will occur 8 weeks after the 
initial testing. We will perform the same procedures in Experimental Days 1 and 9, 
and in Days 2-6. All procedures are explained in detail below. We will check in with 
you regularly via phone or email in between experimental days. 
5. During the screening session, we will schedule your initial experimental days (2 
sessions), and tentatively schedule all other sessions. We will give you a hard copy of 
your schedule to take home with you.   
 
Experimental Days 1 and 7 (Skin Studies):  
1. You will arrive at Dr. Minson’s laboratory in Esslinger Hall at the University of 
Oregon to participate in the experimental protocol. The testing will take 
approximately 4-5 hours. The day before the study, we will contact you (either by 
phone or email depending on your preference) to remind you to refrain from all over-
the-counter medications, including vitamins and supplements, for 24 hours, alcohol 
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and caffeine for 12 hours, food for 4 hours, and heavy exercise for 24 hours. 
Additionally, you will be asked to wear a short-sleeved shirt. 
2. Upon arrival at the laboratory, your height and weight and resting blood pressure will 
be measured. Female subjects will be asked to take a urine pregnancy test. You 
cannot participate in the study if the pregnancy test is positive, as the study 
procedures could be harmful to an unborn child. 
3. We will place 3 small tubes (these are called “microdialysis fibers”, and are about the 
size of sewing thread) in the skin of your forearm. A small needle will be placed just 
under the surface of your skin and will exit back out about 1½ inches from where it 
entered your skin.  The small tubes will be placed inside the needle, and the needle 
will be withdrawn, leaving the small tubes under your skin.  These will remain in 
your skin throughout the rest of the study.  
4. We need to wait about 1-2 hours after the small tubes are placed in your skin to let the 
insertion trauma (redness of your skin around the small tubes) to go away.  During 
this time, a small probe (laser-Doppler probe) will be placed over each area of skin 
where the small tubes are so that we can measure skin blood flow over the small tube.   
5. During the study, we may periodically inflate a small cuff that is placed on your 
middle finger of one of your hands to measure your blood pressure (Portapres 
device).  We will only inflate this cuff for about 10 minutes at a time.  If the cuff 
becomes uncomfortable, let the investigator know and they will turn it off for a few 
minutes. 
6. Blood pressure will also be measured periodically throughout the study using an 
inflation cuff on your upper arm.  
7. During the protocol we will put some very small doses of drugs through the small 
tubes in your skin.  These drugs will cause the vessels of your skin to either widen or 
become narrow.  You should not feel anything when the drugs are going into your 
skin.  However, it is possible you may feel a slight tingling in the skin where the 
probe is. You will receive the following drugs:  
a. L-NNA:  this stops nitric oxide from being produced and causes the skin vessels 
to narrow 
b. Tempol: This is a substance that may cause your blood vessels to open.  
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c. Sodium nitroprusside:  this is a substance that is used to lower blood pressure in 
patients and causes the skin vessels to open 
8. We will heat a small area of your skin with a small heater up to 43.5° Celsius (110 
degrees Fahrenheit) to open the vessels in your skin.  This is below the temperature 
where heating becomes painful (about 113 degrees Fahrenheit) and well below the 
temperature that may burn your skin (about 117 degrees Fahrenheit).  If you think the 
heater is becoming painful, you need to tell the investigator and the temperature will 
be lowered. 
9. After the study, we will remove the small tubes in your skin and a bandage will be 
placed over the area of skin where the tubes were placed. 
10. Although you will not be allowed food or beverages during the study, you will be 
given a light snack and fluids to drink before you leave. 
 
Experimental Days 2-6 (Vascular Function): 
1. You will arrive at Dr. Minson’s laboratory in Esslinger Hall at the University of 
Oregon to participate in the experimental protocol. This testing will take 
approximately 3-4 hours. The day before the study, we will contact you (either by 
phone or email depending on your preference) to remind you to refrain from all over-
the-counter medications, including vitamins and supplements, for 24 hours, alcohol 
and caffeine for 12 hours, food for 4 hours, and heavy exercise for 24 hours. 
Additionally, you will be asked to wear a short-sleeved shirt and shorts that can be 
easily pushed up.  
2. Upon arrival at the laboratory, your height and weight and resting blood pressure will 
be measured. Female subjects will be asked to take a urine pregnancy test. You 
cannot participate in the study if the pregnancy test is positive, as the study 
procedures could be harmful to an unborn child.  
3. We will prep you for the study by placing 5 sticky electrodes on your skin and 
attaching a small wire or lead to each electrode.  These leads will be attached to a 
monitor that will allow us to measure your heart rate and heart rhythm. These 
electrodes will be placed on your skin by a member of the same sex. The electrodes 
will be placed on your body in the following locations: 2 electrodes are placed on 
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your upper chest close to your shoulder (one on the left and one on the right); 2 
electrodes will be placed on your stomach just above your hip bones (just above 
where your pants line is) on the left and right side; and one will be placed on your 
lower ribcage on the left side.  
4. After these electrodes are in place, you will lay down on a padded exam table for the 
remainder of the study.  
5. We will place 1 small flexible needle (these are called “intravenous catheters”, and are 
smaller than the lead of a pencil) into a vein near your elbow. The skin will be 
cleaned before this procedure. This catheter will remain in your vein throughout the 
session. We may take about 40ml of blood, about 2.7 tablespoons, so that we can 
measure various factors in your blood that may be affected by heat exposure. We will 
remove the catheter at the end of the session and place a sterile bandage over the site. 
The vials in which we collect the blood will be coded such that the investigators can 
determine all samples came from the same subject and the time the sample was taken. 
No one will be able to determine your identity from the sample. 
6. During the study, blood pressure will be measured periodically throughout the study 
using an inflation cuff on your upper arm.  
7. We may also periodically inflate a small cuff that is placed on your middle finger of 
one of your hands to measure your blood pressure.  We will only inflate this cuff for 
about 10 minutes at a time.  If the cuff becomes uncomfortable, let the investigator 
know and they will turn it off for a few minutes. 
8. We will use an ultrasound probe to image the large arteries in your neck (carotid) and 
thigh (femoral). We will be measuring the diameter of the arteries, the thickness of 
the artery walls, and the resting blood flow.  
9. You will undergo carotid arterial tonometry with ultrasound. An ultrasound probe will 
be placed on one carotid artery while a non-invasive tonometer device (looks like a 
blunt pencil) is placed on the opposite carotid artery which non-invasively measures 
blood pressure using pressure sensors pressed against the skin over the artery. The 
ultrasound probe measures carotid artery diameter and blood velocity, while the 
tonometer measures the blood pressure wave traveling down the vessel. The two 
values are compared to give an index of the stiffness of the arteries. This is a non-
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invasive procedure and should not be uncomfortable, other than some minor pressure 
of the measurement sites.  
10. Your pulse wave will be measured using tonometry. Two tonometers that measure 
blood pressure waves will be placed on the skin over arteries on your neck and thigh 
(carotid and femoral) and your arm and foot (brachial and posterior tibial or dorsal 
pedal). The time between the onset of the pulse waves from the two locations will be 
measured and compared. This is a non-invasive procedure and should not be 
uncomfortable, other than some minor pressure at the measurement sites.  
11. You will have a blood pressure cuff placed around your forearm, just below your 
elbow. We will position an ultrasound transducer probe on your upper arm (above 
your elbow) at the brachial artery.  We will occlude blood flow to your arm by 
inflating the blood pressure cuff on your lower arm to 250 mmHg for 5 min.  There is 
possible risk of discomfort due to the occlusion of the forearm. This discomfort 
should be mild, and only comparable to the lower portion of the arm falling asleep. 
This discomfort should subside immediately following deflation of the cuff. 
However, if this discomfort exceeds a tolerable level, please alert the investigator so 
that the cuff can be deflated early. We will use the ultrasound transducer probe to 
image your brachial artery before and after the blood pressure cuff is inflated and 
released.  This test may be repeated 1-2 times. If it is repeated, we will allow a rest 
period of at least 20 min in between each blood flow occlusion.  
12. Next, we will administer one spray of nitroglycerin below your tongue and continue 
to image your brachial artery for 10 more minutes. This will cause your blood vessels 
to relax, and will slightly lower your blood pressure. This test causes the smooth 
muscle of your brachial artery blood vessel to relax and dilate allowing an increase in 
blood flow, and we call this test ‘endothelium-independent vasodilation’. You will 
continue to lie supine for at least 15 minutes after nitroglycerin administration to 
ensure your blood pressure has returned to normal.  
13. At the end of the study, we will estimate your total blood volume using a carbon 
monoxide (CO) uptake test.  For this test, you will breathe 100% oxygen for 4 
minutes to remove nitrogen from your lungs (this naturally exists).  Then, you will 
start to breathe on a rebreathing system.  This essentially means you will inhale and 
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exhale into a bag.  The air in this rebreathing system is pre-filled with 100% oxygen.  
After several minutes you will expire all of the air out that you possibly can through 
your nose.  When you cannot get any more air out, your nose will be closed with 
noseclips.  A dose of CO (1.0 mL CO/kg of body mass) will then be injected into the 
breathing system and you will inhale deeply to make sure you inhale as much CO as 
possible.  CO is a gas that quickly moves from the air in your lungs to your blood.  To 
further help this you will hold your breath for ~10 seconds after you deeply inhale.  
You will then breathe 100% oxygen normally for another several minutes.  Small 
blood samples (~5ml) will be taken before you start breathing on the rebreathing 
system and immediately after you stop breathing on the rebreathing system.  These 
blood samples will be taken from the catheter in your arm.  
14. Although you will not be allowed food or beverages during the study, you will be 
given a light snack and fluids to drink before you leave. 
How long will I be in the study? 
You will be in the study for 8-11 weeks. You will participate in one screening session 
(about 60 min) and seven experimental days (a total of up to 25 hours). 
What are the risks of the study?  
1. Venous blood draws and catheters: There may be some discomfort during the blood 
draw. Once the catheter is in place, or once the needle is removed, the pain should 
subside. After the blood draw, the needle will be withdrawn and a sterile dressing will 
be applied. Any swelling or redness after the study should subside by a few hours 
after completion of the study. Although the needles are sterile, there is a slight risk of 
infection at the site where the needle was placed in your skin. You will be instructed 
how to keep the area clean for a day or two following the experimental day. The most 
common complications of inserting a small needle into a vein is a small bruise and 
pain at the site of the needle location which may last several days after removal of the 
needle. A small amount of bleeding may occur directly after removal of the catheter. 
Application of pressure and a gauze dressing will alleviate the bleeding. The 
maximum amount of blood we will draw across the entire study is 195ml, or about 13 
tablespoons, which is well below the volume drawn in a standard blood donation 
(~450ml). Even so, we will exclude you from the study if you have donated blood 
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within the last two months. 
2. Skin microdialysis: There may be some discomfort during the insertion of the small 
fibers in your skin.  Once the needle is in place, the pain should subside.  There is 
also a risk of syncope (fainting) during needle placement. You will be sitting in a 
reclining chair during the study, which reduces this risk, and you will be asked to 
inform the investigator if you feel light-headed, nauseous, dizzy, etc. during needle 
placement. If you do experience any of these symptoms, we will discontinue placing 
the needles and ensure the symptoms subside. Infusions through the fibers should not 
be painful, and there should only be minor swelling at the site.  At the end of the 
study, the fibers will be withdrawn and a sterile dressing will be applied.  Any 
swelling or redness after the study should be gone a few hours after completion of the 
study.  Although the small tubes are sterile, there is a slight risk of infection and/or 
allergic reaction at the sites where the small tubes were placed in your skin.  You will 
be instructed how to keep the area clean for a day or two following the study. If you 
see any signs of infection (redness, swelling, and/or pain around the sites) or 
experience some other abnormal reaction at the insertion site following the study, 
please contact us immediately. We will show you photos of what normal and 
abnormal healing looks like at the sites. There is a possibility the fibers may break 
while in your skin or while they are being removed. We remove the fibers in a way 
such that we can still remove the entire fiber, even if it does break. However, there is 
still a slight risk a small part of the fiber could remain in your skin. If this occurs, the 
piece should be able to work its way out of the skin within a few days (similar to a 
splinter), and we will follow-up with you to ensure this has happened. If the piece 
does not work its way out, or if a site seems infected, we will evaluate the site(s) and, 
if necessary, recommend you seek medical treatment with a healthcare provider. 
3. Microdialysis drugs: We will be infusing very small doses of each drug and only into 
a very small area of your skin.  You will not have any systemic (whole body) effects 
of these drugs, and they will not alter your blood pressure in the small doses given in 
this study.  However, as with any infusions or medications, there is the possibility that 
you are allergic to the drug and may have an allergic reaction to the drug including 
changes in blood pressure and difficulty breathing. In the case of an adverse event, 
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the study will be discontinued. Investigators are trained in Advanced Cardiac Life 
Support and anaphylaxis. 
4. Local Skin Heating:  The local skin heaters may cause some minor skin discomfort.  
The goal is to warm the area of skin to a temperature that has been determined to be 
below the threshold for pain.  If the local heating becomes painful, you should tell the 
investigator and the temperature of the local heater will be lowered.  There is a slight 
risk of burning the skin at this site, so it is important that you tell the investigators of 
any pain you are feeling.  The heating device may be removed at any time if you 
experience any discomfort. 
5. Laser-Doppler Probes:  These probes send a small light into your skin.  You will not 
feel anything except the probe touching your skin. There are no major risks associated 
with this procedure. 
6. Blood Flow Occlusion:  The inflation of the blood pressure cuff to stop blood flow 
may cause a slight tingling sensation and may cause slight bruising.  The sensations 
with prolonged blood flow occlusion greater than 10 minutes are similar to those 
when a limb has “fallen asleep.”  During certain surgical procedures, blood flow is 
often stopped for 2 hours without any significant risk to the patient.  If, at any time, 
you experience any discomfort you may request that the blood pressure cuff be either 
loosened or removed. 
7. Finger Blood Pressure:  In some people, this blood pressure cuff becomes 
uncomfortable after a long period (over 40 minutes).  We will only inflate the cuff for 
10 minutes at a time and then give your finger a rest.  If your finger becomes 
uncomfortable during the 10 minutes the cuff is inflated, let the investigator know and 
they will turn it off for a few minutes.  There are no major risks associated with this 
device. 
8. Nitroglycerin administration: We will administer the standard dose of nitroglycerin 
under your tongue. This drug has minimal risk when used in low doses. Nitroglycerin 
is commonly prescribed to prevent and treat angina pectoris (chest pain), a condition 
occurring from constriction in the arteries of the heart. Nitroglycerin is a potent blood 
vessel dilator, causing the artery to open up and increase blood flow. You may feel 
slight light-headedness or dizziness, but this symptom should not last more than a few 
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minutes. Please inform your investigator if these feelings persist during the study and 
do not simply come and go. You may feel your heart rate slowing as this drug causes 
a drop in blood pressure (transient hypotension), but this will also last only a few 
minutes. After nitroglycerin administration, we will take ultrasound images for 
several minutes to monitor changes in your blood flow and vessel size. You will 
remain laying down on your back for an additional 15 minutes to ensure that your 
blood pressure and heart rate are back to their normal values before we allow you to 
leave the study area. There is a risk that you may experience a headache after this 
treatment, and if you are predisposed, you may experience the onset of a migraine 
headache.  
9. Blood Volume Measurement: This measurement involves exposure to a small amount 
of carbon monoxide. Carbon monoxide is a colorless, odorless gas. We typically 
express CO in the blood as bound to a molecule called hemoglobin (Hb; HbCO).  
Healthy nonsmoking city dwellers typically have 1.5-2.0% of their Hb as HbCO.  
This test will increase this level by roughly 6%.  Although you do not want to 
increase your level of HbCO, the levels used for this test are low and present minimal 
risks.  The side effects associated with excessive HbCO typically occur at levels 
above 8% and may include headache, fatigue, shortness of breath, nausea, cherry-red 
colored lips, dizziness, and death, the last of which rarely occurs below 15% HbCO in 
normal individuals.  This method has been in use in research for measuring blood 
volume for over 100 years without notable complications.  Over time the CO bound 
to Hb in your blood will be removed.  This process will occur naturally over the 
several hours following the test. For every 5 to 6 hours that passes after the test, half 
of the CO will leave your blood.  Thus, after 15-18 hours you would have less than 
1% CO in your blood. 
 In order to assure that subjects remain below the level of %HbCO that is 
associated with side effects, we will test %HbCO in each individual prior to 
administration of CO.  If an individual’s baseline %HbCO is greater than 2.0% we 
will not administer CO to that individual.  Furthermore, if for any reason an 
individual’s post-administration %HbCO rises above 10% or an individual develops 
side-effects associated with excess %HbCO, we will initiate O2 therapy to accelerate 
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CO clearance from their system.  O2 will be given using a nasal administration similar 
to what someone may wear while in the hospital.  Administering O2 reduces the half-
life of CO (speeds up the process of getting rid of it) from ~5 hours to ~80 minutes.  
We will measure %HbCO throughout the O2 administration and periodically 
afterwards.  We will stop treatment if %HbCO is < 8% or the symptoms go away.  If 
symptoms progress or do not improve, the Department of Public Safety (6-6666) or 
911 directly will be called depending on the perceived or real severity of the 
symptoms.  In the unlikely case of an adverse cardiovascular event, the laboratory is 
equipped with an Automatic Electronic Defibrillator (located in a clearly marked 
first-aid cabinet), and Vienna Brunt, Brett Ely, and Dr. Minson are trained in 
Advanced Cardiac Life Support (ACLS). 
10. Emergencies:  In the event of an emergency, you will be transported by ambulance to 
a local emergency facility. 
May I participate if I am pregnant or breast-feeding? 
No. There is not enough medical information to know what the risks might be to a breast-
fed infant or to an unborn child in a woman who takes part in this study.  Breast-feeding 
mothers are not able to take part in this study.  Women who can still become pregnant 
must have a negative pregnancy test no more than 24 hours before taking part in each 
experimental day.  If the pregnancy test is positive (meaning that you are pregnant), you 
will no longer be able to take part in the study. 
Are there benefits to taking part in this study? 
This study will likely not make your health better. This study is being conducted to learn 
about the effects of chronic heat exposure on cardiovascular health. It is possible the 
information gathered in this study could be used to better treat patients with elevated 
cardiovascular risk in the future.  
What other choices do I have if I don’t take part in this study? 
This study is only being done to gather information.  You may choose not to take part in 
this study. 
What are the costs of tests and procedures? 
You will not need to pay for any tests or procedures that are done just for this research 
study. You will receive compensation for completing each session in the study as 
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follows: initial screening session, $10; Experimental Days 1-5, $30 each; Experimental 
Day 6, $50; Experimental Day 7, $40 each. If you complete all parts of the study, you 
will receive $260. This money is for the inconvenience and time you spent in this study, 
and works out to be approximately $10 per hour of participation.  If you start the study 
but stop before the study has ended, you will get part of this money. The partial amount 
will be calculated based on which study sessions you completed. You will receive 
compensation in the form of a check at the end of the study, or if you prefer, 
approximately every 2 weeks into the study. If you choose to receive compensation every 
2 weeks, you will receive an amount corresponding to which study sessions you 
completed in each two-week time interval. There will be no difference in the total 
compensation you will receive if you chose to receive compensation at the end of the 
study versus every 2 weeks. 
Please note, compensation from participation in Human Subjects Research studies 
may be considered taxable income.  Compensation amounts are tracked across all studies 
in which you participate. If compensation totals $600 or more in a calendar year, the 
University is required to report the income to the IRS.  University departments are 
required to track participant compensation and may contact you to complete a W9 form 
for tax reporting purposes.   Because of this, your name will be associated with 
participation in a research study. Department and university administrators will have 
access to this information, but will not have access to research data. 
Who can answer my questions? 
You may talk to Dr. Christopher Minson or his student, Vienna Brunt, M.S. at any time 
about any question you have on this study.  You may contact Dr. Minson by calling (541) 
346-4105, (541) 346-4311 or on his cell phone (541) 953-2231, and Vienna Brunt at 
(541) 346-4507 or on her cell phone at (541) 968-2635. 
What are my rights if I take part in this study? 
Taking part in this research study is your decision.  You do not have to take part in this 
study, but if you do, you can stop at any time. Your decision whether or not to participate 
will not affect your relationship with The University of Oregon. 
You do not waive any liability rights for personal injury by signing this form.  All 
forms of medical diagnosis and treatment whether routine or experimental, involve some 
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risk of injury.  In spite of all precautions, you might develop medical complications from 
participating in this study. 
The investigators may stop you from taking part in this study at any time if it is in 
your best interest, if you do not follow the study rules, or if the study is stopped.  You 
will be told of important new findings or any changes in the study or procedures that may 
happen. 
 If you experience harm because of the project, you can ask the State of Oregon to 
pay you. A law called the Oregon Tort Claims Act limits the amount of money you can 
receive from the State of Oregon if you are harmed. If you have been harmed, there are 
two University representatives you need to contact.  Here are their addresses and phone 
numbers: 
 General Counsel  Research Compliance Services 
 Office of the President University of Oregon 
 University of Oregon  Eugene, OR  97403 
 Eugene, OR 97403  (541) 346-2510 
 (541) 346-3082 
What about confidentiality? 
Any information that is obtained in connection with this study and that can be identified 
with you will remain confidential and will be disclosed only with your permission. 
Subject identities will be kept confidential by assigning you a “subject identification 
number”.  The names associated with each subject identification number will be stored on 
a secure computer with double password protection in Dr. Minson’s office and only one 
list with names and identification numbers will exist.  This list will be destroyed after all 
data has been collected and analyzed and for a period of one year after the results from 
the study have been published. Only coded specimens and data will exist thereafter. 
Your blood will be analyzed for such things as heat shock proteins, hormone 
concentrations, and cytokines (factors released by cells that affect other cells). Your 
muscle tissue will be analyzed for changes in DNA (not genetic testing), RNA, cell 
signaling, and changes in cell structure. The researchers may store the information 
gathered during this study indefinitely.  
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I have had an opportunity to have my questions answered.  I have been given a copy 
of this form.  I agree to take part in this study.   
If you have questions regarding your rights as a research subject, contact Research 
Compliance Services, 5219 University of Oregon, Eugene, OR 97403, 541/346-2510. 
Your signature indicates that you have read and understand the information 
provided above, that you willingly agree to participate, that you may withdraw your 
consent at any time and discontinue participation without penalty, that you will receive a 
copy of this form, and that you are not waiving any legal claims, rights or remedies. 
                                                                                                                       
(Date)                      (Signature of Participant)                                 
                                                                                                                      
                                (Printed Name of Participant)                                  
                                                                                                             
(Date)                      (Signature of Individual Obtaining Consent) 
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